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The Role of BiP Co-chaperone SIL1 in Marinesco-Sjögren Syndrome
Pathogenesis
Abstract
Marinesco-Sjögren syndrome (MSS) is a rare, autosomal recessive, multisystem disorder, which is
characterized by cerebellar ataxia, early-onset bilateral cataracts, and progressive myopathy amongst
other symptoms. MSS has been attributed to mutations in the SIL1 gene, which encodes a nucleotide
exchange factor for the endoplasmicreticulum- resident Hsp70 chaperone, BiP. To date, there are 46 MSSassociated mutations that have been reported in SIL1, which occur throughout this gene and are
predicted to result in a loss of SIL1’s function. The large majority of these mutations cause deletions of
large fractions of the SIL1 protein. Nine MSS-associated mutations are particularly interesting because
they alter less than six amino acids, yet are associated with a phenotype indistinguishable from a near-full
length deletion of SIL1. The mechanisms by which these nine mutations lead to a loss of SIL1’s function
are not well understood. On the other hand, it remains unclear how the loss of SIL1 leads to the
multisystem defects observed in MSS, selectively affecting certain tissues while sparing others. Our goal
was to answer these two questions.
We have shown that the selected nine MSS-associated SIL1 mutations may dramatically alter the protein
microenvironment and disrupt intramolecular interactions, such that it alters the folding properties of SIL1
and renders it aggregation-prone. This offers a potential mechanism by which mutations in SIL1 cause a
loss of its function. We validated that the C57BL/6 Sil1Gt mouse model, which harbors a genetic
disruption of Sil1, phenocopies numerous aspects of the MSS-phenotype and represents a valid
preclinical model system to investigate the MSS-associated pathology and explore pharmacotherapeutic
strategies. Using a combination of the Sil1Gt mice and SIL1- deficient MSS-patient-derived
lymphoblastoid cell lines, we explored the biosynthesis and secretion of immunoglobulins (Ig), which are
the best characterized substrate of BiP to date. In vivo antigen-specific immunizations and ex vivo LPS
stimulation of splenic B cells revealed that the Sil1Gt mouse was indistinguishable from wild-type agematched controls, in terms of both the kinetics and magnitude of antigen-specific antibody responses.
There was no significant accumulation of BiP-associated Ig assembly intermediates or evidence that
another molecular chaperone system was used for antibody production in the LPS-stimulated splenic B
cells from Sil1Gt mice. ER chaperones were expressed at the same level in wild-type and Sil1Gt mice,
indicating that there was no evident compensation for the disruption of Sil1. These results were
confirmed and extended in lymphoblastoid cell lines from individuals with MSS, leading us to conclude
that, surprisingly, the SIL1 was dispensable for antibody production.
Using Sil1Gt mice, we next characterized the molecular aspects of progressive myopathy associated with
MSS. Proteomic-profiling of quadriceps at the onset of myopathy revealed that SIL1 deficiency affected
multiple pathways critical to muscle physiology. We observed an increase in ER chaperones prior to the
onset of muscle weakness, which was complemented by up-regulation of multiple protein degradation
pathways. These responses were inadequate to maintain normal expression of secretory pathway
proteins, including insulin and IGF-1 receptors. There was a paradoxical downstream PI3K-AKT signaling
and glucose uptake in Sil1-disrupted skeletal muscles, all of which were insufficient to maintain systemic
glucose homeostasis and muscle mass. Together, these data reveal defects in maintaining ER
homeostasis upon SIL1 loss, which are countered by multiple compensatory responses that are
ultimately unsuccessful, leading to trans-organellar proteostasis collapse and myopathy.
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ABSTRACT
Marinesco-Sjögren syndrome (MSS) is a rare, autosomal recessive, multisystem
disorder, which is characterized by cerebellar ataxia, early-onset bilateral cataracts, and
progressive myopathy amongst other symptoms. MSS has been attributed to mutations in
the SIL1 gene, which encodes a nucleotide exchange factor for the endoplasmicreticulum-resident Hsp70 chaperone, BiP. To date, there are 46 MSS-associated
mutations that have been reported in SIL1, which occur throughout this gene and are
predicted to result in a loss of SIL1’s function. The large majority of these mutations
cause deletions of large fractions of the SIL1 protein. Nine MSS-associated mutations
are particularly interesting because they alter less than six amino acids, yet are associated
with a phenotype indistinguishable from a near-full length deletion of SIL1. The
mechanisms by which these nine mutations lead to a loss of SIL1’s function are not well
understood. On the other hand, it remains unclear how the loss of SIL1 leads to the
multisystem defects observed in MSS, selectively affecting certain tissues while sparing
others. Our goal was to answer these two questions.
We have shown that the selected nine MSS-associated SIL1 mutations may
dramatically alter the protein microenvironment and disrupt intramolecular interactions,
such that it alters the folding properties of SIL1 and renders it aggregation-prone. This
offers a potential mechanism by which mutations in SIL1 cause a loss of its function. We
validated that the C57BL/6 Sil1Gt mouse model, which harbors a genetic disruption of
Sil1, phenocopies numerous aspects of the MSS-phenotype and represents a valid
preclinical model system to investigate the MSS-associated pathology and explore
pharmacotherapeutic strategies. Using a combination of the Sil1Gt mice and SIL1deficient MSS-patient-derived lymphoblastoid cell lines, we explored the biosynthesis
and secretion of immunoglobulins (Ig), which are the best characterized substrate of BiP
to date. In vivo antigen-specific immunizations and ex vivo LPS stimulation of splenic B
cells revealed that the Sil1Gt mouse was indistinguishable from wild-type age-matched
controls, in terms of both the kinetics and magnitude of antigen-specific antibody
responses. There was no significant accumulation of BiP-associated Ig assembly
intermediates or evidence that another molecular chaperone system was used for antibody
production in the LPS-stimulated splenic B cells from Sil1Gt mice. ER chaperones were
expressed at the same level in wild-type and Sil1Gt mice, indicating that there was no
evident compensation for the disruption of Sil1. These results were confirmed and
extended in lymphoblastoid cell lines from individuals with MSS, leading us to conclude
that, surprisingly, the SIL1 was dispensable for antibody production.
Using Sil1Gt mice, we next characterized the molecular aspects of progressive
myopathy associated with MSS. Proteomic-profiling of quadriceps at the onset of
myopathy revealed that SIL1 deficiency affected multiple pathways critical to muscle
physiology. We observed an increase in ER chaperones prior to the onset of muscle
weakness, which was complemented by up-regulation of multiple protein degradation
pathways. These responses were inadequate to maintain normal expression of secretory
pathway proteins, including insulin and IGF-1 receptors. There was a paradoxical
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enhancement of downstream PI3K-AKT signaling and glucose uptake in Sil1-disrupted
skeletal muscles, all of which were insufficient to maintain systemic glucose homeostasis
and muscle mass. Together, these data reveal defects in maintaining ER homeostasis
upon SIL1 loss, which are countered by multiple compensatory responses that are
ultimately unsuccessful, leading to trans-organellar proteostasis collapse and myopathy.
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CHAPTER 1.

INTRODUCTION

Biosynthesis of Secretory Pathway Proteins – Journey into the ER
Nearly a third of human genomic open reading frames encode proteins that enter
the Endoplasmic Reticulum (ER) and traverse the secretory pathway to reach their final
destination as residents of single membrane-bound organelles, plasma membrane, or the
extracellular space (1). As the newly synthesized polypeptide chain emerges from the
ribosome, the signal recognition particle (SRP) recognizes the typically N-terminal signal
sequence and targets the ribosomal-polypeptide-SRP complex to the ER-localized SRP
receptor (2). The ribosome-polypeptide chain complex is then directed towards a
protein-conducting channel in the ER membrane called the Sec61 translocon. The Sec61
translocon allows efficient vectorial transport of the growing polypeptide across the ER
membrane. Co-translational targeting of secretory pathway proteins via the SRP pathway
is very well characterized, but all proteins do not exclusively adhere to this mode of ERentry. Tail-anchored proteins, one such exception to this mode of translocation, are
generally cytosolically oriented and consist of a C-terminal transmembrane domain,
which is occluded by the ribosome while the protein is being synthesized. Thus, the
availability of the transmembrane domain for recognition and insertion into the ER
membrane can only occur post-synthesis and requires an SRP-Sec61 complexindependent mechanism in this scenario. This alternative mode of insertion into the ER
membrane is mediated by a group of proteins belonging to the GET (Guided Entry of
TA) pathway (3).
The nascent polypeptide entering the ER undergoes a series of protein processing
and modification events, which may include cleavage of the signal sequence, N-linked
glycosylation, intra- and inter-molecular disulfide bond formation, and oligomerization of
subunits in the case of multimeric proteins. In parallel to these events, the maturing
polypeptide also begins to fold into three-dimensional secondary and tertiary structures
governed by its amino acid sequence and macromolecular environment. During the
process of protein folding, tracking the free energy of each conformation assumed by the
polypeptide chain (high free energy) on its journey to becoming completely folded (stable
conformation with minimal free energy) can be imagined as a ‘funnel-shaped’ landscape.
The X and Y axes represent the conformational diversity that the protein can assume
whereas the Z axis tracks the free energy of the assumed conformation. As the
polypeptide begins to form intrachain hydrophobic and electrostatic associations on its
journey to attain the native state conformational ensemble, it traverses down the free
energy funnel with each step restricting its conformational diversity (Figure 1-1).
However, this landscape is more aptly a ‘rough terrain’ and certain protein
conformations, while lower in their free energy, are non-native and need to be reversed
for the folding polypeptide to expand its conformation reach. These ‘pitfalls’ in the free
energy landscape may kinetically trap the protein in a native intermediate state or an
aggregation-prone intermediate state or an aggregated conformation, the latter of which
might be even more thermodynamically stable than the native conformation itself (4, 5).
From an evolutionary perspective, the cell has made an enormous investment to facilitate
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Figure 1-1. The free energy landscape during protein folding and aggregation.
Protein folding and aggregation. Nascent polypeptides fold by sampling various
conformations and sequestering hydrophobic amino acid residues. Partially folded
intermediates, both on- and off-pathway, can become trapped in localized energy minima.
These species are at risk of aggregation by forming aberrant intermolecular contacts,
which can lead to the formation of oligomers, amorphous aggregates, and amyloid fibrils.
Molecular chaperones promote the formation of the native species by lowering freeenergy barriers between kinetically stable intermediates, smoothing the protein folding
landscape (green arrows), and preventing aberrant intermolecular interactions (red
arrow).
Reprinted with permission from Rockefeller University Press. Klaips CL, Jayaraj GG,
Hartl FU. Pathways of cellular proteostasis in aging and disease. J Cell Biol. 2018 Jan
2;217(1):51-63.
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proper protein folding, evolve mechanisms to deal with misfolding rapidly, and to avoid
the formation of toxic protein species that may prove detrimental to its health. The
stability of a protein’s three-dimensional shape and the conformation required to facilitate
efficient biological function present two competing evolutionary pressures. For example,
a protein which might have improved biological function may not possess the right
biophysical properties to fold efficiently. Conversely, a protein that may fold efficiently,
might not be able to mediate sufficient function at its cellular concentration (6).
Space can be a constraint for protein folding. The ribosomal tunnel and the Sec61
translocon can only accommodate α-helix formation within the emerging polypeptide
chain (7). The formation of other secondary structures like β sheets and turns requires
greater spatial and conformational freedom, which is considerably expanded upon entry
into the ER. This expansion of conformation freedom also increases the risk for
unfavorable intrachain interactions. On the other hand, the ER is nearly 30 times more
oxidizing with the ratio of reduced glutathione to the disulfide form (GSH/GSSG) within
the secretory pathway ranging from 1:1 to 3:1, whereas the overall cellular GSH/GSSG
ratio ranges from 30:1 to 100:1 (8); has a high concentration of calcium ions (close to
1mM); and is devoid of any proteolytic machinery. To combat this environment, the ER
is equipped with a multitude of molecular chaperones and folding factors that serve to
shelter the nascent polypeptide chain entering the ER and restrict its conformational
landscape. This slows down the overall folding process and prevents counterproductive
folding, while governing efficient protein processing, modifications, folding, and
oligomeric assembly.
Protein Folding and Quality Control in the Endoplasmic Reticulum
The endoplasmic reticulum possesses a stringent protein quality control (ERQC)
system for newly synthesized secretory pathway proteins. The ER consists of two major
families of molecular chaperones, the Heat Shock Protein (HSP) chaperones, and the
glycan-binding lectin chaperones, both of which are complemented by their diverse
machinery of co-chaperones. These chaperone families are additionally complemented
by peptidyl prolyl cis/trans isomerases, which allow isomerization of the cis and trans
peptide bonds within the amino acid proline, oxidoreductases, and client-specific folding
factors. The resident chaperones and folding factors inhibit, delay, and modulate protein
folding to ensure that folding intermediates, misfolded or aggregated proteins, and
assembly-incompetent or orphan subunits of oligomeric proteins remain within the ER
and do not undergo faulty transportation along the secretory pathway (9).
Despite all the cellular resources dedicated to protein folding, a significant
fraction of the newly synthesized polypeptides fail to attain their correct native structure
(10). These aberrantly folded proteins residing in ER need to be degraded by the cell.
There are two primary means of degrading proteins, by either employing the ubiquitin
proteasomal system (UPS) or by the autophagy-lysosomal machinery. The terminally
misfolded and unassembled subunits of oligomers are recognized by the chaperones and
co-chaperones of the ERQC machinery. These chaperones target the misfolded protein
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for retrotranslocation via a protein-conducting channel (conceptually similar to the
translocon and is referred to as the retrotranslocon) to the cytosol, where it is
simultaneously ubiquitinated by the ER-membrane-resident ubiquitin ligase complexes
and selectively targeted for degradation by the cytosolic proteasome. This process is
referred to as ER-associated degradation (ERAD) (11). It has been suggested that under
rate-limiting conditions of ERAD, excessive amounts of soluble proteins are capable of
traversing the secretory pathway up to the trans-Golgi network where they are selectively
targeted to the lysosome (12). However, dealing with protein aggregates sequestered
within the ER pose a challenge for the ERAD machinery since these aggregates cannot be
efficiently extracted through the retrotranslocon. Such ERAD-incompetent aggregates
are degraded by the autophagy-lysosomal system (12, 13). There are two components to
the autophagy-mediated degradation of ER-aggregates, macroautophagy and ER-phagy.
Macroautophagy is characterized by the generation of double membranous transport
vesicles called autophagosomes that engulf their cargo as they are formed. These
autophagosomes subsequently fuse with the lysosomal compartment upon which the
autophagosomal cargo is degraded by the lysosome-resident lytic enzymes. ER-phagy,
on the contrary, is an organelle-selective process which occurs independently of the core
autophagy components and is characterized by the formation of ER-whorls which are
subsequently taken up by the lysosome (14).
Chaperone Families of the Endoplasmic Reticulum
Lectin chaperones and co-chaperones
Amongst numerous ER-resident chaperones, the local HSP chaperone
superfamily includes BiP/Grp78 (Hsp70), Grp94 (Hsp90), and Grp170 (Hsp110). While
these chaperones serve as the ER luminal counterparts of cytosolic orthologs, lectin
chaperones are exclusively expressed in the ER and include Calnexin (CNX) and
Calreticulin (CRT) (Figure 1-2).
Calnexin is a type I membrane protein and is tethered to the ER membrane
whereas Calreticulin is its soluble paralog. The lectin chaperones share 39% sequence
identity and structural similarities (15). Even though both of these chaperones have
similar lectin binding preferences, they have distinct specificities for the location of the
glycans they bind and also the number of glycans they recognize. Thus, it is postulated
that Calnexin and Calreticulin recognize distinct topologies. Calnexin and Calreticulin
are also capable of binding to polypeptide regions of both glycosylated and nonglycosylated substrates, albeit with altered kinetic properties, and can even suppress their
aggregation (16-18). Calnexin and Calreticulin play crucial roles in ER protein quality
control and calcium homeostasis and are involved in several processes in immunity,
cancer, and apoptosis. These lectin chaperones are further aided by their set of co-chaperones and folding factors. The oligosaccharyltransferase (OST) complex is
responsible for covalently transferring an oligosaccharide sugar moiety from a lipidbound dolichol donor to an asparagine residue within an N-X-S/T motif (where X cannot
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Figure 1-2. The ER protein quality control machinery.
The schematic highlights the role of various co-chaperones and folding factors that assis
the two main chaperone systems within the ER. The lectins calnexin/calreticulin
(CNX/CRT) (a) and the Hsp70 chaperone BiP (b), aid in the proper folding of secretory
pathway proteins (c) or recognize and target them for ER-associated degradation by the
cytosolic 26S proteasome if folding ultimately fails (d).
Reproduced with permission from Elsevier. Behnke J, Feige MJ, Hendershot LM. BiP
and its nucleotide exchange factors Grp170 and Sil1: mechanisms of action and
biological functions. Journal of molecular biology. 2015;427(7):1589-608. Epub
2015/02/24. doi: 10.1016/j.jmb.2015.02.011. PubMed PMID: 25698114; PubMed
Central PMCID: PMCPMC4356644.
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be a proline residue) flanked by a flexible region in the polypeptide that is entering the
ER. This large hydrophilic oligosaccharide itself can affect the solubility and folding
properties of the protein. It can be acted upon by multiple ER-resident glycosyl-enzymes
that modify this sugar moiety, resulting in a ligand that is recognized by the ER-resident
carbohydrate-binding proteins. Glycosidases I and II (GlcI and GlcII, respectively) trim
the glucose oligosaccharide residues, which allows the unfolded, monoglucosylated
glycoprotein to be recognized by either Calnexin or Calreticulin. These chaperones act in
concert with ERp57, the lectin-associated oxidoreductase, which catalyzes the formation
of native disulfide bonds in the folding polypeptides. Some proteins can fold correctly
after a single interaction with the CNX/CRT chaperones. However, numerous proteins
require more than one cycle of association. Incompletely folded intermediates containing
non-native structures can be sensed by the bifunctional UDP-glucose glycoprotein
glucosyltransferase (UGGT) sensor, which allows it to ‘inspect’ non-native structures
within folding polypeptides and re-glycosylate the previously deglycosylated substrates,
allowing them to re-engage with CNX/CRT. Glycoproteins are offered a temporal
window to complete their folding. When the native structure is achieved, glycoproteins
are exported from the ER in cytosolic coatamer protein II (COPII)-coated vesicles. If
folding ultimately fails, proteins are further targeted for ERAD by an ER mannosidase or
an ER degradation enhancing α-mannosidase-like protein (EDEM), resulting in removal
of 4 mannose residues, and OS-9 and XTP3-B, which allow recognition of misfolded
proteins and ERAD-targeting (19).
The HSP70 chaperone BiP/Grp78: It’s ATPase cycle and its co-chaperone network
Pre-B lymphocytes and hybridomas derived from these lymphocytes synthesize
the immunoglobulin (Ig) heavy chain alone, without the light chain. These Ig heavy
chains were identified to non-covalently associate with a 78 kDa protein named
immunoglobulin heavy chain binding protein-BiP (20). Soon after, it was determined
that BiP was an ER-resident protein that transiently, but specifically, bound to free and
incompletely assembled intracellular heavy chains with an unfolded Ig domain, and
dissociated when the Ig heavy chain was completely folded when it associated with the Ig
light chain. The association of BiP with Ig heavy chains retained them within the ER,
thereby implicating BiP as a necessary regulator to prevent premature escape and
secretion of incompletely assembled Ig molecules in the Ig biosynthetic process (21, 22).
Moreover, it has also been shown that BiP plays a key role in governing the half-life of a
protein and was capable of delivering partially folded substrates for degradation by the
proteasome (23). However, the mere presence of a BiP-binding sequence within a client
protein is not an absolute indication of BiP’s binding ability. This interaction is rather
governed by the kinetic rate of folding and stability of the domain-containing protein
(24). This work provided one of the earliest evidence for the crucial role of BiP in ER
protein quality control and the biosynthesis of immunoglobulins (21, 22, 25). It was later
demonstrated that BiP and Grp78 were the same protein and that BiP was capable of
binding other proteins as well, such as the coagulation Factor VIII (25, 26). In
subsequent studies, it has been demonstrated that BiP can be posttranslationally modified
by AMPylation or phosphorylation and this modification is characteristic of BiP that was
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that was not bound to its substrates. This indicates that are at least three forms of the
cellular BiP pool: BiP complexed with its substrates, a free and unmodified monomer,
and free modified oligomers, implying that the modified oligomeric BiP species serve as
a cellular reservoir, which can be readily mobilized to accommodate fluctuations in the
secretory proteome (27-32). BiP also plays a crucial role in the disposal of nonglycosylated substrates and this process relies on the retrotranslocation complex,
including the ER transmembrane proteins Derlin-1, Herp, Hrd1, Sel1L, and VIMP.
These proteins connect the ER luminal chaperone machinery to the to the 26S
proteasomal degradation machinery via VCP/p97, which provides the energy required for
extraction of a protein through the retrotranslocon channel (33).
Work from Dr. Amy S. Lee’s laboratory has shown that the glucose-regulated
proteins can also be upregulated by a variety of cellular stresses in addition to glucose
depletion and play a cytoprotective role. These stresses include the increased expression
of misfolded and underglycosylated proteins, oxidative stress, heat shock, and disruption
of ER calcium homeostasis (34). It has been shown that BiP is upregulated in the inner
cell mass and the trophectoderm during embryonic development stage 3.5, and biallelic
deletion of BiP leads to lethality due to a peri-implantation defect. Thus, BiP is crucial
for embryonic cell growth and survival of pluripotent stem cells (35). Interestingly,
haploinsufficiency of BiP in mice does not affect viability. These mice upregulate Grp94
and protein disulfide isomerase (PDI), which facilitates the correct arrangement of
disulfide bonds within a protein (35). In support of the crucial importance of BiP in
cellular systems, a highly virulent Escherichia coli strain that was responsible for the
hemolytic uraemic syndrome endemic in Australia in 1998 was found to synthesize a
cytotoxin that mediated its toxicity by inactivating BiP, cleaving its interdomain linker,
which is necessary for the allosteric relay between BiP’s NBD and SBD (36).
Mammalian Grp promoters, including that of Grp78, contain multiple copies of
ER stress response elements (ERSE) and UPR response elements (UPRE), which enable
the glucose-regulated chaperones to be upregulated upon insults to the ER which
compromise its homeostasis. The ERSE, an evolutionarily conserved tripartite sequence,
typically consists of a CCAAT(N9)CCACG (N represents a 9-bp GC-rich region)
consensus sequence and is more complex than the UPRE. The transcription factors, NFY and Ying Yang 1 (YY1), both have been reported to enhance the Grp78 promoter
activity under conditions of ER stress. While NF-Y binds to the CCAAT motif of the
ERSE, YY1 binds to the CCACG sequence. In addition, the UPR-sensor ATF6 has also
been reported to bind to the Grp promoters in complex with NF-Y (34).
Hsp70s are highly conserved from E. coli to mammals with nearly 40% sequence
identity (37). In addition to BiP’s role in de novo protein folding and assembly, BiP
plays a key role in regulating ER homeostasis. BiP maintains the permeability barrier of
the ER membrane by sealing the luminal face of the translocon channels that are either
not in an active state of conducting protein or newly targeted translocons that are
associated with a ribosome but haven’t yet begun translational translocation (38). BiP is
also capable of recognizing and stably associating with unfolded regions within a client
protein and targeting them to the cellular degradation machineries (23). BiP can also
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reversibly associate with the luminal domains of UPR transducers and maintain them in a
dormant state (39). In addition, BiP has been shown to be a bona fide ER calcium
storage protein, enhancing the ER’s storage capacity by approximately 25% under resting
conditions (40). Except for BiP’s contribution to the ER’s calcium stores, all other
functions rely on the ability of BiP to bind adenosine triphosphate (ATP) and succesfully
hydrolyze it. Evidence from our laboratory has indicated that mutation of the residues on
BiP’s nucleotide binding domain that interact with ATP or ADP or of residues results in
severe inhibition of its ATPase activity. The mutant BiP is still able to bind ATP and Ig
heavy chains, however, it is deficient in the release of the bound Ig heavy chains (41).
Intriguingly, the expression of these BiP mutants in COS cells not only recapitulated the
defect in BiP being able to efficiently release client proteins, but also revealed the
importance of BiP in maintaining the integrity of ER and preventing disruption of ER
morphology and dilation (42).
BiP’s ATPase activity is tightly regulated by two families of co-chaperones, ERresident DnaJ-like proteins (ERdjs) and nucleotide exchange factors (NEFs) (Figure
1-3). Similar to other members of the Hsp70 family, BiP has an N-terminal nucleotidebinding domain (NBD) and a C-terminal substrate-binding domain (SBD), which are
connected by an interdomain linker. BiP can exist as two distinct nucleotide-bound
conformations, which dictate the conformation adopted by the SBD through ligandinduced conformational changes. Recent evidence suggests that the ATP-bound state of
BiP is a completely closed conformation, which does not allow BiP to engage any
polypeptides via its SBD (43). BiP’s inherent ATPase activity is weak. The association
of BiP with the ER-resident Hsp40 co-chaperones, ERdjs, via the J-domain has been
postulated to facilitate a partial opening of the SBD to initiate stable binding of the
substrate. This conformation is capable of rapidly engaging new susbtrates. However,
the affinity of this comformation for clients is low and they are rapidly released as well.
Association of BiP with ERdjs and the substrate together stimulates BiP’s ATPase
activity, leading to the hyrolysis of the bound ATP molecule to ADP and subsequent
dissociation of the ERdj protein. Multiple ERDJs (ERDJ3-6) have also been reported to
engage substrates themselves directly and transfer them to BiP upon association. The
ADP-bound BiP conformation possesses high-affinity for the substrate and serves as a
holdase for its substrate, preventing off-target folding pathways. However, the substrate
cannot fold while bound to BiP since the SBD’s closed lid restricts the substrate’s
conformational freedom and need to be released from BiP on its own and require the
function of NEFs. There are two ER-resident co-chaperones, which have been reported
to possess NEF-activity towards BiP, Sil1 and Grp170. Interestingly, Grp170 has been
recently demonstrated to also function as a bona fide ER chaperone that is capable of
binding incompletely folded substrates and is regulated by a mechanism distinct from that
of BiP (44). NEFs introduce a torsional strain within the BiP-NBD, which allows
disengagement of the bound ADP molecule by breaking the hydrogen bonded contacts.
The release of the ADP molecule allows the BiP-NBD to engage a new ATP molecule,
which causes an active release of the bound polypeptide substrate and closes
the SBD. This mechanism prevents BiP from repeatedly engaging the same substrate and
additionally provides a spatial and temporal window in which that substrate may fold (43,
45).
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Figure 1-3.

The ATPase cycle of BiP and the co-chaperones regulating it.

Reproduced with permission from Elsevier. Behnke J, Feige MJ, Hendershot LM. BiP
and its nucleotide exchange factors Grp170 and Sil1: mechanisms of action and
biological functions. Journal of molecular biology. 2015;427(7):1589-608. Epub
2015/02/24. doi: 10.1016/j.jmb.2015.02.011. PubMed PMID: 25698114; PubMed
Central PMCID: PMCPMC4356644.
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Grp170
Lhs1p’s (the yeast homolog of Grp170) discovery stemmed from the yeast
genome sequencing project, which revealed an open reading frame that would encode a
novel Hsp70-like protein. Indeed, this protein was shown to be an ER-luminal
glycoprotein that is induced upon UPR-activation and was designated as luminal Hsp70
or Lhs1. Further efforts to characterize the role of this protein revealed that the deletion
of Lhs1p does not yield a lethal phenotype, unlike the deletion of Kar2p (the yeast
homolog of BiP). However, Lhs1p deletion resulted in an activation of the UPR and a
severe defect in the translocation of multiple secretory pathway proteins. The combined
deletion of Lhs1p with Ire1p, which alone would blunt the cell’s ability to activate the ER
stress response, or along with Kar2p, both resulted in cellular lethality. Thus, Lhs1p was
postulated to be an ER luminal chaperone important for polypeptide translocation into the
ER and subsequent protein folding of secretory pathway proteins, and was shown to
contain an UPRE in its promoter region, similar to that of Kar2p, which enabled
induction of this genetic locus upon UPR activation (46, 47). Surprisingly, studies in
yeast and mammals later demonstrated that the postulated molecular chaperone Lhs1p
and its human homolog, Grp170, are also capable of nucleotide exchange activity for
their respective Hsp70-partners, Kar2p and BiP. It was also shown that Kar2p
reciprocally activated the ATPase activity of Lhs1p, indicating that the ATPase activity
of Lhs1p and Kar2p were coupled, which was important for normal ER function in vivo
(48-50). Lhs1p has also been shown to play an important role in the conformational
repair, refolding, and stabilization of denatured protein aggregates, similar to its cytosolic
ortholog Hsp104 (51, 52). Dr. Bernd Bukau’s group further demonstrated that the
mechanism of Grp170’s nucleotide exchange was similar to that of the cytosolic Hsp110
(53). Grp170 is conserved in eukaryotes and is ubiquitously expressed within humans. It
contains an N-terminal ER-targeting signal sequence, NBD, followed by a β-sheet and
an α-helical domain and a C-terminal KNDEL ER-retention sequence. The nucleotide
binding domain of Grp170 is very similar to that of BiP and both of these proteins overall
share a similar domain organization with each other and with conventional Hsp70s (33).
It has been shown that Grp170 and BiP are capable of binding to the same molecular
species of different substrates and that the dissociation of BiP from the substrate was not
a prerequisite for Grp170-binding (44). However, there are functional and structural
differences between the Grp170 and conventional Hsp70s. The binding of Hsp70substrate complex is governed by the occupancy of the nucleotide binding domain.
When ATP occupies the NBD, the substrate is released from Hsp70. However,
consistent with the disaggregase activity shown for Hsp110, the occupancy of Grp170’s
NBD by either ATP or ADP does not influence substrate release from this molecular
chaperone. In addition, using mutational analysis, the α-helical domain of Grp170 and
the unstructured loop docked within its β-sheet domain have also been reported to
influence Grp170’s substrate-binding ability (44). Recent evidence has highlighted that
Grp170 can facilitate the degradation of certain substrates, as observed in the case of the
epithelial sodium channel subunit (54).
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ERdjs
ERdjs are characterized by the presence of a J-domain, which mediates
association of Hsp40 members with their respective Hsp70-binding partners. There are
eight ERdjs (Erdj1-8) reported to date (55, 56). ERdjs primarily serve two functions.
They enable BiP to engage its substrate by transforming the ATP-bound BiP to an open
conformation (43) and, secondly, deliver the substrate to BiP. ERdjs can be categorized
into three groups on the basis of their structural characteristics. Type I ERdjs (Erdj3)
consist of an N-terminal J domain, a glycine/phenylalanine-rich domain, and a substratebinding domain, which contains a cysteine-rich zinc-binding domain. Type II proteins
(ERdj4) possess only the J-domain and the glycine/phenylalanine-rich domain and
poorly-defined substrate-binding site. Type III ERdjs only have a J domain
(ERdjs1/2/5/6). ERdjs are present at substoichiometric amounts compared to BiP and
have been shown to vary widely in their concentrations among each other within a cell.
These DnaJ-like proteins also vary in their ability to be induced by the UPR and only
ERdjs3/4/5/6 have been reported to show this induction. Growing evidence suggests that
ERdjs play a crucial role in determining the fate of a substrate (55).
ERdj1, a transmembrane protein, serves as a translational checkpoint by dually
associating with the translating ribosome via its cytosolic domain and with BiP via its J
domain. ERdj1 ensures that BiP is present in the vicinity to engage newly synthesized
polypeptides as they enter the ER lumen. ERdj2 is a multipass transmembrane protein,
has been shown to associate with the translocon channel, and plays an important role in
translocation of proteins. ERdj3 has been independently identified as an Hsp40 cochaperone that assists in the trafficking of Shiga toxin and also as a part of the chaperone
complex that binds unassembled Ig heavy chains. ERdj3 plays a major role in protein
folding and even in ERAD of certain substrates by maintaining them in a soluble state
compatible with ERAD. ERdj4 is the least abundant ERdj, which also displays the
greatest induction upon activation of the UPR. ERdj4 has been shown to play a role in
the ERAD of certain clients of BiP. ERdj5 possesses four thioredoxin domains in
addition to the J domain and has been shown to interact with the retrotranslocon
machinery. ERdj5 is an oxidoreductase and has been shown to reduce the disulfide
linkage in ERAD-targeted substrates, allowing efficient retrotranslocation. Recently, it
has also been suggested that ERdj5 is involved in maintaining ER calcium homeostasis
via ERdj5-mediated regulation of the ER calcium channel, SERCA2b. ERdj6 has been
shown to possess three tetratricopeptide domains, which allows it to engage unfolded
proteins, and is postulated to play a pro-folding role in the ER lumen. ERdj7 is a
transmembrane protein with an ER-luminal J domain. However, little is know about is
known about its function within the cell. ERdj8 is the most recently discovered ERdj
protein and is suggested to be prevalent at ER-mitochondrial association sites where it
play a role in negatively regulating autophagy (55, 56).
The ATPase cycle of BiP is crucial to its function as a substrate holdase.
Mutations in BiP that severely inhibit its ATPase activity prevent the release of substrates
from BiP, as exemplified in the case of Ig heavy chains and light chains, and even
prevents their secretion (41, 57). The binding of BiP to its substrates is rather
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promiscuous, which allows it to bind a diverse set of substrates. It is known that BiP
preferentially binds a 7-9 amino acid sequence that is composed of alternating aromatic
and hydrophobic amino acid residues. This sequence is generally buried within the
native conformation of a relevant protein but is exposed when it is unfolded or misfolded
(58). A recent study from our laboratory confirmed and expanded upon previous findings
on BiP-binding sequences, using Ig as a model system to reveal intriguing findings into
the nature of substrate engagement by BiP, Grp170, and ERdjs3-5. This study found that
BiP and Erdj3 have numerous binding sites within an Ig, which likely allows efficient
recognition upon entry into the ER. Contrarily, Grp10, Erdj4, and Erdj5, all recognized
nearly identical sequences, which display a high propensity for aggregate formation and
have been implicated to play an important role in ERAD. This suggests a convergence in
evolutionary mechanisms to stringently deal with aggregates (59).
SIL1
The first nucleotide exchange factor was not identified until the mid-1990s when
several laboratories independently discovered them in three organisms. A conditional
lethality screen in the yeast Yarrowia lipolytica to detect cellular components which
interacted with the 7S RNA or SRP in the process of co-translational translocation led to
the identification of the Sls1p gene (60). The Sls1p-encoded protein was an ER-luminal,
426-amino acid-long polypeptide, which contained an N-terminal signal sequence and a
C-terminal ER-retention motif. Sls1p fractionated with the membranous fraction and was
shown to interact with the Sec61p translocation apparatus. It was also determined that
this gene was induced by ER stresses such as heat shock and inhibition of glycosylation.
Deletion of the Sls1p gene resulted in a temperature-sensitive growth phenotype and
resulted in decreased levels of mature secretory proteins. Interestingly, overexpression of
Sls1p had a similar phenotype, suggesting a cellular stoichiometric preference for the
amount of Sls1p. This protein was also shown to bind Kar2p (the yeast homolog of BiP)
and disruption of this interaction significantly affected the secretion of a cotranslationally translocated reporter protein (61). Thus, Sls1p was thought to act in the
translocation process where it assisted in the ER-luminal entry of secretory pathway
proteins or their folding (60).
Sil1 was identified as a gene whose overexpression rescued the severe growth
defect observed in yeast ΔIre1ΔLhs1 double mutants and, thus, was named as the
suppressor of Ire1 and Lhs1 deletion 1 (Sil1). Sil1p was determined to an ER-resident
protein, which bound the ATPase domain of Kar2p (62). It was further shown that
although deletion of Sil1p on its own was not lethal, a combined deletion of Sil1p and
Lhs1 proved to be lethal with an absolute block in protein translocation into the ER (62).
Mammalian (human) Sil1, was discovered in our laboratory using a yeast twohybrid screen aimed at identifying proteins which interacted with a mutant ATPase
domain of BiP and was initially named as the BiP-associated protein (BAP) (63). The
BAP gene encoded a 461-amino acid protein with a putative N-terminal ER-targeting
sequence and two N-linked glycosylation sites and displayed nucleotide exchange

12

activity (63). BAP was determined to be similar to the yeast Sls1p protein and Sil1p,
which interacts with the NBD of the yeast BiP homolog, and also similar to the cytosolic
Hsp70-binding protein, HspBP1. It was further shown that BAP/Sil1 is ubiquitously
expressed in mice and humans, and its expression displayed a tissue-specific pattern in
humans that was highly similar to that of BiP, ERdj3, and ERdj4, suggesting that these
co-chaperones of BiP function together (63, 64).
Sil1 has an elongated, “kidney bean”-like, molecular shape which consists of 16
α-helices (A1-A16) and lacks β-sheets (Figure 1-4). The central helices A3-A14 form
the Armadillo-like repeats (ARM1-ARM4) (45), which are named after the armadillo
repeats found in β-catenin. Each ARM repeat is composed of three α-helices that pack
into a superhelix. From the resolved Sil1 structure complexed with BiP, it appears that
Sil1 acts as a “wrench,” which wraps around lobe IIb of BiP’s NBD and makes additional
contact with lobe Ib. Sil1’s interaction with the ADP-bound BiP causes lobes Ib and IIb
to move away from each other by ~3.7°, which is likely to disrupt the hydrogen bonds
between ADP and BiP, leading to the release of ADP (45). Although the ER has two
NEFs that mediate nucleotide exchange for BiP, it has been reported that these
interactions are mechanistically distinct (Figure 1-5). The binding of Lhs1 to BiP
requires the NBD as well as the linker. However, lobe IIb of the NBD is sufficient for
Sil1p association and point mutations in the Sil1p-interacting site of BiP’s NBD
specifically disrupted Sil1p binding, but not Kar2ps’s interaction with Lhs1 (65).
Intriguing data from Dr. Carolyn Sevier’s group has recently shown that Sil1p
also acts as a reductant for BiP (66). Protein folding within the highly oxidizing
conditions within the ER is a significant source of cellular reactive oxygen species
(ROS), comparable to that of ROS generated during mitochondrial respiration. Oxidative
stress has a detrimental impact on BiP’s function by modifying a conserved cysteine
within BiP’s NBD that decouples the relay of information about NBD’s nucleotide
occupancy to its SBD, and thereby disrupts its ATPase cycle (67, 68). How this cysteine
was reduced to restore BiP’s normal function is not understood. Recently, it has been
demonstrated that Sil1 has the potential to reduce the oxidized cysteine within BiP’s
NBD and restore BiP’s function. Thus, in addition to the nucleotide exchange activity of
Sil1, the Sil1-BiP pair are also important in sensing redox imbalance within the ER.
The Unfolded Protein Response
The protein folding capacity of the ER is governed by the composite capacity of
the ER-resident chaperones to effectively accommodate the protein folding and
processing load of newly synthesized proteins and the ability to efficiently deal with any
abnormalities in the folding pathway. Cellular insults, either physiological or
pharmacological, disrupt ER homeostasis and culminate in the accumulation of unfolded
or misfolded proteins. This presents an additional burden on the ERQC machinery,
leading to ER stress (ERS). The triage response to salvage ER stress is called as the
Unfolded Protein Response (UPR), which leads to the initiation of an ER-to-nuclear
signal transduction pathway to globally halt further protein synthesis and simultaneously
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Figure 1-4.

Structure of Sil1 and Sil1 complexed with BiP’s NBD.

Reproduced with permission from Portland Press. Yan M, Li J, Sha B. Structural
analysis of the Sil1-Bip complex reveals the mechanism for Sil1 to function as a
nucleotide-exchange factor. The Biochemical journal. 2011;438(3):447-55. Epub
2011/06/17. doi: 10.1042/bj20110500. PubMed PMID: 21675960. © Biochemical
Journal.
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Figure 1-5. Differences in the mechanisms of nucleotide exchange by Sil1 and
Grp170, the two ER-resident NEFs of BiP.
Reproduced with permission from Elsevier. Behnke J, Feige MJ, Hendershot LM. BiP
and its nucleotide exchange factors Grp170 and Sil1: mechanisms of action and
biological functions. Journal of molecular biology. 2015;427(7):1589-608. Epub
2015/02/24. doi: 10.1016/j.jmb.2015.02.011. PubMed PMID: 25698114; PubMed
Central PMCID: PMCPMC4356644.
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enhance the ER’s protein folding and degradation capacities (Figure 1-6). The UPR is
orchestrated via three transmembrane proteins: dsRNA-activated protein kinase-like
protein kinase (PERK), inositol-requiring enzyme 1α (IRE1α), and activating
transcription factor 6 (ATF6) (69). These UPR sensors are maintained in an inactive
state by formation of a stable complex between their ER luminal domains and BiP.
Perturbation of protein folding and the accumulation of unfolded and misfolded proteins
in the ER sequesters BiP away from these UPR sensors, leading to their activation (39).
Dissociation of BiP from the ER-luminal binding pocket of the type I
transmembrane kinase, PERK, leads to its homodimerization and autophosphorylation.
This step in turn activates PERK’s kinase domain that can now phosphorylate the
eukaryotic initiation factor 2α (eIF2α) subunit, leading to a global translational initiation
arrest. During this period of ER stress, a subset of mRNAs containing an internal
ribosomal entry site, such as ATF4, are selectively translated. ATF4 is a transcription
factor that activates the growth arrest and DNA-damage-inducible protein 34 (GADD34)
and C/EBP homologous protein (CHOP). GADD34 directs eIF2α dephosphorylation to
restore global mRNA translation when ER stress is resolved. On the other hand, CHOP
regulates ER stress-mediated apoptosis. The expression of CHOP is initially suppressed.
However, constitutive PERK activation due to unresolved or chronic ER stress overrides
the adaptive phase of the UPR and leads to apoptosis (69). It has been reported that
initial activation of the UPR leads to a decline in Cyclin D and Cyclin E-dependent
kinase activities due to their translational inhibition, leading to a G1 cell cycle arrest.
This represents an ER stress-governed cellular checkpoint that prevents cell cycle
progressions in cases of disruption of cellular homeostasis (70).
Similar to PERK, IRE1 is a type I transmembrane protein with a cytosol-facing
serine/threonine kinase domain. Upon dissociation of BiP from its luminal domain, IRE1
oligomerizes, leading to its autophosphorylation and subsequent activation (69). It has
been reported that unfolded peptides are capable of directly binding to and activating
IRE1, representing an alternative mode of IRE1 activation (71). Unlike PERK, IRE1 also
has a cytosolic endoribonuclease domain, which can recognize a consensus mRNA
sequence and cleaving it in a process called IRE1-dependent decay of mRNA (RIDD).
Activated IRE1 also cleaves XBP1 mRNA to facilitate an unconventional splicing
mechanism, which leads to a frame-shift, now encoding a transcriptionally active XBP1
protein (sXBP1s). sXBP1 regulates the expression of genes whose products enhance the
protein folding capacity of the ER. These genes include chaperones, co-chaperones, and
components of the ERAD machinery. In addition, ectopic overexpression of sXBP1 can
inhibit CHOP expression, which serves to promote cell survival (69), and can lead to a
physical expansion of the ER (72). Whereas IRE1-mediated splicing of XBP1 mRNA
serves a cytoprotective function, RIDD activity may preserve ER homeostasis or, upon
chronic IRE1-activation, is capable of inducing cell death by apoptosis (69).
ATF6, on the contrary, is a type II transmembrane protein, consisting of a
cytosolic cAMP-responsive element-binding (CREB) or ATF basic leucine zipper (bZIP)
domain. ATF6 is retained within the ER by its association with BiP. When BiP
dissociates from ATF6, it traffics to the Golgi, where it undergoes proteolytic processing

16

Figure 1-6. The three branches of the UPR.
(A-C) Homeostasis and stress within the ER are sensed by three families of ER
transmembrane proteins that relay an ER-to-nuclear signal transduction (ATF6, PERK,
and IRE1) to drive transcription of UPR target genes.
Reproduced with permission from AAAS. Walter P, Ron D. The Unfolded Protein
Response: From Stress Pathway to Homeostatic Regulation. Science.
2011;334(6059):1081-6. doi: 10.1126/science.1209038 (73).
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by Golgi-resident S1P and S2P proteases to generate a transcriptionally active cleaved
ATF6 protein. Cleaved ATF6 mediates the adaptive response of UPR by inducing genes
that serve to increase the protein folding capacity of the ER. PERK-eIF2α signaling
facilitates the selective translation of ATF6, and cleaved ATF6 upregulates XBP1
mRNA, both of which serve as feed-forward loops of the UPR (69). Contrary to the
association characteristics of BiP with either PERK or IRE1, the association of BiP with
ATF6 is rather unique. It has been argued that the association of BiP with ATF6 cannot
support a competitive model where misfolded proteins compete with ATF6 to engage BiP
but is instead a relatively stable association that requires actively restarting BiP’s ATPase
cycle to dissociate it from ATF6 (74).
Marinesco-Sjögren Syndrome
A syndrome characterized by cerebellar ataxia, congenital cataracts, and physical
and mental retardation was first described in 1931 by Marinesco and colleagues (75).
Nearly 20 years later, Sjögren expanded upon the patient population with a similar
phenotype, additionally reporting a hereditary nature of this disease, which was
transmitted in an autosomal recessive manner (76). Thereafter, multiple additional
reports followed, reporting the occurrence of this disease in an equivalent proportion of
males and females and in patients of numerous nationalities and ethnicities. This whole
gamut of symptoms came to be termed as the Marinesco-Sjögren Syndrome (MSS;
OMIM 248800).
MSS is a multisystem disorder. However, the cardinal features used for a clinical
diagnosis include cerebellar dysfunction and ataxia, bilateral cataracts, mental
deterioration, impaired physical development and skeletal deformities, and progressive
myopathy (77). Figure 1-7 displays the relative frequency of signs and symptoms
observed in MSS (78). Cerebellar symptoms represent the most frequent and one of the
earliest clinical presentations of MSS and are characterized by cerebellar ataxia due to
cerebellar degeneration, primarily consisting of Purkinje and granule cell loss (64).
Bilateral cataracts are nearly as frequent as the prevalence of cerebellar ataxia and
precipitate during infancy with an associated visual impairment (Figure 1-7) (77).
Numerous reports have noted varying characteristics of the observed bilateral cataracts,
spanning from fine dot-like depositions to flaky deposits in concentric layers of the
cortex and powdery opacities within the nucleus (77). However, the overall etiology has
remained elusive. Mental retardation in MSS presents as learning disabilities and
regressive tendencies. It is characterized by chronic atrophy of the nerve cells rather than
an inflammatory process, as first reported by Marinesco (75, 77). The atrophy of skeletal
muscles and accompanying hypotonia are also one of the most frequent symptoms of
MSS, and the earliest reports indicate a progressive nature of these symptoms. Myopathy
has been emphasized to be a cardinal feature and an early sign of MSS (79). It is
characterized by variations in fiber size, rounding and hypertrophy, degeneration and
regeneration of fibers, internalization of myonuclei, infiltration of endomysial fat, and
fibrosis (79). Sewry, Voit, and Dubowitz revealed the presence of membranous
autophagic whorls, particularly, a membranous structure surrounding the nucleus (80). A

18

Figure 1-7.

The relative frequencies of signs and symptoms associated with MSS.

Reproduced with permission from Oxford University Press. Krieger M, Roos A, Stendel
C, Claeys KG, Sonmez FM, Baudis M, et al. SIL1 mutations and clinical spectrum in
patients with Marinesco-Sjögren syndrome2013 2013-10-30 00:00:00.
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detailed ultrastructural study by Goto and colleagues further implicated the role of the
autophagy-lysosomal system in the pathogenesis of the MSS-myopathy, indicating an
ongoing autophagic phenomenon and hinting at possible metabolic defects in MSS (81).
They further suggested that myofibrillar degeneration accompanied by autophagy and
rimmed vacuole formation might be the primary reason for the observed muscle
weakness in MSS, in addition to reporting type I fiber predominance, whereas the rare
mitochondrial abnormalities were likely to be secondary consequences (81). This double
membranous structure of possible sarcoplasmic reticular origin, engulfing the nucleus,
came to be recognized as a hallmark of the MSS-associated myopathy (82). However,
the atrophy of skeletal muscle is a distinct feature of this disease, which spares the heart,
a commonly affected system in spinocerebellar degenerative disorders (77). It has also
been reported that the observed myopathy lacks a neurogenic component to it (83, 84).
Thus, Marinesco-Sjögren Syndrome was classified as a distinct disorder, arguably
varying from other disorders with a partially overlapping symptoms, such as Friedreich’s
ataxia, and from spinocerebellar degenerative disorders and myopathies (77).
Nearly 70 years after the first report of MSS, using homozygosity mapping, MSS
was attributed to segregate with the chromosomal locus of 5q31, albeit with some genetic
heterogeneity (85). In subsequent years, two groups independently identified mutations
in the ER co-chaperone SIL1 in MSS patients, with the elimination of SAR1B, which lies
in close chromosomal proximity to SIL1 within the 5q31 locus (64, 86). It was noted that
a subset of these mutations led to premature truncations, which might affect SIL1’s
stability or the stability of its encoding mRNA. Notably, mutations affecting a serinerich region, which lead to an in-frame deletion of exon 6, are also associated with MSS,
indicating an essential role of the encoded domain (64). It was postulated that disruption
of SIL1 might be compensated by the presence of GRP170, the alternative BiP’s cochaperone with NEF-activity, in non-affected tissues (64). Around the same time, Dr.
Susan Ackerman’s group reported that the genetic disruption of Sil1 in mice leads to an
adult-onset cerebellar ataxia, characterized by Purkinje cell apoptosis, intracellular
protein accumulations, and induction of the UPR (Figure 1-8) (87). Sil1-disruption by
either a spontaneous insertion of an ETn retrotransposon into intron 7 or the artificial
insertion of a gene-trap cassette, both of which would disrupt normal splicing and the
transcript beyond exon 7, resulted in an identical cerebellar phenotype. However, the
insertion of the ETn retrotransposon, which would act as a splicing acceptor, would yield
a prematurely truncated protein encoded by a chimeric transcript composed of exons 1-7
of Sil1, 96 nucleotides of the ETn (encoding 32 amino acids), followed by an in-frame
stop codon. On the other hand, the insertion of the gene-trap construct, consisting of a
splicing acceptor, a CD4 transmembrane domain for retaining the β-galactosidase in the
cytosol, and a β-geo cassette for selection, would yield a rather large chimeric protein
encoded by exons 1-7 of Sil1 fused with the gene-trap construct (87). Intriguingly, it was
noted that although Sil1 was widely expressed in the brain, only the cerebellar Purkinje
cells visibly developed protein accumulations and are vulnerable to degeneration, which
does not seem to affect lobule X and ventral lobule IX of the vestibulocerebellum (87).
Sanderek et al. utilized homology mapping and the available crystal structures of the
cytosolic homologs to model the Sil1-BiP interaction. This revealed that exons 6 and 9
encoded Sil1 domains constitute major BiP-binding sites, whereas exon 10 encodes a
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Figure 1-8.

Genetic disruption of murine Sil1 phenocopies MSS symptoms.

The cartoon in the upper schematic depicts the genetic disruption of Sil1 in intron 7 using
a gene-trap cassette. The lower panel indicates that the Sil1Gt mice also develop severe
cerebellar atrophy, offering great promise to study MSS in depth since they recapitulate
many of the symptoms observed in this disease.
The lower panel has been reproduced with permission from Nature Publishing Group.
Zhao L, Longo-Guess C, Harris BS, Lee JW, Ackerman SL. Protein accumulation and
neurodegeneration in the woozy mutant mouse is caused by disruption of SIL1, a
cochaperone of BiP. Nature genetics. 2005;37(9):974-9. doi: 10.1038/ng1620. PubMed
PMID: 16116427.
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minor-BiP interaction site, and mutations affecting these domains are likely to affect the
characteristics of the Sil1-BiP interaction (86). This model was later confirmed by
structural insights into the Sil1-BiP interaction (45). Sanderek et al. further suggested
that a compromised Sil1 would affect BiP’s ATPase dependent functions, such as
translocon gating or protein folding, which might cause an activation of the UPR and
trigger cell death (86). These studies, together, implicate SIL1 as the causative gene in
classical MSS and suggest protein folding and biosynthesis defects to be an essential part
of the observed pathology in MSS.
In a follow-up study to address the genetic heterogeneity observed in MSS,
Anttonen and colleagues ruled out the possibility that MSS could also be caused by
mutations in either BiP (HSPA5), GRP170 (HYOU1), or amino-acyl tRNA synthetase
(AARS) (88). In addition, they detected that in vitro expression of certain C-terminal
SIL1 mutations, such as the Leucine to Proline conversion at residue 457 (p.L457P),
results in the aggregation of SIL1 itself, signifying that SIL1 is a metastable protein and
its C-terminus is particularly vulnerable to alterations in its protein sequence (88).
Indeed, mutations that specifically affect the C-terminal five or six amino acids,
postulated to be a divergent ER-retention motif, revealed that these changes particularly
destabilize SIL1, resulting in rapid proteasomal-mediated clearance or aggregation within
the ER (89). This result is in agreement with SIL1-modeling, which reveals that the very
C-terminus plays an essential role in its structural integrity rather than a role in localizing
SIL1 to the ER (89). At least subset of SIL1 mutations, which retain BiP-interaction sites
but yield unstable proteins, might represent promising candidates for pharmacological
stabilizing agents. Additionally, in support of this hypothesis, an in-frame deletion of
two amino acids (p.V231_I232del), five amino acids (p.R411_D415del), or a single
amino acid substitution (p.G312R), have disastrous consequences on SIL1’s stability, and
either exacerbate its stability or its aggregation propensity (78, 90). Thus, SIL1 was
identified to be the major MSS-causing gene (78).
It has been reported that the primary cause of classical MSS and an MSS-like
disease in mice are loss-of-function mutations in the ER co-chaperone, SIL1, which leads
to a multisystem disorder characterized by accumulation of protein aggregates, induction
of the UPR, involvement of the autophagy-lysosomal system, and apoptotic cell death
(64, 86, 87). However, the underlying precise molecular events and mechanisms by
which loss of a component of BiP’s co-chaperone arsenal triggers the observed defects
and pathologies has not been well understood. A rather challenging and complex
question that remains unanswered till date is why only certain tissues or certain parts of a
tissue are affected in MSS and are particularly vulnerable to imbalances in cellular
protein homeostasis (proteostasis), even though SIL1 is ubiquitously expressed (63, 64).
Furthermore, the tissues displaying the highest expression of SIL1 are not generally the
most severely affected tissues in MSS or in woozy mice. In addition, it remains poorly
understood why the alternative NEF for BiP, Grp170, which is also a bona fide molecular
chaperone, is not able to compensate for the loss of SIL1 to an extent that is capable of
preventing pathology (44, 50, 53). Interestingly, only transgenic overexpression of
Grp170 has been shown to rescue the cerebellar pathology observed in Sil1-deficient
mice, whereas decreasing its expression exacerbates this phenotype (91). In addition, it
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has been postulated that the cell might modulate its levels of ERdjs to achieve slower
BiP’s ATPase cycling, which might improve protein folding in the face of BiP’s ATPase
cycling deregulation due to loss of Sil1. Indeed, a concomitant loss of Dnajc3/ERdj6
with that of Sil1, ameliorated ER stress and rescued neurodegeneration in Sil1-deficient
mice (91). It has already been established that the two NEF’s of BiP mechanistically
differ in their NEF activity (65). However, functional differences in the BiP clientele
they assist have largely evaded discovery. There are 46 MSS-associated mutations
reported to date, a majority of which consist of frameshifts or premature truncations.
However, an interesting subset results in the alteration of only a few amino acids in the
native SIL1 sequence, offering the opportunity to dissect the significance of these
residues in either supporting SIL1’s structural integrity or functional abilities, and further
inquiring if pharmacological modulators of the protein folding landscape are able to
rescue structural and stability defects in the case of specific SIL1 mutations.
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CHAPTER 2. SIL1, A NUCLEOTIDE EXCHANGE FACTOR FOR BIP, IS NOT
REQUIRED FOR ANTIBODY ASSEMBLY OR SECRETION*
Introduction
It has been estimated that one-third of the human genome encodes proteins that
will populate the single membrane bound organelles of the cell or that will be secreted or
expressed at the cell surface. These proteins are translocated into the endoplasmic
reticulum (ER) lumen as they are synthesized and often undergo modifications and fold
co-translationally. The proper maturation of these proteins is both assisted and monitored
by the resident molecular chaperones of this organelle to prevent off-pathway folding,
which might lead to aggregation, and to ensure that only those molecular forms of the
newly synthesized proteins that can pass ER quality control measures are permitted to
leave the ER for their proper destination (1, 92). Until that time, nascent proteins are
retained in the ER via their interaction with molecular chaperones, and those proteins that
ultimately fail to mature properly are retrotranslocated to the cytosol where they are
marked for degradation by the ubiquitin proteasome system. Two major chaperone
families exist in the ER; the Hsp70 family member BiP and its co-factors, and the lectin
chaperones, calnexin and calreticulin and their attendant co-factors.
Like other Hsp70 family members, BiP is composed of an N-terminal nucleotide
binding domain (NBD) and a C-terminal substrate binding domain (SBD) that
communicate with each other via a linker region. The binding of BiP to substrates is
regulated by its nucleotide bound state (57, 93-95). When ATP occupies the NBD, the
lid of the SBD is open allowing ready access to extended regions of nascent proteins or
substrates, but this open conformation does not promote stable binding. However, the
binding of substrate to the SBD triggers ATP hydrolysis, which in turn induces at least
partial closing of the lid over the bound substrate and stabilizes this association (57, 94).
The substrate does not fold while bound to BiP but is protected from off-pathway
intermediates or aggregation. The lid of the SBD must be re-opened to release the
substrate so it can fold, which requires the bound ADP to be exchanged for ATP.
Although three different structurally unrelated groups of nucleotide exchange factors
(NEFs) exist in the cytosol of eukaryotic organisms, only two types, each with a single
representative, have been identified in the ER: the HSPBP1 orthologue, BAP/SIL1 (63,
96), and the large Hsp70 member, Grp170 (48, 50). While SIL1 seems to only function
as a NEF, the large Hsp70 proteins, including Grp170, also bind directly to substrates
(44, 54, 97, 98), making their functional activity more complex and currently less clear.
Structural analysis of yeast Sil1p reveals that it binds to the NBD of BiP and disrupts a
-------------------*Reprinted from final submission with permission. Ichhaporia, V. P., Sanford, T.,
Howes, J., Marion, T. N., & Hendershot, L. M. (2015). Sil1, a nucleotide exchange factor
for BiP, is not required for antibody assembly or secretion. Molecular Biology of the
Cell, 26(3), 420–429.
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hydrogen bond between the two lobes, which results in a rearrangement of the NBD that
induces the release of ADP from BiP (45). Based on homology mapping with the
cytosolic orthologue HspBP1, exons 6 and 9 of SIL1 are predicted to constitute the major
interaction site with the NBD of BiP with exon 10 providing a minor interaction (86).
Mutations in the SIL1 gene have been found in over half of the cases of
Marinesco-Sjögren syndrome (MSS) (64, 86), an autosomal recessive disease
characterized by multi-system defects including ataxia due to Purkinje cell loss, cataracts,
and progressive myopathy (76, 78). MSS-associated mutations occur throughout the
SIL1 gene and most lead to the disruption of significant portions of the protein (88, 99),
although the fate of most of these fragments has not been well-characterized. In fact, it
remains unclear whether the associated pathologies arise from reduced maturation of
essential secretory pathway proteins, depletion of BiP stores resulting in activation of the
ER stress response, toxicity due to aggregation of secretory pathway proteins, or even
perhaps of the mutant SIL1 protein itself. Three MSS-associated mutations have been
identified that disrupt only the last 4 or 5 amino acids, which were shown to reduce the
solubility of the mutant proteins and decrease their stability leading to significantly
diminished expression of mutant SIL1 (88, 89). Although a SIL1-null mouse is not
available, the gene has been disrupted spontaneously by transposon insertion, Sil1wz, and
by gene-trap methodology, Sil1Gt (87). In both cases, the Sil1 gene is disrupted between
exons 7 and 8, resulting in loss of amino acids 261-465 of the SIL1 protein. The
resulting mice are referred to as woozy mice and have been reported to phenocopy some
of the pathologies associated with MSS including cerebellar loss resulting in ataxia (87)
and a progressive myopathy (100). Examination of cerebella from these mice revealed
the presence of protein aggregates and activation of the ER stress response, which is
induced by the accumulation of unfolded proteins in this organelle.
To begin to understand the effects of Sil1 gene disruption on secretory pathway
protein maturation, we chose to examine the assembly and secretion of immunoglobulins,
which are the best studied BiP substrates (20, 21, 101-103). Immunoglobulin is a
heteromeric protein composed of two heavy and two light chains (HC and LC,
respectively) that are combined in the ER. BiP binds to all the assembly intermediates
and prevents their secretion, but does not interact with completely assembled complexes
(21, 102). Co-expression of BiP mutants that cannot be released from Ig heavy chains
with ATP prevents the assembly and secretion of antibodies (57, 104), suggesting a NEF
might be required for this process normally. Lastly, we considered that the incredibly
large quantities of antibodies produced by plasma cells, which puts particularly high
demands on ER homeostasis, would make these cells particularly sensitive to disruptions
in the chaperone network. Together these points argue that antibodies would represent a
good model to examine the requirements for a nucleotide exchange factor in BiPmediated folding. The availability of a mouse model with a disrupted Sil1 gene and
Epstein–Barr virus (EBV) transformed B lymphoblastoid lines (LBLs) from individuals
with MSS provide important biological tools for examining the effect of SIL1 protein
loss on antibody assembly and secretion both in vivo and ex vivo, which in addition to
establishing the requirement for SIL1 in Ig assembly and secretion could also shed light
on humoral immune function in patients.
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Results
Detection of disrupted Sil1 transcripts in woozy mice
The Sil1 gene has been disrupted beyond exon 7 in woozy mice by either a
spontaneous insertion of an ETn retrotransposon, Sil1wz, or the insertion of the β-geo
gene-trap cassette, Sil1Gt (87). In both cases, exon 7 is spliced to the inserted gene
generating a fusion protein that should possess the N-terminal 260 amino acids (out of a
total 465 amino acids) encoded by the Sil1 gene followed by either 32 amino acids of the
transposon or a CD4 transmembrane region and a β-geo cassette, respectively (Figure
2-1). In spite of the very different fusion proteins generated in these two woozy mice, the
phenotypes appear to be very similar suggesting both may lead to a loss of functional
SIL1 protein. Importantly, the chimeric product of neither SIL1 disruption has been
examined, but a truncated version of SIL1 possessing only the N-terminal 260 amino
acids was expressed in COS-1 cells. This mutant is less stable and binds BiP with a
reduced affinity compared to the wild-type SIL1 protein (87). As Sil1 expression had not
been previously measured in plasmablasts and previous reports suggest that levels can
vary significantly between various tissues in humans (63) and mice (105), we first
examined SIL1 transcript levels in day 4 LPS stimulated splenic B cells from wild-type
and woozy mice by real-time PCR. Primers were selectively designed to amplify regions
that are either shared by the Sil1WT and Sil1Gt transcripts (primer pair 1) or are present
exclusively in Sil1WT transcripts (primer pair 2) (Figure 2-1). For reasons that are
unclear, we found that Sil1Gt transcripts were present at only a third of the level of the
wild-type SIL1 transcripts. As expected, the SIL1 transcripts from the Sil1Gt mouse
could not be amplified with the primer pair extending across exons 9 and 10,
demonstrating that the plasmablasts are indeed derived from Sil1Gt homozygous mice as
opposed to mis-genotyped heterozygous mice. All mice used for immunizations and LPS
stimulation assays were genotyped at least three times to ensure accuracy of genotypes
being used.
Characterization of immune populations in wild-type and woozy mice
We first examined the effects of Sil1 disruption on the distribution of cellular
subpopulations present in the spleen and thymus. The relative percent of CD3+/CD4+ T
helper and CD3+/CD8+ cytotoxic T-lymphocytes, B-lymphocytes (B220+), macrophages
(Mac1+), granulocytes (Gr1+) and natural killer cells (NK1.1+) were very similar between
wild-type and Sil1Gt mice (Figure 2-2A). Thymocytes were stained for a variety of
markers to identify the various developmental stages of T-cell populations in the Sil1Gt
mouse compared to their wild-type littermates (Figure 2-2B, C). We observed no
significant helper and CD3+/CD8+ cytotoxic T-lymphocytes, B-lymphocytes (B220+),
macrophages (Mac1+), granulocytes (Gr1+) and natural killer cells (NK1.1+) were very
similar between wild-type and Sil1Gt mice (Figure 2-2A). Thymocytes were stained for a
variety of markers to identify the various developmental stages of T-cell populations in
the Sil1Gt mouse compared to their wild-type littermates (Figure 2-2B, C). We observed
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Figure 2-1.

Schemes for quantifying SIL1 mRNA and genotyping mice.

(A) Schematic of expected SIL1 transcripts produced in Sil1WT and Sil1Gt mice with
location of the primer pairs used for amplifying cDNA. (B) The relative mRNA levels of
SIL1 in day 4 LPS-stimulated splenic B cells were analyzed by real-time PCR with the
indicated primer pairs. The region amplified by primer pair 1 is shared between Sil1WT
and Sil1Gt transcripts, whereas the product of primer pair 2 is exclusively present in
Sil1WT transcripts; thus Sil1Gt transcripts are not detected. (C) Schematic displaying the
insertion of the β-geo gene-trap cassette into intron 7 (not to scale) with location of
primer pairs used for genotyping mice.
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Figure 2-2. Disruption of Sil1 gene does not affect splenocyte or thymocyte
populations.
(A) Single cell splenocytes from wild-type (black bars) and woozy mice (gray bars) were
stained with the indicated antibodies, subjected to FACS analyses, and expressed as a
percent of nucleated, singlet splenic cells. (B, C) Thymocytes from wild-type and woozy
mice were stained to identify developmental subpopulations and similarly portrayed.
Error bars indicate means ± s.d.
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no significant differences in the numbers of any of the developmental stages of T-cells.
Thus, disruption of the Sil1 gene did not appear to affect the maturation or survival of any
of the indicated immune populations.
Sil1Gt mice produce normal levels of antigen-specific antibodies in response to
immunization with a T-dependent antigen
Although mature B and T cell subpopulations in the woozy mouse appeared
normal, we examined their ability to respond to immunization with the T-dependent
antigen, NP15-KLH. Ten wild-type and ten woozy mice were immunized and boosted 2
weeks later. Sera were obtained at the indicated days post-immunization, and NP15-KLH
specific antibodies were quantified to detect differences in either the magnitude or
kinetics of antibody production. We chose to measure three antibody isotypes, including
two that assemble via the H→HL→H2L2 pathway (IgM and IgG2b) and one that
assembles through H→H2→H2L→H2L2 intermediates (IgG1). Since heavy chains
remain incompletely folded until they associate with light chains (101), we reasoned that
antibodies assembling through the latter pathway might be more dependent on BiP and as
a result show a greater need for functional SIL1. Somewhat surprisingly, we found that
there was no significant difference in either the magnitude or kinetics of producing IgM,
IgG2b, or IgG1 antibodies to NP15-KLH (Figure 2-3). This argued that the loss of SIL1
function did not prevent the secretion of antibodies regardless of their route of assembly.
LPS-stimulated B cells from Sil1Gt mice synthesize and secrete IgM antibodies
similar to wild-type littermates
We next examined Ig synthesis in purified murine splenic B cells stimulated with
LPS ex vivo. This allowed us to directly examine Ig secretion over a shorter time span
and to determine whether unassembled immunoglobulin chains accumulated in the
woozy splenocytes. Isolated splenic B cells were cultured with LPS, and cells and
culture supernatant were isolated every day, for four days. There was no significant
difference in the growth rate of stimulated B cells from woozy mice compared to their
wild-type littermates (data not shown). Western blot analysis of cell lysates revealed
robust up-regulation of the secretory type of IgM heavy chains (Ps) and N light chain in
both wild-type and woozy mice to very similar levels (Figure 2-4A). When culture
supernatants were analyzed for secreted IgM, similar levels of μ heavy and κ light chains
were readily detected after two days of stimulation and continued to increase throughout
the course of the experiment in both cases (Figure 2-4B). We determined the assembly
status of IgM present in the splenocytes after 3 and 4 days of LPS stimulation on nonreducing gels. Under steady state conditions, the μ heavy chains in the cells from both
wild-type and woozy mice were present predominantly as H2L2 monomers and H2L2
polymers, which are likely to be pentamers, although a polymeric intermediate can be
detected with both anti-μ and anti-κ antisera (Figure 2-4C). Trace amounts of HL
hemimers and LC dimers were detected. However, there was no evidence that
unassembled or incompletely assembled Ig molecules accumulated in plasmablasts from
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Figure 2-3. Sil1Gt mice respond to T-dependent antigens similarly to age-matched
Sil1WT mice.
Sil1WT (black line) and Sil1Gt (gray line) mice were challenged with NP15-KLH as
described, and serum was collected at the indicated intervals. Red arrow indicates the
booster immunization. Antigen-specific responses comprised of IgM (A), IgG1 (B) and
IgG2b (C) were determined by ELISA. Each point displays the median value. N=10
Sil1WT and Sil1Gt mice each. Error bars indicate interquartile range of values.
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Figure 2-4. Disruption of Sil1 gene does not adversely affect IgM biosynthesis or
secretion in response to ex vivo LPS stimulation.
Isolated splenocytes were cultured with LPS for the indicated times, and lysates
corresponding to equivalent numbers of cells were analyzed under reducing (A) or nonreducing (C) conditions followed by blotting with the indicated immune reagents. Actin
served as a control for loading. (B) Culture supernatants corresponding to an equivalent
number of cells for each day were immunoprecipitated with anti-μ HC antibody,
analyzed by reducing SDS-PAGE, and probed with the indicated antibodies. The center
lane contains only the immunoprecipitating antibody (Ppt Ab), which is recognized by
the secondary antibody used to identify the mouse κ LC. Its mobility is designated with
asterisks on the left.
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the woozy mice to a greater extent than observed in the wild-type cells. To assess
whether unassembled IgM was aggregating in these cells, we examined the NP-40
insoluble fraction for the presence of IgM. Very small amounts of insoluble N light
chains and μ heavy chains could be detected in the differentiating splenic B cells, but the
levels of both were very similar in the two genotypes (Figure 2-5A). Thus, we found no
evidence that the woozy mice were compromised in their ability to assemble or secrete
antibodies, suggesting that SIL1 was not required to release BiP from immunoglobulin
heavy chains.
Sil1 disruption does not affect chaperone levels in LPS stimulated B cells
Our examination of day 4 LPS-simulated splenic B cells revealed that SIL1
transcripts were present in wild-type cells and in lesser amounts in the woozy cells
(Figure 2-1). Most ER molecular chaperones and resident proteins are normally upregulated during plasma cell differentiation (106, 107). This occurs via activation of a
limited UPR (108, 109), which serves to maintain homeostasis in the dramatically
expanded ER in preparation for the massive production of antibodies. However, since
Sil1 is not induced by the UPR (63), we considered the possibility that the SIL1 protein
expression remained unchanged during plasma cell differentiation and therefore did not
contribute significantly to BiP-mediated folding in these cells. To address this
possibility, we examined SIL1 protein levels in the wild-type and woozy mice over the
course of LPS-induced differentiation. Although basal levels were quite low in the
unstimulated splenic B cells, SIL1 protein became readily detectable over the course of
differentiation in the wild-type plasmablasts (Figure 2-6A). However, when the
differentiating woozy splenocytes were examined with this antibody, we were unable to
observe a unique band in the region corresponding to the predicted molecular weight for
the chimeric Sil1Gt protein (Figure 2-5B).
The loss of SIL1-function in mouse Purkinje cells leads to activation of the
unfolded protein response (UPR), which results in higher than normal levels of some ER
chaperones including Grp170, and eventually to cell death (87). Both of these
consequences could be prevented by transgenic over-expression of Grp170 (91), which
has both nucleotide exchange (48, 50) and chaperone activity (44, 110). Thus, we wished
to determine if the loss of SIL1 might be compensated by an even greater increase in
expression of Grp170 or other chaperones during plasma cell differentiation. When cell
lysates from wild-type and woozy LPS-stimulated splenic B cells were examined, the upregulation of Grp170 and other chaperones like Grp94, calnexin, and calreticulin, all of
which have been reported to bind μ heavy chains (97, 111, 112), appeared to be very
similar (Figure 2-6A, B). Thus, unlike the Purkinje cells of the woozy mouse, there was
no compensating over-expression of Grp170 or any other ER chaperone examined.
The ER also possesses a number of DnaJ-like co-factors that serve to bind
unfolded protein substrates and deliver them to BiP (55). A previous study reported that
deletion of one of the ER-localized ERdj proteins in the Sil1Gt mice partially suppressed
the Purkinje defects associated with Sil1 disruption (91), perhaps due to decreased
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Figure 2-5. Disruption of Sil1 does not increase Ig heavy or light chain
aggregation.
(A) NP-40 insoluble proteins were solubilized in SDS and equivalent fractions of the
SDS-solubilized (Insol.) and NP-40 soluble (Sol.) material were electrophoresed under
reducing conditions and probed with the indicated antibodies. Exposure times for NP-40
soluble and insoluble material are identical. (B) Full membrane of the SIL1 panel used in
Figure 2-4A probed with an anti- SIL1 antibody from Proteintech. The region
corresponding to the predicted molecular weight for the Sil1Gt protein is indicated. Note
the membrane was previously cut for probing with different antibodies. The cut line is
indicated with an arrow.
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Figure 2-6.
Sil1Gt mice.

Chaperone levels are unaltered during plasmablast differentiation in

Direct cell lysates were prepared, electrophoresed under reducing conditions as described
in Figure 3, and probed with the indicated antibodies to molecular chaperones (A,B) and
BiP co-factors (C-E). As samples were run on different gels a loading control is included
for each. The anti- SIL1 antibody used in panel (A) was purchased from Proteintech.
The anti-calreticulin antibody (CRT) used in panel B detected an additional unknown
band only in the unstimulated splenocytes, which is indicated with an asterisk.
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transfer of substrates to BiP. Therefore, we compared levels of several of the resident ER
DnaJ proteins during differentiation. All three ERdj proteins examined were similarly
up-regulated in wild-type mice and their woozy littermates in response to plasma cell
differentiation (Figure 2-6C-E). This includes ERdj3, which is specific for Ig heavy
chains (113) and ERdj5, which also interacts with unassembled Ig heavy chains (our
unpublished data). Thus, there is no evidence that the loss of SIL1 function is
compensated by increasing Grp170 levels or decreasing these ERdj BiP co-factors.
Immunoglobulin synthesis is not relegated to a different chaperone system in SIL1
disrupted splenic B cells during differentiation
Although we saw no evidence that woozy mice compensated for the loss of SIL1
function by abnormally up-regulating Grp170 or altering the expression of other ER
resident proteins, it was conceivable that in the absence of SIL1, immunoglobulin
synthesis was controlled by another ER chaperone. Notably, Grp94 (112) and Grp170
(44, 97) can bind directly to immunoglobulin chains as a chaperone, and the lectin
chaperones have also been demonstrated to interact with μ heavy chains (111). To
determine if IgM antibodies were relying on another chaperone for its assembly, we
performed pulse-chase experiments on splenic B cells that were stimulated with LPS for
2 days and prepared cell lysates under conditions most conducive to maintaining
association of client proteins for each of the chaperones. For BiP and Grp170, lysates
were prepared with apyrase or Mg2+-ATP respectively, while for Grp94, calnexin and
calreticulin no supplements were added. When the pulse-labeled samples were examined
(Figure 2-7 A, B) there was no evidence of μ heavy chains co-precipitating with Grp170,
Grp94, calnexin or calreticulin in either genotype above the background observed with
Protein A agarose, and consequently no μ heavy chains were co-isolated with the
chaperones immunoprecipitated from chase samples (Figure 2-7C, D). This strongly
argues that IgM antibodies were not utilizing one of these chaperones in the Sil1Gt cells.
The fact that μ heavy chains and BiP migrate identically on these gels made it impossible
to determine if the heavy chains were interacting with BiP in both genetic backgrounds,
although the signal in the BiP immunoprecipitated material appeared slightly more sharp
and less strong in the chase sample compared to the pulse. To determine if μ heavy
chains were interacting with BiP in the Sil1Gt cells, we performed immunoprecipitation
coupled to western blotting assays. We found the secretory form of μ (μs) coimmunoprecipitated with BiP, and correspondingly BiP was co-isolated with anti-μ
precipitated material in plasmablasts from both wild-type and woozy mice (Figure 2-8).
Thus, although SIL1 was dispensable for IgM production, it was not because BiP was not
used during Ig assembly in the Sil1Gt cells. Together these data demonstrate there is no
evidence antibodies are dispatched to a different chaperone system when SIL1 is not
available to release BiP from Ig heavy chains nor do unassembled heavy chains remain
bound to BiP in these cells.
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Figure 2-7.
system.

Loss of SIL1 does not redirect IgM assembly to another chaperone

LPS stimulated splenic B cells from day 2 were pulse labeled with 35S methionine and
cysteine and chased for 0 or 1 hour. (A,C) Aliquots of the cells were lysed with apyrase
(lanes 1-3 and 8-10), without apyrase (lanes 4-7 and 11-14), or (B,D) with the addition of
Mg2+-ATP (lanes 1-3 and 5-7). The lysates and media (m) were immunoprecipitated
with the indicated antibodies and analyzed by reducing SDS-PAGE. The migration of
these chaperones are denoted with the following symbols; BiP (*), Grp94 (§), calreticulin
(‡), and calnexin (#), and mobility of heavy and light chains are indicated.
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Figure 2-8.
chain.

Disruption of SIL1 does not alter BiP’s interaction with the Ig heavy

Splenic B cells were stimulated with LPS for 2 days and lysed in the presence of apyrase.
Cell lysates were immunoprecipitated as indicated, separated on reducing SDS-gels, and
blotted with antibodies against μ HC (A) or BiP (B). For lanes 1 and 4 in both cases, 1/10
the amount of lysate was immunoprecipitated compared to lanes 2, 3, 5, and 6.
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Antibody assembly and secretion are normal in lymphoblastoid lines from
individuals with MSS
We were surprised to find that there was no aspect of antibody production in vivo
or ex vivo that was affected by SIL1 disruption, even though these woozy mice have
profound defects in a variety of other tissues (91, 100, 105). Since the immune systems
of mice and man do not always function identically (114), we obtained lymphoblastoid
lines produced from three related individuals with MSS and two non-affected relatives
(115). In sequencing genomic DNA to verify the alteration of the Sil1 gene, we
discovered a novel mutation in the 5’ GT-rich region of the splice donor site of intron 9
(c.1029+6T>C) in addition to the previously reported c.1030-18G>A mutation, 18 bases
upstream of exon 10 (115) (Figure 2-9A). Sequencing of cDNA confirmed that this
resulted in aberrant splicing of exon 9 causing a frameshift after Lys 343 and a premature
stop 13 amino acids later (Figure 2-9B). Western blot analyses of these lines revealed
that all three of the MSS cell lines produced both heavy and light chains, which would
allow us to examine Ig assembly and secretion (Figure 2-9C). Using both our polyclonal
antiserum raised to the full-length SIL1 protein and an antibody that was raised to a
region of SIL1 that is retained in the predicted MSS protein, we were unable to detect the
mutant SIL1 protein under steady state conditions in any of the MSS lines (Figure
2-10A), suggesting that either the mutant protein is not readily translated or is unstable.
To test this possibility, a control and MSS patient-derived lymphoblastoid cell lines were
incubated with and without MG132 to prevent proteasomal degradation. A faint band
corresponding to the predicted size of the SIL1 mutant protein could be detected only
after inhibiting degradation indicating that the truncated MSS-associated protein was
unstable (Figure 2-10B). There was no visible change in the expression of Grp170, BiP
or calreticulin (Figure 2-10A), which is in keeping with our data from the LPSstimulated murine plasmablasts (Figure 2-5). To examine Ig assembly and secretion, we
chose MSS lines #1 and #2, which both produced IgG antibodies that assemble through
the H→H2→H2L→H2L2 pathway, as well as one of the control lines that used the same
Ig assembly pathway. Pulse-chase experiments revealed that both MSS cell lines were
able to readily assemble and secrete IgG antibodies and that there was no evidence of
incompletely assembled precursor molecules accumulating in the cells (Figure 2-11).
Together, these data indicate that SIL1 protein/function is not required for BiP release
from antibodies during their production.
Discussion
SIL1 is not required for Ig assembly or secretion
Mutations in SIL1 in individuals with Marinesco-Sjögren syndrome results in
multiple system defects (84, 99, 116, 117), many of which are phenocopied by disrupting
this gene in mice (87, 100). To begin to understand the consequences of losing SIL1
function on the release of substrates from BiP, we turned to immunoglobulins, which can
be studied in vivo and ex vivo, allowing greater scrutiny of the process. Surprisingly, we
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Figure 2-9. Characterization of Lymphoblastoid cell lines from normal controls
and MSS affected individuals.
(A) Sequencing of the Sil1 gene revealed a previously unreported substitution
(c.1029+6T>C) in intron 9 (left panel) in addition to the reported homozygous mutation
(c.1030-18G>A) in this intron, which creates an aberrant splice acceptor site (right panel)
in these MSS patients. The electropherograms of a wild-type control (top) and an
affected individual (bottom) are shown. (B) Schematic representation of the region
affected by the mutations on the SIL1 protein (blue), including the non-related amino
acids resulting from the frameshift (yellow), which are listed below in red and italicized.
The bar under the schematics indicates the portion of the protein used by LifeSpan
Biosciences to generate the anti- SIL1 antibody, which is retained in this SIL1 mutant
protein. (C) Direct cell lysates from the indicated LBLs were electrophoresed under
reducing conditions and blotted with the indicated immune reagents. Isotypes produced
by the cell lines are indicated below each lane.
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Figure 2-10. Disruption of Sil1 gene in MSS-patient-derived LBLs does not
adversely affect the levels of ER chaperones.
(A) Direct cell lysates were prepared for western blotting and probed with the indicated
antibodies to ER chaperones. Our rabbit polyclonal antiserum was used to detect SIL1
protein here, but similar results were obtained with the antibody from LifeSpan
Biosciences. The anti-human BiP reagent recognizes a non-specific band that is denoted
with a single black asterisk. The expected mobility of the SIL1 truncated protein
generated in the MSS cell lines (Sil1**) is indicated. (B) A control and MMS
lymphoblastoid line were treated with MG132 (+) for 5 hours or left untreated (-).
Lysates were prepared for western blotting and directly analyzed with an anti- SIL1
antibody from Proteintech. A band migrating with the predicted molecular weight for
this mutant SIL1 protein (Sil1**) can be detected in the MSS line after proteasomal
inhibition.

40

Figure 2-11. B Lymphoblastoid cell lines produced from individuals with
Marinesco-Sjögren syndrome synthesize and secrete IgG antibodies normally.
One control and two LBL lines from MSS individuals that produce IgG were pulse
labeled with 35S methionine and cysteine and chased for the indicated times. Cell lysates
were immunoprecipitated with anti-γ heavy chain and electrophoresed under reducing
(A) or non-reducing (C) conditions. Culture supernatants were similarly
immunoprecipitated and analyzed under reducing conditions (B).
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found no evidence that B cell development was affected nor was there a decrease in
either the kinetics or magnitude of antibodies produced in response to antigen stimulation
in vivo or LPS stimulation of purified splenic B cells for any isotype analyzed. This was
not due to the fact that plasma cells do not make SIL1 protein, as we observed increases
in this NEF during the course of differentiation in wild-type plasmablasts and
lymphoblastoid lines from control individuals had readily detectable amounts of SIL1.
We did not detect any unique changes in the complement of ER chaperones induced
during plasma cell differentiation or any evidence that another chaperone system was
utilized to support antibody synthesis in the absence of SIL1. Contrary to our findings
one recent report on an individual with MSS noted decreased levels of serum IgG2 and
IgA, but not IgM (118). However, based on the fact that recurrent infections are not
included in common symptoms experienced by MSS patients (78) and our data on normal
Ig production in LBL cell lines from affected individuals, it seems more likely that the
reduced levels of Ig in this patient were unrelated to the loss of SIL1 function.
How is BiP released from Ig subunits to allow their assembly when SIL1 is absent?
An obvious candidate for releasing BiP is Grp170, the resident ER large Hsp70
family member, which also possess nucleotide exchange activity (50). A recent study in
yeast on the cytosolic orthologues of Grp170 and SIL1, Sse1 and Fes1 respectively,
found that Sse1 was more critical for both protein folding and degradation, whereas
neither protein was required for renaturation of heat-aggregated proteins (119).
However, we did not detect an increase in Grp170 expression in the woozy splenic B
cells above that which normally occurs during plasma cell differentiation, which is in
contrast to the findings with Purkinje cells (91) and muscle tissue (100) from woozy
mice. It is possible that sufficient levels of Grp170 are already present in the
plasmablasts to induce the release of BiP from assembling antibodies. There are
currently no data to establish relative levels of Grp170 versus SIL1 in a variety of tissues,
to assess whether the loss of SIL1 might be felt more acutely in some tissues than others.
A previous analysis of tissue blots from our lab found that SIL1 transcript levels were
particularly high in placenta, liver, kidney, skeletal muscle, and heart (63). With the
exception of a progressive myopathy, these represent tissues that are not usually affected
in MSS patients (78, 99). A closer examination of relative levels of SIL1 and Grp170 in
tissues that are affected by SIL1 loss compared to those that are not might shed light on
this possibility. Alternatively, it is conceivable that additional BiP nucleotide exchange
factors exist in the ER that have not yet been identified, which could compliment the loss
of SIL1 in plasma cells and other non-affected tissue. The eukaryotic cytosol expresses a
third family of NEFs, the Bag1 proteins (120), but there are no obvious ER orthologues
in the mammalian databases. Lastly, we have considered the possibility that the
association of LC is sufficient to by-pass the need for BiP or to displace wild-type BiP
without requiring nucleotide exchange. In the case of IgM and IgG2b, where LC can
bind the HC co-translationally driving assembly through the H→HL→H2L2 pathway, it is
conceivable that the requirement for BiP, and thus for a nucleotide exchange factor is
relatively small. However, we also found that both mouse and human IgG subclasses that
combine through the H→H2→H2L→H2L2, which interact with BiP throughout the
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assembly process, were equally unaffected, making this possibility less viable but as yet
untested in vitro.
Why do SIL1 disrupted mice and MSS patients have defects that only appear to
affect some systems?
The dependence of only some tissues on SIL1 remains one of the puzzling
manifestations of the disease and of the phenotypes observed in woozy mice. In fact, it
appears that highly secretory organs like the pancreas, liver, and plasma cells, where one
might expect adverse consequences when a component of the chaperone machinery is
lost, are relatively less affected by SIL1 loss. Instead the effects are greatest in the
Purkinje cells of the cerebellum, the eye lens, and skeletal muscle (78), which are not
associated with the production of large amounts of secretory proteins that are BiP
substrates. Perhaps the more classical secretory tissues are better able to respond to or
accommodate changes in the client load of the ER. It is conceivable that there is some
BiP:client specificity for the two NEFs of the ER, but this has yet to be demonstrated in
any organism, organelle, or system.
Another interesting possibility is that the various clinical symptoms associated
with MSS represent a progressive inability to maintain ER homeostasis with aging, which
might occur at distinct times in various tissues, a phenomenon referred to as proteostasis
collapse (121). In support of this possibility, the Purkinje cell loss leading to ataxia and
the progressive myopathy associated with MSS and woozy mice can occur with quite
different kinetics. While we have not rigorously examined immune responses in aged
Sil1Gt mice, we quantified splenic populations in a 22-month-old mouse and found no
significant differences in any subpopulations (data not shown). However, one of our
aged Sil1Gt mice experienced a severe infection with Pasteurella pneumotropica, which
usually only occurs in immunodeficient mice (122). As sufficient numbers of our Sil1Gt
mice age, we intend to revisit the ability of older mice to produce antibodies.
In summary, we have conducted a rigorous study of the effects of SIL1 loss on the
synthesis of antibodies, the best characterized BiP-dependent substrate. We found no
change in either the magnitude or kinetics of antigen or LPS-stimulated production of
antibodies in the Sil1Gt mice compared to age-matched littermates. Furthermore, there
was no evidence that the other ER NEF, Grp170 was abnormally up-regulated or that a
different chaperone system was used to synthesize antibodies. Similar data were
obtained with lymphoblastoid cell lines produced from individuals with MSS. We
conclude that although loss of SIL1 in humans and mice can cause serious multi-system
defects, these are not extended to the production of antibodies.
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Materials and Methods
Generation of wild-type and Sil1-disrupted mice
The Sil1 gene-trap mouse strain B6;129Sil1Gt (pGT2TMpfa)1Slac was kindly provided
by Dr. Susan Ackerman (87). Sil1Gt heterozygous mice were crossed to generate
homozygous woozy mice and wild-type littermates. At 3 weeks of age, DNA was
isolated from mouse tail snips and genotyped as reported (87). The primers for the wildtype allele were: 5’-CTATAGCCCGCCTCAGGAGTGTTGTA-3’ and 5’ATTGCCCCATAGAGCCATTTGTTGT-3’, and those for the disrupted allele were: 5’CACCGGATGCAGAAAAGCCACAAT-3’ and 5’GCAACTCGCCGCACATCTGAACTT-3’. Mutant mice were born at expected
Mendelian ratios. The breeding and housing of mice were approved by the Animal Use
and Care committee and Animal Research Center at St. Jude Children’s Research
Hospital, which adhere to NIH guidelines.
Detection of mutant transcripts and protein in woozy mice
To determine the relative transcript levels of SIL1 in Sil1Gt mice compared to
wild-type littermates, we isolated total RNA from wild-type and mutant plasmablasts
after 4 days of LPS stimulation using the RNeasy® Plus Mini Kit (Qiagen) according to
manufacturer’s instructions. RT-PCR was performed with 2μg of total RNA using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems®) and a PTC-200
Thermal Cycler (MJ Research). Quantitative Real Time PCR (qPCR) primers were
obtained from Invitrogen. The primer pairs used were Sil1 FP1 5’AGGAATTTGATGAGCTGAACGT-3’ and Sil1 RP1: 5’TCCTGTGCGTTATCCATCTGA-3’, which produces a fragment that extends across
exon 6 and the exon 6-exon 7 boundary, and detects both Sil1WT and Sil1Gt transcripts;
Sil1 FP2: 5’-CTGCGCCACTTCCCCTAT-3’ and Sil1 RP2: 5’GCAAACATCTTCTCAGTGACCA-3’, which produces a fragment that extends across
exon 9 and the exon 9-exon 10 boundary, and detects only Sil1WT transcripts; and HPRT
FP: 5’-AGGGAGAGCGTTGGGCTTACCT-3’ and HPRT RP: 5’CCTGGTTCATCATCGCTAATCACGA-3’. The qPCR was performed with 7900HT
Fast Real-Time PCR System (Applied Biosystems) using the Power SYBR® Green PCR
Master Mix (Applied Biosystems). All qPCR reactions were carried out in triplicate.
The signal obtained for SIL1 mRNA with both primer pairs was normalized to that
obtained for HPRT mRNA, which served as an internal control. The value for wild-type
SIL1 mRNA was set to 1 and the value for Sil1Gt mRNA presented as a fraction of this
number.
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Characterization of immune cell populations in spleen and thymus
Murine spleen and thymus were excised from three, 3 to 6-month-old male
C57BL/6 Sil1WT and Sil1Gt mice. Splenic cell suspensions were stained with CD3-APC,
CD4-FITC, CD8-APC-Cy7, NK1.1-PE, B220-e605, Gr1-PE-Cy7, Mac1-Alexa700 and
DAPI. Splenic subpopulations were analyzed as follows: CD3+/CD4+, CD3+/CD8+,
B220+, Mac1+, Gr1+, Mac1+/Gr1+ and NK1.1+ cells. Thymic cell suspensions were
stained with Lin (B220/Mac1/Gr1)-FITC, CD3-PE, CD4-PerCP-Cy5.5, CD44-PE-Cy7,
CD25-APC, CD8-Alexa700 and DAPI. T-cell subpopulations were identified as follows:
double negative, DN (CD4-/CD8-), DN1 (CD4-/CD8-/CD25-/CD44+), DN2 (CD4-/CD8/CD25+/CD44+), DN3 (CD4-/CD8-/CD25+/CD44-), DN4 (CD4-/CD8-/CD25-/CD44-), DP
(CD4+/CD8+), CD4SP (CD4+/CD8-) and CD8SP (CD4-/CD8+). Staining and flow
cytometry were performed by the SJCRH Flow Cytometry and Cell Sorting shared
resource on a LSR II Flow Cytometer (BD Biosciences) and analyzed using BD
FACSDiva software (BD Biosciences). All antibodies were procured from BD
Biosciences.
Immunization protocol and ELISA for antigen-specific response
Ten each of Sil1WT and Sil1Gt mice were immunized with a 1:1 homogenate of the
T-dependent antigen 4-Hydroxy-3-nitrophenylacetyl conjugated to Keyhole Limpet
Hemocyanin (NP15-KLH) (Biosearch Technologies) in Freund’s complete adjuvant,
injected intraperitoneally, and boosted after two weeks with NP15-KLH in Freund’s
incomplete adjuvant. Blood was collected on the indicated days by alternating retroorbital and tail vein bleedings. Antigen-specific serum IgM, IgG1, and IgG2b antibody
titers were determined by direct ELISA. Bound antibody was detected with goat antimouse isotype specific, biotin-conjugated antibodies (Southern Biotech) and
Streptavidin-conjugated alkaline phosphatase (Jackson ImmunoResearch). Absorbances
at 410 nm were read on a Benchmark Plus plate reader after incubation with phosphatase
substrate (Thermo Scientific). Serum concentrations were determined from standard
curves with purified mouse IgM, IgG1 or IgG2b proteins (BD Pharminigen). Only
triplicates with a CV <10% were used to calculate serum concentrations.
Ex vivo stimulation of purified splenocytes with LPS
Spleens were harvested from three 10 to 12-week-old male Sil1WT and three age
matched male Sil1Gt mice, and single cell suspensions were prepared. After lysing red
blood cells, the non-B cells were immune-depleted with antibodies to cell surface
markers TER-119, CD4, CD8, Gr1, Mac1, and NK1.1 using an AutoMACS cell separator
(Miltenyi Biotec). Aliquots of the resulting samples were stained with anti-B220
conjugated to Allophycocyanin (APC) and analyzed on a LSR II Flow Cytometer using
BD FACSDiva software to determine the purity of remaining B cells, which was >80%
for all experiments. All reagents utilized were procured from BD Biosciences. The
purified primary B cells were seeded at an initial cell density of 1x106 cells/mL in RPMI
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1640 supplemented with 20% (v/v) FBS Premium (Atlanta Biologicals), 2mM LGlutamine, 100U/mL Pen/Strep antibiotics, 1x (v/v) MEM Non-Essential Amino Acids
(Gibco) and 55 μM 2-Mercaptoethanol (Gibco) at 8% CO2 and induced to differentiate
using 50μg/mL LPS (Escherichia coli 055:B5; Sigma). 4x106 cells were harvested each
day along with an equivalent volume of culture supernatant. Media was changed daily
and cells were maintained below a density of 2x106 cells/mL.
EBV-transformed lymphoblastoid cell lines
EBV-transformed peripheral blood lymphocytes from three related individuals
with MSS and two unaffected family members were kindly provided by Dr. William R
Wilcox (Emory University). The resulting cell lines were cultured in RPMI 1640
(Cellgro) supplemented with 10% (v/v) FBS Premium (Atlanta Biologicals), 2mM LGlutamine, 100U/mL Pen/Strep antibiotics and Gentamicin Reagent Solution (10μg/mL)
at 37°C in 5% CO2.
Western blotting
Nonidet P-40 cell lysates from B lymphoblastoid lines and LPS-stimulated
plasmablasts were produced as previously described (44). The resulting clarified lysates
were designated as the NP-40 soluble fraction. The NP-40 insoluble pellets were
dissolved in 50μl Tris-SDS-buffer and prepared as described (123). For direct western
blotting, the NP-40 soluble and insoluble fractions were normalized for equivalent cell
number (plasmablasts) or protein amount (lymphoblastoid cells), and electrophoresed on
10% SDS-polyacrylamide gels under reducing or non-reducing conditions as indicated.
In cases where IgM secretion was analyzed, a corresponding amount of culture
supernatant was first immunoprecipitated with goat-anti-mouse μ and CaptivATM
PriMAB Protein A agarose beads. For experiments to determine if the mutant SIL1
protein made in LBLs produced from individuals with MSS was unstable, cells were
treated with 10μM MG132 (Calbiochem) for 5 hours or left untreated. In all cases, after
electrophoresis on SDS-polyacrylamide gels the separated proteins were transferred to
Immun-Blot® PVDF membrane (Bio-Rad) and incubated with antibodies specific for the
indicated proteins. Antisera to rodent BiP (42), SIL1 (63), ERdj3 (113), Grp170 (44),
and Grp94 and calnexin (124) were produced in our lab. The anti-human BiP antiserum
was kindly provided by Dr. Ineke Braakman (Utrecht University, Utrecht, The
Netherlands) and the anti-ERdj1 antiserum was a generous gift from Dr. Richard
Zimmermann (Universität des Saarlandes, Homburg, Germany). Antibodies to human Ig
κ LC, calreticulin, Hsc70, and actin were purchased from Santa Cruz, and the anti-ERdj5
was obtained from Abnova. Two anti- SIL1 reagents were purchased; one from LifeSpan
Biosciences, which was raised to a fragment that is preserved in the MSS mutant SIL1
proteins studied here, and the other from Proteintech, which was produced against fulllength human SIL1 protein. Goat anti-mouse μ HC and κ LC, anti-human μ HC, γ HC,
and λ LC antibodies were obtained from Southern Biotech, and horseradish peroxidase-
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conjugated, species-specific secondary immune reagents were purchased from Santa Cruz
Biotechnology.
Metabolic labeling
4x106 plasmablasts from day 2 and 3 LPS cultures were pulse-labeled with
300μCi EasyTagTM EXPRESS35S Protein Labeling Mix (Perkin Elmer) for 20 minutes
and either lysed immediately (0h chase) or re-cultured for 1 h in complete media
supplemented with 2mM unlabeled L-Cys and L-Met (1h chase). In the case of anti-BiP
immunoprecipitations, 10 units/ml of apyrase (Sigma-Aldrich) was added to the lysing
buffer, whereas for anti-Grp170, the lysis buffer was supplemented with 2mM Mg2+-ATP
(Sigma-Aldrich) and 25mM KCl (Fisher Scientific) as described (44). Antisera to
calreticulin (Abcam) and calnexin were added directly to unsupplemented cell lysates. In
all cases immune complexes were isolated with Protein A agarose beads, and isolated
proteins were subjected to reducing SDS-PAGE. The resulting gels were incubated in
Amplify (GE Healthcare, Pittsburgh, PA), supplemented with 3% glycerol, for 30 min at
room temperature before they were dried, and exposed to film (Fuji Film). To determine
if SIL1 deficient lymphoblastoid cells exhibit a difference in their ability to synthesize
and secrete antibodies, we performed pulse-chase experiments. 6x106 lymphoblastoid
cells were labeled with 400μCi 35S methionine and cysteine for 30 minutes and chased in
complete media for 0, 1.5 or 3 hours, respectively. Post-lysis, the NP-40 soluble fraction
and an equivalent amount of culture supernatant were first immunoprecipitated for γ HC
and then analyzed on reducing or non-reducing SDS polyacrylamide gels as indicated.
Sil1 sequencing
Sequence analysis was performed for the Sil1 gene (GenBank NM_001037633)
and transcript from control and MSS-derived lymphoblastoid cells. Genomic DNA
(gDNA) and RNA were extracted using the DNeasy® Blood & Tissue Kit (Qiagen) and
RNeasy® Plus Mini Kit (Qiagen), respectively, according to the manufacturer’s
instructions. Using gDNA as template, we PCR-amplified regions spanning exon 9 and
the 5’ region of intron 9 using primer pairs 5’-GGGACTAATTTGGGGCACCT-3’ and
5’-CCTCAGCCTTTTGTCCCCTC-3’; and the 3’region of intron 9 and the translated
region of exon 10 using primer pairs 5’-TGGGGATAGAGGAAGAGGTGG-3’ and 5’GTCCTCCTGCCTGAGAAGC-3’. 2μg of total RNA was used to synthesize cDNA as
described above. We PCR-amplified the region spanning exons 9-10 using primer pairs
5’-AAGAAGAAGGTCCTGTTTGCAC-3’ and 5’-GAAGTAGCCCTCGTCCTCAC-3’,
to verify the frameshift mutation caused by c.1030-18G>A (86, 115). Primer pairs were
removed using the Wizard® SV Gel and PCR Clean-up System (Promega), and products
were sequenced using Big Dye® Terminator (v3.1) Chemistry on Applied Biosystem
3730XL DNA Analyzers by the Hartwell Center, St. Jude Children’s Research Hospital.
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Statistical analysis
Statistical analyses were computed using Student’s t test utilizing GraphPad Prism
6 (GraphPad Prism Software, Inc). Error bars represent means ± s.d., except in Figure
2-3 where error bars indicate interquartile range of values. Statistical significance was
concluded at P<0.05.
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CHAPTER 3. SIL1, THE ENDOPLASMIC-RETICULUM-LOCALIZED BIP
CO-CHAPERONE, PLAYS A CRITICAL ROLE IN MAINTAINING
SKELETAL MUSCLE PROTEOSTASIS AND PHYSIOLOGY*
Introduction
Nearly one-third of the human genome encodes proteins that enter the
endoplasmic reticulum (ER) lumen, where they are often modified by N-linked glycans
and fold into complex tertiary and quaternary structures that are stabilized by disulfide
bonds (1). This intricate maturation process is vulnerable to mistakes at any of these
steps, which could result in aberrant proteins that are devoid of function at best, and
prone to toxic aggregate formation at worst. The ER is populated with a host of
molecular chaperones that bind directly to vulnerable unfolded proteins and serve to aid
in their proper maturation by restricting off-pathway folding intermediates.
Alternatively, if this process fails some of these same chaperones can identify and target
the unfolded or misfolded clients for degradation through a process referred to as ERassociated degradation (ERAD) (125, 126). These stringent ER quality control (ERQC)
measures ensure that only properly modified, folded, and assembled proteins are allowed
to traffic to other organelles of the secretory pathway, to be expressed at the cell surface,
or to be secreted (92, 127). Intrinsic to the ERQC machinery is a feed-back mechanism
that allows the ER to respond to imbalances in normal protein folding by activating the
Unfolded Protein Response (UPR) in an effort to adjust and maintain ER homeostasis
(73).
ER chaperones can be grouped into two major families - the Hsp70 and the lectin
chaperones - each having numerous co-factors that regulate their activity and interactions
with nascent client proteins. Like all Hsp70 family members, the ER cognate BiP binds
client proteins in an adenosine-nucleotide-regulated manner. The ATP-bound form of
BiP readily engages clients, albeit with low affinity. This triggers ATP hydrolysis,
transforming BiP into a high affinity, ADP-bound form (128). Two sets of co-factors
further regulate BiP’s ATPase cycle; ER-localized DnaJ-like proteins (ERDJs) and
nucleotide exchange factors (NEFs). A subset of known ERDJs (ERDJ3-6) can directly
bind clients, transfer them to BiP, and assist in promoting either pro-folding or prodegradation functions of BiP (55). Unfolded clients are protected from aggregation or
misfolding while bound to BiP, but must be released in order to fold completely. This
requires the action of NEFs that specifically release ADP from the BiP-client complex,
allowing a new molecule of ATP to rebind. Consequently, the affinity of
-------------------*Reprinted from final submission with open access permission. Ichhaporia, V. P., Kim,
J., Kavdia, K., Vogel, P., Horner, L., Frase, S., & Hendershot, L. M. (2018). SIL1, the
endoplasmic-reticulum-localized BiP co-chaperone, plays a crucial role in maintaining
skeletal muscle proteostasis and physiology. Disease Models & Mechanisms, 11(5),
dmm033043.

49

BiP for the bound client protein is lowered, leading to its release. Two ER localized
proteins have been identified that possess NEF activity; SIL1 (63) and GRP170 (44).
Both are ubiquitously expressed but do not appear to be completely redundant. While
both SIL1 and GRP170 contribute to the release of cholera toxin from BiP, allowing it to
be retrotranslocated to the cytosol (129); only GRP170 is able to stimulate the release of
SV40 viral particles from BiP for their ER-to-cytosol transportation (130). Similarly,
GRP170 has been reported to function in the release of two misfolded proteins from BiP
(i.e., the NHK-variant of α1-antitrypsin and a transthyretin mutant), thereby promoting
their degradation, whereas SIL1 does not appear to contribute in this case (131).
While unique functions for SIL1 in either BiP-mediated folding or degradation of
endogenous clients have largely eluded identification, the discovery that mutations in
SIL1 are the leading cause of Marinesco-Sjögren syndrome (MSS) indicates that there are
SIL1-specific functions (64, 86). MSS is an autosomal recessive, multisystem disorder
that adversely affects Purkinje cells, leading to a profound cerebellar ataxia, and is further
clinically characterized by progressive myopathy and bilateral cataracts, among other
tissue pathologies (99, 115). Mutations in GRP170 have not yet been linked to any
disease, but attempts to make a GRP170-null mouse were not successful, revealing it to
encode an essential protein (132). GRP170 is also a bona fide molecular chaperone (44,
110). This might account for the mouse embryonic lethality observed upon its loss,
because SIL1 has no known chaperone function that could compensate. However, it
remains unclear why the lack of SIL1 causes no apparent problem in some tissues (133)
while others are severely crippled, since both proteins are highly expressed in most
secretory tissues (63, 134).
Our goal was to identify the molecular pathway(s) underlying the progressive
myopathy associated with MSS. Two mouse models have been created in which the Sil1
gene is disrupted in all tissues; one by a spontaneous transposon-mediated insertion
known as the woozy mouse, Sil1wz, and the other by gene-trap methodology, referred to
as the Sil1Gt mouse model (87). These mice have been reported to phenocopy at least
some of the MSS-associated pathologies, including severe Purkinje cell loss leading to
ataxia in both models (87), and myopathy in the Sil1wz mouse model (100). Using the
Sil1Gt mouse model, we observed a progressive loss of skeletal muscle mass and strength,
which is characterized by a multifocal, myogenic, myopathy. Proteomic analyses
revealed that the effects of SIL1 loss extended far beyond the ER, compromising all
major organelles and pathways critical to normal muscle physiology. Consistent with a
function for SIL1 in ERQC, we observed disruption of ER homeostasis, up-regulation of
ER chaperones and components of cellular protein degradation pathways, and aberrant
expression of secretory pathway proteins critical for maintaining glucose and protein
homeostasis in skeletal muscles. Our analyses provide molecular insights into why
disruption of a component of the ERQC machinery results in loss of skeletal muscle
mass, strength, and function.
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Results
Sil1Gt mice display evidence of a progressive myogenic myopathy
As the Sil1Gt mice aged, we noticed that they began to have difficulty holding on
to the wired food tray while eating. We hypothesized that this might be indicative of a
muscular weakness, similar to that observed in MSS patients (80, 117), and in keeping
with pathology and biochemical data obtained from Sil1wz mice (100). We used an
inverted screen test to examine limb muscle strength of Sil1Gt mice and their wild-type
littermates at ages ranging from 1-22 months (Figure 3-1A). As early as 6 months, Sil1Gt
mice displayed a significantly reduced ability to hold on to the inverted screen, which
became progressively worse with age. Necropsy revealed a corresponding decrease in
Sil1Gt quadriceps mass with age, which was not observed in soleus or heart (Figure 3-1B
and Figure 3-2).
To characterize the loss in muscle strength and mass, we conducted histological
and electron microscopy (EM) analyses on a variety of muscle groups. Hematoxylin and
eosin (H&E) staining showed that a subset of Sil1Gt skeletal muscles had numerous fibers
with internalized nuclei and myofibril disruption (Figure 3-3A, D), and displayed
evidence of adipose infiltration (Figure 3-4C, D). Staining of skeletal muscles for
laminin, a major component of the extracellular matrix, revealed muscular dystrophy
with a loss of the typical polygonal myofiber morphology in Sil1Gt skeletal muscles and a
wide range in myofiber diameter, including large, rounded hypertrophic fibers and
shrunken, degenerating atrophic fibers (Figure 3-4A, B). Immunostaining of skeletal
muscle cross-sections for IgG (150 kDa) and IgM (900 kDa) did not show accumulation
of these serum proteins in Sil1Gt skeletal muscles, indicating that the hypertrophic
myofibers maintained intact sarcolemmal integrity (Figure 3-4E-H). Epaxial muscles
are composed of both predominantly glycolytic fast myofibers and largely oxidative slow
myofibers, which can be distinguished by the type of myosin heavy chain (MyHC) they
express. Thus, MyHC immunostaining can be readily used to determine if there is any
specificity in the type of myofibers that are affected upon SIL1 disruption. We found that
the affected fibers were almost entirely limited to those expressing MHC type II,
indicative of fast-twitch, glycolytic myofibers (Figure 3-3B, E). In keeping with this
observation, the soleus, which is predominantly composed of oxidative myofibers, did
not appear to be affected in any of the analyses performed, whereas the biceps brachii,
gastrocnemius, quadriceps femoris, and tibialis anterior, which are all largely made up of
glycolytic myofibers, showed significant pathological changes as observed in (Figure
3-3 and Figure 3-4). The heart, composed of specialized oxidative cardiomyocytes, also
remained unaffected in these mice, arguing that glycolytic myofibers are uniquely
vulnerable to SIL1 loss. Immunostaining for desmin, an intermediate filament protein,
revealed significant disruption of myofiber architecture and accumulation of this protein
in degenerating Sil1Gt myofibers (Figure 3-3C, F). EM analyses were consistent with
these findings, and additionally revealed dramatically dilated sarcoplasmic reticulartriads in atrophying fibers (Figure 3-3G, H), degenerating nuclei, rare mitochondrial
abnormalities, and the double membranous structure enveloping the nucleus (Figure
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Figure 3-1.

SIL1 is required to maintain muscle strength and mass as mice age.

(A) Age-matched wild-type and Sil1Gt mice ranging from 1 to 22 months were subjected
to an inverted screen test for up to 120 seconds, and the duration of time they were able
to hold onto the screen was measured. Number of mice in each group is indicated in
white within bars. Error bars indicate means ± s.e.m. (B) Quadriceps femoris were
obtained from wild-type and Sil1Gt mice at the indicated ages, and number of mice
included in each group is shown within bars. Error bars indicate means ± s.d. Statistical
differences were computed using unpaired, two-tailed Mann-Whitney tests (A) or
Student’s t-tests (B), and are indicated as *P≤0.05, **P≤0.01, ***P≤0.001, and
****P≤0.0001.
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Figure 3-2.

Loss of SIL1 predominantly affects glycolytic skeletal muscles.

(A) Representative images of quadriceps, soleus, and heart derived from wild-type and
Sil1Gt mice at the indicated ages depicting that loss of SIL1 specifically affects the
glycolytic quadriceps, while sparing the oxidative skeletal muscle, soleus, and specialized
cardiac muscle. (B, C) Comparison of wild-type and Sil1Gt soleus (B) and heart (C)
weights at the indicated ages. Error bars indicate mean ± s.d.; The number of mice is
indicated within the bar graphs. Although there was a trend of slight decrease in the
Sil1Gt soleus weights, these values were not statistically different from the wild-type
soleus weights.
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Figure 3-3.
myofibers.

The myopathy resulting from SIL1 loss predominantly affects fast

Skeletal muscle cross-sections shown here were derived from 12-mo. wild-type (A-C)
and Sil1Gt (D-F) mice. (A, D) H&E staining revealed hypertrophic and atrophic fibers
with internalized nuclei in the Sil1Gt skeletal muscles (arrows), compared to peripheral
nuclei in Sil1WT samples. (B, E) Epaxial muscles were immunostained with fast- (brown)
and slow- (pink) MyHC antibodies. Arrows indicate myopathic myofibers with
internalized nuclei, which stain positive for fast myofiber-specific MyHC. (C, F) Desmin
staining shows evidence of aggregation and loss of cyto-architecture in degenerating
Sil1Gt skeletal muscle fibers (arrows). (G, H) Representative electron micrographs from
10 mo. wild-type (G) and Sil1Gt (H) bicep femoris displaying triads (arrows). (I, J)
Electron micrographs from 10 mo.-old Sil1Gt quadriceps demonstrating accumulation of
cytoplasmic inclusion bodies (I) and membranous whorls (J) (indicated by arrows), all of
which are characteristic of MSS. (A-F) Images were captured at the same 40x
magnification. Scale bars in (G, H) represent 400 nm, and in (I, J) represent 2 μm.
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Figure 3-4.

Sil1Gt skeletal muscles display characteristic myopathic signatures.

(A-J) Representative hind-limb skeletal muscle cross-sections derived from 12 month-old
wild-type (A,C,E,G,I) and Sil1Gt (B,D,F,H,J) mice are stained with anti-laminin (A,B), an
extracellular matrix protein; H&E (C,D) depicting adipose infiltration in peripheral
skeletal muscles, predominantly affecting muscles in close proximity of adipose tissue;
anti-immunoglobulins IgM (E,F) and IgG (G,H) to asses sarcolemmal integrity. (I,J)
H&E staining of lumbo-sacral spinal cord sections display apparently normal motor
neurons. Images were either captured at the same 40x (A-B,E-J) or 4x (C,D)
magnifications, respectively. (K-M) Representative electron micrographs from 10
month-old wild-type (K) and Sil1Gt (L,M) biceps brachii (K,L) and quadriceps (M)
reveal multiple myopathic features, including degenerating myonuclei (L; black arrows),
electron-dense aggregates (L; white arrow), disruption of the cytoskeletal architecture,
and a double membranous structure surrounding the nucleus (M; arrows), which is
characteristic of MSS, and implicated to be a nuclear envelope pathology in woozy mice.
Scale bars in (K,L) represent 2 μm, and in (M) 500 nm.
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Figure 3-4.

Continued.
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3-4K-M). We observed electron-dense material and cytoplasmic bodies in various
myofibers, suggestive of protein aggregation, and an accumulation of membranous
whorls, indicative of autophagosomes (Figure 3-3I, J). Together, these alterations
strongly resemble ultrastructural changes observed in muscle biopsies of individuals with
MSS (80, 81) and quadriceps from Sil1wz mice (100), and explain the decreased muscle
mass and strength occurring in Sil1Gt mice. The dispersed, multi-focal, and dystrophic
myopathy we observed in Sil1Gt glycolytic skeletal muscles is most compatible with a
myogenic myopathy. This is in contrast to the clustered myopathy with angular crosssectional myofiber morphology reported in Sil1wz mice, which is more indicative of a
neurogenic origin (135). Furthermore, H&E-stained lumbo-sacral spinal sections did not
reveal any obvious neurogenic pathology (Figure 3-4I, J), arguing against a major
contribution of motor neuron defects in the Sil1Gt progressive myopathy and revealing
some differences in these two genetic models.
SIL1 disruption leads to widespread changes in the quadriceps proteome
In an unbiased approach to understand the Sil1Gt-associated myopathy at the
molecular level, we performed proteomics analyses on quadriceps derived from wild-type
and Sil1Gt male mice at six months of age. This was the age at which the myopathy first
became physiologically and pathologically evident. Among skeletal muscles strongly
affected by SIL1 disruption, quadriceps femoris were our tissue of choice due to their
composition of predominantly glycolytic myofibers, the availability of sufficient amounts
of protein due to their relatively large mass, and the ease of dissection. Five mice of each
genotype were sampled. A total of 5512 proteins were identified, of which 5384 could be
quantified. Bioinformatics analyses identified 515 proteins whose expression was
significantly altered (log2 ratio<-0.5 or >0.5; P<0.01) in Sil1Gt quadriceps, relative to
those from wild-type mice. Of these, 301 proteins were up-regulated and 214 were
decreased in expression (Supplementary Table S1). Manual curation of these proteins,
sorted by their resident subcellular compartments according to the GeneCards database
(http://www.genecards.org/) (136), revealed that loss of the ER co-chaperone SIL1 led to
changes in protein expression extending to all major cellular compartments (Figure
3-5A). Gene-set enrichment analysis (GSEA) identified a significant number of proteins,
belonging to signaling pathways and functions critical to muscle physiology, including
insulin receptor (IR) signaling, glucose metabolism, and cation channel activity, to be
altered in the quadriceps of 6-month-old Sil1Gt mice. We verified the indicated changes
in expression of a number of these proteins by western blotting (Figure 3-5B-E and
Figure 3-6). Altered expression of ER chaperones, secretory pathway proteins that are
synthesized in the ER, and elements of the cellular degradation machinery could be
readily anticipated by loss of a component of the ER protein folding machinery.
However, possible mechanisms leading to altered expression of proteins throughout other
organelles was not immediately clear.
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Figure 3-5. SIL1 disruption perturbs all major cellular organelles and pathways
critical for normal quadriceps function.
(A) Graphical representation of the organellar distribution of proteins that were identified
by proteomic analyses to be significantly (log2 ratio<-0.5 or >0.5; P<0.01) upregulated
(left) or downregulated (right) in quadriceps from 6-month-old Sil1Gt mice relative to that
from wild-type mice (n=5). Inner band indicates compartments of the secretory pathway.
SMBO, single membrane bound organelles; PM, plasma membrane. (B-E) Heat maps of
GSEA-identified gene-sets that are enriched (B, C) or depleted (D, E) in the Sil1Gt
quadriceps. PPP indicates Pentose Phosphate Pathway. Subsets of proteins for each
gene-set were selected for verification by western blotting and are shown below the heat
maps.
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Figure 3-6. Proteomic study reveals that loss of SIL1 affects pathways critical for
normal muscle physiology.
(A, B) Heat maps of (A) proteins involved in cation channel activity that were
significantly depleted, and (B) proteins annotated to play a role in the actin cytoskeleton
organization that were significantly enriched in Sil1Gt quadriceps, respectively. A subset
of proteins for each gene-set was selected for verification by western blotting and is
shown below the heat maps. (A) Concomitant with a decrease in levels of the ryanodine
receptor (RYR) Ca2+-release channel subunits, proteomics indicated a significant increase
in the levels of calsequestrin 2 (CSQ2), which serves as the sarcoplasmic reticular Ca2+
buffering protein. (C) GSEA-derived enrichment plots for the respective pathways and
associated heat maps depicted in Figure 3-5 and Figure 3-6A, B.

60

Loss of SIL1 disrupts ER homeostasis as mice age
To begin to understand the widespread changes in protein expression that
occurred upon SIL1 disruption, we examined time points both prior to and after the onset
of muscular weakness, and began with proteins that contribute to ERQC, since this is
where SIL1 functions. We combined quadriceps lysates from at least three male mice,
for each age shown, to obtain an average expression for the proteins queried. The folding
of secretory pathway proteins entering the ER as nascent chains is both aided and
monitored by a host of molecular chaperones and their co-factors. Beginning as early as
3 months, we observed a slight increase in BiP expression in Sil1Gt quadriceps, which
became more dramatic by 6 months and remained elevated (Figure 3-7A and Figure
3-8C). GRP170, the other ER NEF (50), showed a modest increase in expression
beginning at 6 mo., whereas the lectin chaperones (Calnexin and Calreticulin) and their
co-factor, ERP57, were more robustly up-regulated. The delayed up-regulation of these
proteins suggested that loss of SIL1 suggested a progressive disruption of ER
homeostasis. These proteins can be up-regulated at the transcriptional level by activation
of the UPR due to the accumulation of unfolded proteins in the ER. We found evidence
for the up-regulation of targets of all three upstream transducers (PERK, ATF6, and
IRE1) in Sil1Gt muscles relative to age-matched wild-type mice (Figure 3-8A-C). As an
independent means of detecting disruptions in ER homeostasis, we examined the relative
solubility of BiP and Calnexin. Both are normally soluble ER chaperones that bind
unfolded proteins to help maintain them in a soluble form. However, if they are unable to
do so, these chaperones can become trapped in detergent-insoluble complexes with client
proteins. Unlike quadriceps, which were lysed in 8M Urea for proteomic and kinetics-ofonset studies, we used milder, NP40-mediated lysis conditions and examined NP40soluble and -insoluble fractions at three time points. As early as 3 months, a very small
amount of BiP was detected in the NP40-insoluble fraction of Sil1Gt quadriceps, which
became more prominent in the 6- and 12-months samples (Figure 3-7B). It is
noteworthy that as the Sil1WT mice aged, a small amount of BiP was also detected in the
insoluble fraction. This is in agreement with reports of age-related disruptions in protein
homeostasis, also referred to as proteostasis, which is a hallmark of skeletal muscle aging
(137, 138).
Consistent with the observation of dilated sarcoplasmic reticular triads, the
presence of BiP in the insoluble fraction implied that loss of SIL1 was likely to affect the
maturation of cargo proteins that are synthesized in the ER and traffic through the
secretory pathway. Indeed, the proteomics data indicated that secreted (19% upregulated,
8% downregulated) and plasma membrane (19% upregulated, 19% downregulated)
proteins represented a significant fraction of proteins with altered expression (Figure
3-5A). We chose to investigate four integral membrane proteins that showed reduced
expression, including three subunits of heterodimeric cell surface receptors - insulin
receptor β chain (IR-β), insulin-like growth factor 1 receptor β chain (IGF1R-β), and
PDGF receptor α chain (PDGFR-α) - as well as ryanodine receptors (RYR), which are
transmembrane proteins that form calcium channels in the sarcoplasmic reticulum.
Examination of quadriceps lysates at various time points confirmed a reduction in the
expression of all four membrane proteins, although the kinetics and magnitude of these
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Figure 3-7.
age.

SIL1 is required to maintain ER proteostasis in quadriceps as mice

(A) Wild-type and Sil1Gt quadriceps lysates (n=3-5 pooled), solubilized in 8M urea,
isolated from mice at the depicted ages were normalized for an equivalent amount of total
protein, pooled, and subjected to reducing SDS electrophoresis, followed by transfer to
PVDF membranes, and blotting with the indicated immune-reagents for ER chaperones
and co-chaperones. GAPDH serves as a control for loading. (B) Wild-type and Sil1Gt
quadriceps obtained from mice at the designated ages were lysed with NP40 lysis buffer.
The resulting NP40-soluble and NP40-insoluble fractions were processed for western
blotting with BiP and calnexin antisera. HSC70 serves as a loading control for the NP40soluble fraction. (C) Urea-solubilized quadriceps lysates derived from mice of the
indicated genotypes and ages were probed with antibodies to proteins that traffic through
the secretory pathway. (D) NP40-solubilized quadriceps lysates from 12-month-old mice
were processed for western blotting to detect the insulin receptor precursor (pro-IR) and
the mature subunit (IR-β). (E) Graphical representation of normalized mRNA fold
changes of proteins probed in (C) from Sil1Gt quadriceps, relative to wild-type quadriceps
(n=3) (set to 1; indicated by the dotted line), at 3 (gray) and 15 (blue) months. Error bars
indicate means ± s.e.m. Statistical differences were computed using unpaired, two-tailed
Student’s t-tests, and are indicated as *P ≤0.05, ***P ≤0.001, and ****P ≤0.0001.
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Figure 3-8.

Loss of SIL1 leads to activation of the Unfolded Protein Response.

(A) Graphical representation of the indicated transcripts from Sil1Gt quadriceps, relative
to the levels in wild-type quadriceps (n=3), and represented as fold change at 3 (gray) and
15 (blue) months. The arm of the UPR that regulates these components during ER stress
is indicated below the bar graph. Error bars indicate means ± s.e.m. Statistical
differences were computed using unpaired, two-tailed Student’s t-tests, and are indicated
as ɸP <0.1 but >0.05, *P ≤0.05, **P ≤0.01, ***P ≤0.001, and ****P ≤0.0001. (B) Ureasolubilized lysates from Figure 3-7 were probed for CHOP. (C) Graph represent
densitometric quantitation of western blotting data from Figure 3-7 and Figure 3-8B.
Dotted vertical line at the 6-month-time point indicates the age of onset of muscular
weakness in Sil1Gt mice and at which quantitative proteomic profiling of quadriceps was
carried out.
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changes varied slightly (Figure 3-7 and Figure 3-9A). We quantified their mRNA levels
to ensure that these changes were not due to a transcriptional effect. IR-β and IGF1R-β
transcripts were not significantly altered at either time point tested in Sil1Gt mice, whereas
PDGFR-α transcripts were actually increased compared to that in Sil1WT skeletal muscles
(Figure 3-7). In fact, when NP40-soluble protein lysates from 12-month quadriceps were
analyzed, although the insulin receptor precursor levels were nearly identical to those in
wild-type muscles, we observed a significant reduction in mature IR-β subunit expression
in Sil1Gt muscles (Figure 3-7D and Figure 3-9C). In the case of IGF1R, both the
precursor and mature forms were decreased (Figure 3-9B, C). Thus, the reduced
expression of these three proteins was likely a result of decreased protein stability due to
disrupted ER homeostasis. However, Ryr1 mRNA was modestly reduced making it more
difficult to attribute the extent of change in protein levels to a folding defect. Conversely,
our proteomic data indicated that the levels of multiple apolipoproteins (APOM, APOA1,
APOA2, APOD, and APOE), which are secreted proteins (139), were increased in Sil1Gt
quadriceps. Indeed, western blotting for cellular APOE, which has been found to
abnormally accumulate in Inclusion Body Myositis (140), showed a readily detectable
increase as early as 6 months and remained elevated throughout the latter time points
(Figure 3-7C and Figure 3-9A). While ApoE transcripts were up-regulated in Sil1Gt
samples, they did not change between 3 and 15 months of age, whereas the protein levels
increased significantly at 15 months compared to 3 months (Figure 3-7E), implying
differences in post-translation regulation of this protein in Sil1Gt myofibers. Importantly,
unlike membrane proteins, which remain cell-associated when properly folded, secretory
proteins exit the cell. Thus, a faster rate of transport for the properly folded APOE
protein in the Sil1WT muscle compared to the rate at which a misfolded protein is
recognized and targeted for degradation could account for the increased APOE protein
levels in Sil1Gt skeletal muscles.
Evidence for inadequate compensation by cellular degradation systems
Based on the demonstration of altered expression of several secretory pathway
proteins, and because BiP and the lectin chaperones participate in both the folding of
clients and the targeting of misfolded proteins for degradation, we queried the expression
of their ERAD-associated co-factors, ERDJ4, ERDJ5, and EDEM1, respectively. ERdj4
and Edem1 transcripts were significantly increased in Sil1Gt quadriceps when compared
to age-matched Sil1WT tissue, particularly at the later time point (Figure 3-10A).
Transcripts for Herp/Herpud1, a component of the retrotranslocon, displayed a slight
increase, which was statistically significant, as did HERP protein levels (data not shown).
Together these data indicate an increased demand for the disposal of misfolded ER
proteins. Improperly matured or aggregated ER proteins, as well as damaged ER, can
also be disposed of by lysosomal and autophagy pathways. In keeping with a role for
these systems in managing ER proteostasis failures, we detected a relative increase in
transcription factor EB (TFEB), a key mediator of lysosomal biogenesis, as early as 6
months (Figure 3-10B, E). Consistent with this, we detected multiple TFEB-targets that
play a role in lysosomal function to be significantly upregulated by our proteomics study
(Figure 3-11A and Supplementary Table S2). We validated one of these, the mannose-
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Figure 3-9.

Loss of SIL1 leads to disruption of ER proteostasis.

(A) Graphs represent densitometric quantitation of western blotting data from Figure 37C. Dotted vertical line at the 6-month time point indicates the age of onset of muscular
weakness in Sil1Gt mice and at which quantitative proteomic profiling of quadriceps was
carried out. (B) NP40-solubilized quadriceps lysates from 12-month-old mice were
processed for western blotting to detect the IGF-1 receptor precursor (pro-IGF1R) and the
mature subunit (IGF1R-β). (C) Graph represent densitometric quantitation of western
blotting data from Figure 3-7D and Figure 3-9B (n=3). Error bars indicate means ±
s.e.m. Statistical differences were computed using unpaired, two-tailed Student’s t-tests,
and are indicated as ***P ≤0.001 and ****P ≤0.0001.
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Figure 3-10. Loss of SIL1 results in compensating increases in all cellular protein
degradation systems.
(A) Graph of normalized mRNA fold changes of ERAD components (Herp, ERdj5,
ERdj4, and Edem1), mediators of autophagy (Sqstm1/p62 and LC3B), and lysosomal
hydrolases [cathepsin L (Ctsl) and cathepsin H (Ctsh)] in quadriceps (n=3) obtained at 3
(gray) and 15 (blue) months of age, respectively. Error bars indicate means ± s.e.m.
Statistical differences were computed using unpaired, two-tailed Student’s t-tests, and are
indicated as ɸP <0.1 but >0.05, **P ≤0.01, ***P ≤0.001, and ****P ≤0.0001. (B, C)
Urea-lysed, pooled cellular extracts (n=3-5) isolated at the indicated ages were probed for
markers of autophagy and lysosomal biogenesis (B), and also for the accumulation of
ubiquitinated proteins (C) by western blotting. GAPDH is a control for equivalent
loading in both panels. (D) Lysates were probed for the indicated proteins involved in
sequestering misfolded proteins and maintaining the cytoskeleton. (E, F) Graphs
represent densitometric quantitation of western blotting data from Figure 3-10B-D.
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Figure 3-11. Loss of SIL1 leads to aggregation of cytosolic small heat shock
chaperones and disruption of cytosolic proteostasis.
(A, B) Graphical representation of TFEB-regulated genes that were implicated in (A)
autophagy and lysosomal function or in (B) mitochondrial biogenesis. The total number
of genes annotated in each study is represented by green and grey segments of each pie
chart. The green segment of these pie charts (Supplementary Table S2) represents the
fraction of these TFEB-regulated genes whose proteomic signature was detected in our
proteomics study. The bar chart adjacent to it displays the number of proteins
significantly (log2 ratio <-0.25 or >0.25; P<0.01) upregulated (blue) or downregulated
(red) in Sil1Gt quadriceps, compared to wild-type muscles. (C-H) Representative hindlimb skeletal muscle cross-sections derived from 12-month-old wild-type (C, F) and
Sil1Gt (D, E, G, H) mice are stained with markers of autophagy, LC3B (C-E) and p62 (FH). (E, H) Display a higher magnification of the indicated area from (D, G), respectively.
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6-phosphate receptor (Figure 3-10B, E), which transports lysosomal enzymes and clients
to lysosomes (141). Transcripts for cathepsin L and cathepsin H, two lysosomal
hydrolases, were also significantly increased (Figure 3-10A). TFEB over-expression has
also been reported to drive mitochondrial biogenesis (142). Although our proteomics
data captured 46 TFEB-regulated proteins involved in this process, most were either
unchanged or diminished (Figure 3-11B), arguing that TFEB did not apparently reach
sufficiently high levels to contribute to their expression. Proteins and damaged
organelles are also delivered to the lysosome via autophagy. Both the unmodified and
lipidated forms of the microtubule-associated protein 1 light chain 3 beta (LC3B), the
latter of which initiates the formation of autophagic vesicles, were significantly upregulated in Sil1Gt quadriceps at even the earliest time point queried. Similarly, we
observed a modest increase in the levels of the autophagic adaptor protein, SQSTM1/p62,
which promotes the sequestration of ubiquitinated target proteins into autophagosomes,
leading to lysosomal degradation of both p62 and associated proteins (Figure 3-10B, E).
This increase in the protein levels of LC3B and p62 was not due to a corresponding
increase in their transcripts (Figure 3-10A). In addition, we detected the presence of
LC3B- and p62-positive puncta in Sil1Gt skeletal muscles by immunohistochemistry
(Figure 3-11C-H). Thus, the accumulation of unmodified LC3-I and p62 by western
blotting, cellular aggregation of these two proteins in puncta, and build-up of
autophagosomes observed by EM together indicate impaired autophagy, which precedes
the stimulus for lysosomal biogenesis in Sil1Gt skeletal muscles.
Although our data show an up-regulation of components involved in cellular
clearance pathways in response to SIL1 disruption, this was apparently not sufficient to
dispose of all misfolded proteins, as Sil1Gt quadriceps samples also displayed a greater
accumulation of ubiquitinated proteins relative to Sil1WT samples beginning at 3 months
of age and extending throughout the time course measured (Figure 3-10C, F). This
taxation of the ubiquitin-proteasome system likely also compromises the turnover of
proteins in other organelles including the cytosol, as indicated by the up-regulation of two
cytosolic small heat shock proteins (sHSP), HSP27 and αB-Crystallin (Figure 3-10D, F),
coinciding with the accumulation of ubiquitinated proteins in the Sil1Gt samples. In
addition to their primary roles in chaperoning multiple cytoskeletal proteins, these sHSPs
play a more general cytoprotective role by sequestering cytosolic protein aggregates
(143), which is in keeping with the presence of these sHSP chaperones in the NP40insoluble fraction (Figure 3-12) in Sil1Gt quadriceps. We also observed an increase in
the cytoskeletal proteins, α-tubulin (Figure 3-10D) and desmin (Figure 3-6B and Figure
3-12), which rely on sHSPs to fold correctly (144). If the protein folding capacity of
these sHSPs becomes limiting, it is likely to impinge on client folding, consistent with
desmin aggregation in Sil1Gt skeletal muscles (Figure 3-3F).

Disruption of SIL1 has profound effects on components of the insulin signaling
pathway
Insulin and IGF-1 signaling in skeletal muscles helps regulate systemic glucose
homeostasis and maintain muscle mass [reviewed in (145, 146)]. These hormones signal
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Figure 3-12. Loss of SIL1 leads to aggregation of cytosolic small heat shock
chaperones and disruption of cytosolic proteostasis.
(A) Wild-type and Sil1Gt quadriceps obtained from 12-month-old mice were lysed with
NP40 lysis buffer. The resulting NP40-soluble and NP40-insoluble fractions were
processed for western blotting for the indicated proteins. GAPDH and histone H3 serve
as markers of NP40-mediated lysis efficiency. The Ponceau stained western blot serves
as the loading control. (B) Graph represents densitometric quantitation of western
blotting data from Figure 3-12A (n=3). Error bars indicate means ± s.e.m. Statistical
differences were computed using unpaired, two-tailed Student’s t-tests, and are indicated
as *P ≤0.05 and ***P ≤0.001
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through two highly homologous tyrosine kinase receptors that activate the PI3K-AKT
pathway (Figure 3-13A). We had verified that both IR-β and IGF1R-β expression were
decreased in the Sil1Gt quadriceps beginning at 6 months (Figure 3-7C). Our proteomic
data suggested that this decrease was accompanied by changes in the expression of
numerous downstream components of the IR/IGF1R signaling pathway, including an
unexpected increase in the levels of total AKT (Figure 3-5D). We also observed reduced
levels of key regulatory enzymes of glucose metabolism, including those involved in
gluconeogenesis, glyconeogenesis, glycolysis, and the pentose phosphate pathway
(Figure 3-5E). Thus, we examined the IR/IGF1R signaling pathway more closely in
quadriceps from ad libitum-fed mice, which were the source of all our studies to this
point. Paradoxically, we observed increased phosphorylation of their downstream target,
PI3K, on tyrosine 199 beginning at 6 months and continuing through later time points
(Figure 3-13B and Figure 3-14C, D). To better understand the significance of PI3K
activation, we focused on the phosphorylation status of a number of both direct and
indirect effectors of this kinase (147). First, due to their respective contribution to
skeletal muscle atrophy and translation repression, the FOXO transcription factors and
4E-BP1 were examined. A relative increase in phosphorylation was observed for
FOXO1, FOXO3a, and 4E-BP1 on the AKT- and mTOR-dependent residues,
respectively, which in each case suppresses their activity. Reduced transcriptional
activity of FOXO is further supported by decreased levels of two of its targets, the E3
ubiquitin ligases, Atrogin-1 and MuRF1, at the latter time point (Figure 3-15A).
Correspondingly, we observed a striking increase in Fgf21 mRNA (Figure 3-15B), an
AKT-regulated myokine that has been implicated in metabolic adaptations to autophagy
inhibition and ER stress (148). Together, these data demonstrate the aberrant increase in
PI3K activation in the Sil1Gt skeletal muscle is driving downstream responses, which are
likely to limit the loss of muscle strength and mass.
Despite a sustained increase in PI3K-AKT signaling, the Sil1Gt mice continued to
lose muscle mass and strength as they aged. Although we did not observe evidence of an
overt mitochondrial phenotype in these mice, impairment in energy production can lead
to myopathy. Thus, the pronounced activation of AMPK, an energy stress sensor, can
inhibit mTOR-mediated signaling, leading to a decrease in skeletal muscle mass. We
checked the activation status of AMPK and its downstream target, Acetyl-CoA
carboxylase (ACC). Although there was a modest increase in AMPK phosphorylation at
two time points, this did not correspond to a significant increase in phosphorylation of its
target, ACC (Figure 3-14B, E), suggesting that decreased energy production was not a
significant driver of this myopathy. We also examined transcripts of GADD45A, a
critical mediator of skeletal muscle atrophy, because it can be up-regulated by the PERK
pathway (149), which is in keeping with our observation that CHOP, another PERK
target, was induced (Figure 3-8B, C). Indeed, there was a significant increase in
Gadd45a mRNA in Sil1Gt quadriceps as early as 3 months, which continued to climb as
these mice aged, as well as a modest increase in Ncam1, a marker of atrophy (Figure
3-15A). Two other mediators of atrophy, Atrogin-1 and MuRF1, were not induced, likely
due to the suppression of FOXO by AKT, thus resulting in a dampened atrophic
response. This, coupled with the absence of a regeneration driven by an increase in
PAX7, MYOD1, and myogenin (Figure 3-15A), apparently cause the slow, progressive
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Figure 3-13. Loss of SIL1 has profound effects on IR signaling.
(A) Schematic of the IR/IGF1R signaling pathway. Asterisks indicate proteins identified
to be decreased by proteomics (red *), western-blotting-validated decreases (orange *)
and increases (blue *), and proteins displaying increased basal phosphorylation (green *),
relative to Sil1WT levels. (B, C) Pooled, urea-solubilized, quadricep lysates derived from
mice at the depicted ages (n=3-5) were analyzed by western blotting with antibodies
against multiple components of the IR- and IGF1R-signaling pathways. GAPDH serves
as a control for equivalent loading. (D) Representative gastrocnemius electron
micrograph from 10-month-old Sil1Gt mice displaying myopathic alterations very similar
to those observed in the quadriceps, including degenerating nuclei and dilated triads.
Scale bar: 2 μm. (E) Graphical representation of 18F-fluorodeoxyglucose (18F-FDG)
uptake over 60 minutes in wild-type (blue) and Sil1Gt (red) gastrocnemii (n=4) assayed by
PET-μCT. Statistical differences were computed using unpaired, two-tailed Student’s ttests, and are indicated in the graph. %ID/g, % injected dose per gram body weight.
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Figure 3-14. Loss of SIL1 leads to basal activation of growth factor signaling.
(A, B) Urea-solubilized quadriceps lysates derived from mice of the indicated genotypes
and ages were probed with antibodies against phosphorylated 4E-BP1 downstream of
PI3K-AKT-mTOR signaling (A), and phosphorylation-mediated activation of AMPK and
ACC (B). (C-F) Graphs represent densitometric quantitation of western blotting data
from Figure 3-13B, C and Figure 3-14A, B.
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Figure 3-15. Evaluating the expression of genes involved in skeletal muscle
regeneration, atrophy, and glucose uptake.
(A, B) Graphical representation of normalized mRNA fold changes in Sil1Gt quadriceps
(n=3) of genes involved in (A) satellite cell activation (Pax7), early myogenesis (Myod1),
terminal myogenesis (Myog), atrophy (Atrogin-1, MuRF1, Gadd45a, Ncam1, and
MUSK); or (B) glucose uptake (Glut1, Glut4, AS160/Tbc1d4, Tbc1d1, and Fgf21) at 3
(gray) and 15 (blue) months, respectively. Error bars indicate means ± s.e.m. Statistical
differences were computed using unpaired, two-tailed Student’s t-tests, and are indicated
as ɸP <0.1 but >0.05, *P ≤0.05, **P ≤0.01, ***P ≤0.001, ****P ≤0.0001.
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myopathy observed in Sil1Gt mice.
We also observed a dramatic increase in the levels of GLUT4, the insulinresponsive glucose transporter, beginning at 6 months, whereas GLUT1, which is an
insulin-independent glucose transporter, was only modestly increased (Figure 3-13C and
Figure 3-14F). The small increase in GLUT1 expression may be due to a similar
increase in its transcripts, whereas Glut4 mRNA levels were actually slightly decreased
(Figure 3-15B), suggesting post-translational stabilization of this transporter. A
significant pool of GLUT4 is maintained in intracellular vesicles that can be rapidly
deployed to the cell surface to allow glucose uptake in response to insulin signaling
through the IR (Figure 3-13A). This relocation of GLUT4 is negatively regulated by two
GTPase-activating proteins, TBC1D1 and AS160 (TBC1D4), and they are in turn
inactivated by phosphorylation through the insulin signaling pathway [as reviewed in
(150)]. We observed a slight steady state increase in phospho-AS160 beginning at 6
months (Figure 3-13C) and a significant decrease in Tbc1d1 transcripts in our 15-month
samples (Figure 3-15B). Together this indicates a reduction in both negative regulators
of GLUT4 transport, arguing for a plausible increase in the cell surface localization of
GLUT4 in Sil1Gt quadriceps.
To understand the physiological relevance of increased GLUT4 levels and an
inhibition or reduction of the negative regulators of GLUT4-trafficking under steady state
conditions, we measured basal glucose uptake rate in skeletal muscles using 18F-labeled
fluorodeoxyglucose (18F-FDG) PET-μCT. Due to technical limitations, we were unable
to analyze the signal originating from quadriceps, our tissue of choice. Thus, as an
alternative, we monitored 18F-FDG uptake in gastrocnemii, which are also primarily
glycolytic skeletal muscles and display a pathology similar to that observed in quadriceps
upon SIL1 disruption (Figure 3-13D). We observed an accelerated rate and increased
magnitude of glucose uptake in gastrocnemii of Sil1Gt mice, compared to age-matched
wild-type mice (Figure 3-13E). This indicates that the observed increases in basal
phosphorylation of multiple components of the AKT pathway indeed represents
functional activation of this signaling cascade and likely provides at least some
compensation in the face of decreased IR-β and IGF1R-β protein expression.
Discussion
Evaluation of the SIL1-deficient quadriceps proteome revealed that loss of SIL1
not only had a large effect on the expression of secretory pathway proteins that are
synthesized in the ER, but also led to significant changes in all major cellular organelles,
as well as pathways critical for normal muscle physiology. Our interpretation of the
causes of these wide-ranging effects on cellular homeostasis is as follows (Figure 3-16).
The loss of SIL1, a NEF for the ER chaperone BiP, results in an imbalance in the proteinfolding capacity of the ER, as evidenced by post-translational alterations in the levels of
multiple secretory pathway clients and the presence of ER chaperones partially
partitioning in the NP40-insoluble fraction, putatively bound to secretory pathway protein
aggregates. This results in the up-regulation of ER chaperones and components of
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Figure 3-16. Schematic model describing the molecular responses to SIL1 loss in
skeletal muscles leading to myopathy.
(1) A functional depletion of SIL1 compromises the chaperoning ability of BiP, leading
to an increase in chaperones in an attempt to maintain normal protein folding in the ER.
However, this compensation is insufficient, resulting in client misfolding and
aggregation. (2) Degradation pathways are up-regulated to deal with accumulating
misfolded proteins but are heavily taxed, leading to the build-up of ubiquitinated proteins
and induction of small heat shock proteins to sequester aggregates. (3) In keeping with
SIL1’s role in protein folding, disruption of ER homeostasis adversely affects maturation
of secretory pathway clients in the ER. (4) Consequentially, this results in a decrease in
the amount of some clients, such as IR-β and IGF1R-β, which play critical roles in
maintaining skeletal muscle protein- and glucose-homeostasis. Disruption of normal
signaling via these axes, in combination with other factors, such as an increase in
GADD45A levels, eventually shifts the balance between anabolic and catabolic cellular
mechanisms towards catabolic, atrophy-causing pathway(s) that lead to cyto-architecture
disruption as well as decreased muscle mass and strength in the Sil1Gt MSS-mouse
model.
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multiple cellular protein degradation pathways due to an increased demand for both.
However, these responses seemed unable to wholly compensate for an apparent
perturbation in ER homeostasis. As a result, cellular protein degradation pathways are
heavily taxed, secondarily affecting the turnover of proteins throughout the cell, as
evidenced by the accumulation of ubiquitinated proteins, cytosolic sHSP chaperones
fractionating in the detergent-insoluble fraction, likely bound to protein aggregates, and
the presence of electron-dense material and cytosolic bodies detected by EM. Multiple
studies document a basal activation of the UPR in normal adult murine skeletal muscles
(151-153), which contributes to myogenesis (154) and adaptation to exercise (155). Thus,
the up-regulation of numerous effectors of the UPR observed in our study indicates an
increase that exceeds basal activation. However, the basal engagement of the UPR in
adult skeletal muscles may restrict the extent to which this pathway can be further upregulated physiologically in the event of a disruption in ER homeostasis, as observed
upon SIL1 loss. This would explain why despite UPR activation, the SIL1-deficient ER
has not been able to completely resolve its proteostasis defects.
In keeping with a disruption in ER homeostasis, we identified significant
decreases in the expression of IR-β and IGF1R-β, which are synthesized in the ER and
likely fail to mature properly under these conditions, leading to their disposal by ERAD
or lysosomal systems. Although we observed decreases in the up-stream transducers of
this pathway, paradoxically we found evidence of higher basal stimulation of downstream
components in Sil1Gt quadriceps. It is noteworthy that mice with a muscle-specific dual
knockout of IR and IGF1R (MIGIRKO) also displayed a compensatory basal activation
of the PI3K-AKT-mTOR pathway and increased surface expression of the GLUT1 and
GLUT4 glucose transporters (156), confirming that skeletal muscles can respond to
decreased (or completely absent) levels of these two receptor tyrosine kinases by
constitutively inducing their shared effector pathway. Interestingly, spliced B-boxbinding protein 1 (sXBP1) has been demonstrated to preserve sensitivity of the PI3KAKT signaling axis during high-fat diet induced ER stress by negating the inhibitory
effects of IRE1-mediated JNK activation (157). Thus, the concomitant upregulation of
sXbp1 in Sil1Gt quadriceps is likely to contribute to the maintenance of a sensitive growth
factor signaling axis in the face of decreased IR and IGF1R levels. Skeletal muscle mass
is maintained by a dynamic balance between anabolic (hypertrophic increase in protein
synthesis rates) and catabolic (atrophic increase in protein degradation pathways)
processes. Signaling through the PI3K-AKT pathway positively regulates muscle growth
and mass by increasing cellular protein synthesis through mTOR signaling (158, 159) and
AKT-dependent phosphorylation of FOXO transcription factors to suppress their
atrophy-inducing activity. Although we observed both these cues in Sil1Gt quadriceps,
muscle mass continued to decline, suggesting that these counteracting mechanisms were
insufficient to prevent atrophy. It is intriguing to hypothesize that the seemingly
compensatory activation of mTOR signaling in Sil1Gt skeletal muscles, which would
maintain high protein synthesis rates and inhibit autophagy (160), might in fact further
exacerbate the demands on an already abnormally taxed protein folding machinery. In
support of this hypothesis, there is a growing body of literature that emphasizes the
beneficiary effect of reduced PI3K-AKT-mTOR signaling on reducing proteotoxicity
associated with protein misfolding diseases in worms and mice (161, 162). In keeping
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with this hypothesis, over-expression of the translation inhibitor 4E-BP dramatically
suppressed pathological phenotypes in a Drosophila model of Parkinson’s Disease (163),
and inhibition of mTOR with rapamycin abolished cognitive defects and reduced βamyloid levels in a murine Alzheimer’s Disease model (164).
Aging is the principal risk factor in various protein folding diseases, such as
BAG3-, CRY αB-, and DNAJB6-associated myofibrillar myopathies, as well as familial
amyotrophic lateral sclerosis, Alzheimer’s, Huntington’s, and Parkinson’s Diseases, all of
which have been characterized as “gain-of-toxic-function” diseases (165). Although all
of these diseases result from germline-encoded mutation(s), disease-associated symptoms
and even aggregation of the affected proteins does not occur until later in life. This has
been attributed to a progressive, age-related, decline in chaperone function, clearance of
aberrantly folded proteins, and the ability to mount successful stress responses, all of
which collectively maintain the proteome integrity. These changes have been
documented in multiple tissue types, including muscles, and in organisms ranging from
nematodes to fruit flies and mammals (166). This decline in proteostasis maintenance
during aging predicts that, as the buffering capacity of the chaperones and stress
responses diminish, misfolded proteins begin to aggregate. Powers et al., have used
mathematical modeling to argue that there are limits on the capacity of the proteostasis
network in cells and that metastable proteins would be the first to be affected as this
network declines (167). Although SIL1 is a component of the ER chaperone machinery,
and might be expected to affect the proper maturation of numerous secretory pathway
proteins, we also observed alterations in protein expression in other subcellular organelles
and a similar delay in the onset of physiological symptoms and molecular responses.
Thus, we argue that the resulting disruption of ER function in Sil1Gt skeletal muscles
provides a sufficient burden to accelerate the usual age-restricted limitations of the
proteostasis network. Furthermore, we find that the alterations in ER homeostasis
secondarily impinge on proteostasis in other organelles, supporting the hypothesis that
organellar boundaries are susceptible to disruption in trans (167).
One might speculate that any of the secretory pathway proteins that show altered
expression upon Sil1-disruption represent clients that are critically dependent on SIL1 for
release from BiP. However, alterations in the expression of the secretory pathway
proteins that we examined did not become apparent until the mice were 6 mo. of age.
This argues that Sil1Gt mice were able to control the expression of these proteins normally
in the absence of SIL1 at earlier time points and raises the question of why they are
unable to do so later. It is possible that basal levels of GRP170, another ER NEF for BiP,
are initially sufficient to compensate for the loss of SIL1 function but cannot do so at
later time points. Alternatively, an intriguing possibility comes from recent studies in
yeast showing that Sil1p (yeast SIL1) can also act as a reductase for oxidized yeast BiP
(Kar2p), thereby restoring Kar2p’s chaperone activity during recovery from oxidative
stress. Sil1p’s reductase activity is mediated through two cysteines present near its Nterminus (66). Although there are two N-terminal cysteines that are highly conserved in
mammalian SIL1 sequences, algorithms for signal sequence cleavage predict that they are
not retained in the mature protein. If in fact they are part of the mature SIL1 protein, a
similar reductase activity for mammalian SIL1 could readily explain the delayed effects
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on secretory pathway protein expression, as the need for this reductase activity might be
dependent on accumulated oxidative insults to the ER, leading to the oxidization and
inactivation of BiP. Further investigation is required to determine if mammalian SIL1
possesses a reductase activity for BiP and whether this is a plausible explanation for the
pathologies associated with MSS.
In toto, our study revealed that SIL1 loss leads to early and persistent defects in
ER homeostasis, which invokes a triage response to increase both the protein folding and
degradation capacity of the ER, which is ultimately inadequate. One consequence of the
inability to restore proper ER function is a post-translational decrease in IR-β and IGF1Rβ expression in SIL1-deficient skeletal muscles. While we observed evidence of a
compensatory increase in basal PI3K-AKT signaling and expression of glucose
transporters in Sil1Gt skeletal muscles, these mice were not able to successfully counteract
the activation of atrophy-causing degradation pathways. The physiological requirement
of constitutive UPR activation in skeletal muscles, combined with the proteotoxicity
associated with increased mTOR signaling and the age-associated decline in the ability to
maintain proteostasis, particularly in the absence of a pronounced regenerative response
is likely to trigger the loss of skeletal muscle mass and strength upon loss of SIL1.
Together, these findings provide molecular insights into the progressive myopathy and
cellular triage responses attempted upon loss of an ERQC component.
Materials and Methods
Mice
The Sil1Gt mouse strain B6;129Sil1Gt (pGT2TMpfa)1Slac was generated by gene-trap
methodology (87) and was obtained from Dr. Susan Ackerman (HHMI and University of
California San Diego). Heterozygous mice were crossed to generate homozygous male
and female Sil1Gt mice and wild-type littermates. At weaning, DNA was isolated from
mouse tail snips using DNeasy® Blood & Tissue Kit (Qiagen, Valencia, CA) and
genotyped as previously reported (87). The primers for the wild-type allele and for the
disrupted allele are mentioned in the Supplementary Table S3. Mutant mice were born
at expected Mendelian ratios. Mice were housed and treated in accordance with the
Animal Use and Care Committee and the Animal Research Center at St. Jude Children's
Research Hospital, adhering to the National Institutes of Health guidelines.
Inverted screen test
To measure the muscular strength of male and female Sil1Gt and wild-type mice,
we performed an inverted screen test (168) using a 12” x 8” screen (0.5” metal grid) that
was surrounded by 9” plexiglass walls to prevent mice from climbing onto the top of the
screen during the assay. A pillow was placed below the apparatus to cushion the fall.
Each mouse was placed on the screen, allowed to acclimatize for a few seconds, and the
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screen was rotated 180° to position the mouse upside down, at which point timing began.
The length of time that each mouse was able to hold on to the screen was recorded with
an assay maximum limit of 120s. Each mouse was subjected to a total of three trials
successively and the average was determined. Mean times for wild-type and Sil1Gt mice
of each age-group were statistically compared using Prism Ver. 6 (GraphPad Software,
La Jolla, CA) by Mann-Whitney tests (unpaired; two-tailed).
Histopathology and immunohistochemistry
Immediately after euthanization, mice were perfused with 10% buffered Formalin
(Thermo Fisher Scientific, Waltham, MA) through the left cardiac ventricle. Skeletal
muscles and spinal cords of perfused mice were post-fixed by immersion in 10% buffered
Formalin for at least 24 hours before being decalcified in formic acid (TBD-2
Decalcifier; Thermo Fisher Scientific). Tissues were embedded in paraffin, sectioned at
4 μm, and mounted on positively charged glass slides (Superfrost Plus; Thermo Fisher
Scientific). Tissue sections were processed for IHC using the automated Discovery Ultra
platform (Ventana-Roche, Tucson, AZ) after heat-induced antigen retrieval for up to 48
mins. using the Discovery Cell Conditioning CC1 buffer, which included Proteinase K
treatment in the case of Laminin IHC. Sections were then stained with the respective
primary and secondary antibodies, counter-stained with Hematoxylin II followed by
treatment with Bluing Reagent, and detected using the DISCOVERY ChromoMap DAB
Kit (RUO) alone or in conjunction with the DISCOVERY Purple kit (RUO) for the
double-staining of MyHC fast and slow isoforms.
Transmission electron microscopy
For ultrastructural analysis by EM, post-euthanization the animals were perfused
with 2.5% glutaraldehyde/ 2% paraformaldehyde in 0.1M sodium cacodylate buffer, pH
7.4 (EM fixative). Necropsy was performed to harvest major skeletal muscles and heart,
and submitted to the St. Jude CTI-EM shared resource. The samples were fixed with EM
fixative overnight and post fixed in 2% osmium tetroxide in 0.1M cacodylate buffer with
0.3% potassium ferrocyanide for 1.5 hours. After rinsing in the same buffer, the tissue
was stained in 4% aqueous uranyl acetate, and dehydrated through a series of graded
ethanol-to-propylene oxide transitions. The samples were then infiltrated in a series of
propylene oxide and EPON resin gradients, with processing through 100% EPON resin
overnight. All processing was performed using a Leica EM TP Tissue Processor. The
following day, tissues were embedded using fresh EPON resin and polymerized at 70°C
overnight. Semi-thin sections (0.5 μm) were stained with toluidine blue for light
microscopy-examination. Ultrathin sections (80 nm) were cut and imaged using the Jeol
1200 Electron Microscope with a 2K AMT 2K Digital Camera.

79

Mass spectrometry
Protein digestion and peptide isobaric labeling by Tandem Mass Tags (TMTs)
Mass spectrometry was performed as previously described (169) with a slight
modification. Quadriceps tissues from five Sil1WT and five Sil1Gt 6-month-old male mice
were lysed in a 50 mM HEPES (pH 8.5)-based buffer containing 8M urea and 0.5%
sodium deoxycholate. Protein concentration of lysates was determined by a Coomassiestained short gel with bovine serum albumin as standard. 100 μg of protein for each
sample was digested with LysC (Wako) at an enzyme-to-substrate ratio of 1:100 (w/w)
for 2 hours at room temperature. Following this, the samples were diluted to a final
concentration of 2M urea in 50 mM HEPES (pH 8.5), and further digested with Trypsin
at an enzyme-to-substrate ratio of 1:50 (w/w) for at least 3 hours. The digestion was
terminated and acidified by adding trifluoroacetic acid to 1%, desalted using C18
cartridges, and dried by SpeedVac. The purified peptides were resuspended in 50 mM
HEPES (pH 8.5), labeled with 10-plex TMT reagents, following the manufacturer’s
recommendation (ThermoFisher Scientific).
Two dimensional HPLC and mass spectrometry
The TMT-labeled samples were mixed in an equal proportion, desalted, and
fractionated on an offline high-performance liquid chromatography (HPLC) apparatus
(Agilent 1220) using basic pH reverse phase liquid chromatography (pH 8.0, XBridge
C18 column, 4.6mm x 25cm, 3.5μm particle size). The fractions were dried and
resuspended in 5% formic acid and analyzed by acidic pH reverse phase LC-MS/MS
analysis. The peptide samples were loaded on a nanoscale capillary reverse phase C18
column (New Objective, 75μm ID x ~40cm, 1.9μm C18 resin from Dr. Maisch GmbH)
by a HPLC system (Waters nanoAcquity) and eluted by a 150 minute-gradient. The
eluted peptides were ionized by electrospray ionization, and detected by an inline
Orbitrap Fusion mass spectrometer (ThermoFisher Scientific). The mass spectrometer is
operated in data-dependent mode with a survey scan in Orbitrap (60,000 resolution, 2 X
106 AGC target and 50 ms maximal ion time) and MS/MS high resolution scans (60,000
resolution, 1 X 105 AGC target, ~150 ms maximal ion time, 38 HCD normalized
collision energy, 1 m/z isolation window, and 20s dynamic exclusion).
Mass spectrometry data analysis and bioinformatics
The MS/MS raw files were processed by a newly developed tag-based hybrid
search engine, JUMP, which displayed better sensitivity and specificity than commercial
package (e.g. Proteome Discoverer) (170). The data was searched against the UniProt
mouse database concatenated with a reversed decoy database for evaluating false
discovery rate. Searches were performed using a 25 ppm mass tolerance for precursor
ions and 15 ppm mass tolerance for fragment ions, fully tryptic restriction with two
maximal missed cleavages, three maximal modification sites, and the assignment of a, b,
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and y ions. TMT tags on lysine residues and N-termini (+229.162932 Da) were used for
static modifications and Met oxidation (+15.99492 Da) was considered as a dynamic
modification. MS/MS spectra were filtered by mass accuracy and matching scores to
reduce protein false discovery rate to ~1%. Proteins were quantified by summing
reporter ion counts across all matched peptide spectrum matches using the JUMP
software suite.
Bioinformatics analyses were performed to determine significant protein
expression, gene ontology (GO), and pathway representation. Using Partek Genomics
Suite 6.6 (Partek Incorporated, St Louis, MO), the values of 5384 quantified proteins
were log2 transformed followed by quantile normalization and compared using ANOVA
between five replicates in each of the two groups. Expressions of a total of 515 proteins
were identified as significantly altered (P < 0.01; log2 ratio < -0.5 or > 0.5) in the Sil1Gt
quadriceps relative to those from age-matched wild-type mice. DAVID
(https://david.ncifcrf.gov/) Bioinformatics Resources 6.7 was then used for GO analysis.
Annotations for cellular components were only available only for 490 proteins out of 515,
which were then manually curated using the GeneCards database (www.genecards.org) to
compute the percentage of proteins belonging to major cellular compartments according
to their score. Gene Set Enrichment Analysis (GSEA,
http://software.broadinstitute.org/gsea/) software was further performed to identify
significant enrichments in differentially expressed gene signatures, including pathways
based on gene-sets defined from KEGG, BioCarta, and Reactome pathway databases.
Western blotting
Male Sil1Gt and wild-type mice (n=3 for each genotype and age-group, with the
exception of the 6-month time point, for which five male mice of each genotype were
used) were used for western blotting studies. Immediately after euthanization, mice were
perfused with ice-cold PBS through the left cardiac ventricle. Quadriceps were harvested
at necropsy and flash frozen in liquid nitrogen and either processed immediately or stored
until further use. The frozen tissue was pulverized using a liquid nitrogen-chilled mortar
and pestle, and stored at -80°C until further use. The pulverized tissue was lysed, as
described for mass spectrometry analysis, normalized for equivalent protein
concentration using a BCA Protein Assay Kit (Pierce–ThermoFisher Scientific,
Rockford, IL), and samples from the indicated number of mice at the same age were
pooled. To separate NP40-soluble proteins from -insoluble ones, pulverized tissue was
lysed in 50 mM Tris (pH 7.5) buffer containing 150 mM NaCl, 0.5% Nonidet P40, and
0.5% deoxycholic acid. The clarified lysates obtained after centrifugation at 21,130g for
20 minutes were designated as the NP40 soluble fraction. The NP40 insoluble pellets
were washed once with NP40 lysis buffer and then solubilized in 50 mM Tris (pH 8)
buffer, containing 0.6% SDS, sonicated for 4 minutes (30s on-30s off cycles), and
incubated at 95°C for 10 mins to prepare the NP40-insoluble fractions. All buffers
contained 0.25 mM phenylmethylsulphonyl fluoride (PMSF), and a protease inhibitor
cocktail (Complete, Roche). In all cases, tissue lysates were electrophoresed under
reducing conditions on gels ranging from 8 to 16%, or on 4 to 20% gradient gels (Mini-
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PROTEAN® TGX™ Precast Protein Gels, Bio-Rad, Inc., Hercules, CA), depending on
the size of the examined protein. The antibodies used for western blotting are listed in
Supplementary Table S3. HSC70 and GAPDH served as loading controls. Western
blots from the pooled samples in each of the figures were quantified using either Image
Studio™ Lite (LI-COR Biosciences, Inc., Lincoln, NE) or ImageQuant™ TL (GE
Healthcare Life Sciences, Inc., Issaquah, WA). These values were normalized to their
respective GAPDH control values and graphically expressed as fold change in Sil1Gt
protein expression, relative to the wild-type levels set to 1, at each age. Statistical
analyses (Figure 3-9C and Figure 3-12B) were performed compared using Prism Ver. 6
(GraphPad Software, La Jolla, CA) by Student’s t-tests (unpaired; two-tailed).
Real-time PCR
Three male Sil1Gt and wild-type mice for each genotype and age-group,
respectively, were used for quantitative PCR (qPCR) studies. Total RNA was isolated
from pulverized skeletal muscle using RNeasy® Fibrous Tissue Mini Kit (Qiagen, Inc.,
Valencia, CA), according to the company protocol. 1 μg total RNA was reverse
transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA) and subjected to SYBR® Green chemistry-based qPCR
using the QuantStudio 3 Real-time PCR System (Applied Biosystems, Foster City, CA).
Primers were obtained from ThermoFisher Scientific. The primer sequences used are
listed in Supplementary Table S3. Gapdh, Hprt1, Rer1, Rn18s, and Rpl41 were tested
as potential endogenous reference controls, as indicated (171). Gapdh, Rer1, and Rpl41
were comparable in expression between the wild-type and the Sil1Gt quadriceps and, thus,
used as controls. Relative mRNA fold change was computed from the QuantStudiogenerated Ct values by using the 2-ΔΔCt method. Wild-type mRNA levels were
normalized to 1, and Sil1Gt mRNA levels were plotted as a relative measure of the wildtype levels. Statistical analyses were performed using Prism Ver. 6 (GraphPad Software,
La Jolla, CA) by Student’s t-test (unpaired; two-tailed).
Skeletal muscle glucose uptake
Small animal PET-μCT was performed on docked Siemens Inveon DPET and
micro-CT (Siemens Medical Solutions USA, Inc., Malvern, PA) instruments. Four 6
mo.-old wild-type and Sil1Gt male mice were fasted overnight, anesthetized with 2%
isoflurane, and placed supine on a heated animal bed, following which an intraperitoneal
catheter was placed for 18F-FDG injection. Whole-body dynamic PET scan was acquired
over 60 minutes. 18F-FDG (100-120 μCi, 200 μl) was injected via the i.p. catheter 1 min.
after initiating scanning. μCT data were acquired using a 2048 x 3072 mm Field of View
with whole body coverage achieved using automatic stitching of two bed positions (36%
overlap). Projections were acquired at 80 kVp and 500 μA (250ms exposure) over a
rotation of 180° (120 steps), providing an isotropic resolution of 107 μm, and used for
PET attenuation correction. PET Images were reconstructed by three-dimensional
Ordered Subset Expectation Maximization (OSEM 3D) with binning scheme of 5-20, 10-
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60, 5-180, 5-240, and 2-400 (number of bins-time in seconds). The Inveon Research
Workspace (IRW) software was utilized for data processing and image co-registration.
Volumes of interests (VOIs) were drawn over the gastrocnemius, heart, and bladder.
Data from these VOIs were used to calculate radioactivity accumulation for each animal
and plotted versus time. Statistical comparisons of %ID/g were performed by Student’s
t-tests (unpaired; two-tailed) using Prism Ver. 6 (GraphPad Software, La Jolla, CA).
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CHAPTER 4.

MSS-ASSOCIATED MUTATIONS DESTABILIZE SIL1 AND
CAN CAUSE MARINESCO-SJÖGREN SYNDROME
Introduction

Marinesco-Sjögren Syndrome (MSS; OMIM 248800) is a multisystem,
progressive disorder with autosomal recessive inheritance. MSS is clinically
characterized by the triad of cerebellar ataxia, bilateral cataracts, and progressive
myopathy, but is often accompanied by intellectual disability, impaired physical
development, skeletal deformities, and hypergonadotropic hypogonadism (78). The
primary cause of MSS has been attributed to mutations in the SIL1 gene (64, 86),
mapping to the chromosomal locus, 5q31 (85). SIL1 encodes an adenine nucleotide
exchange factor (NEF) for the endoplasmic-reticulum (ER)-resident Hsp70 chaperone,
BiP (63). BiP is a crucial regulator of ER function where it plays a myriad of roles,
including gating the ER translocon that provides a channel for nascent proteins entering
the secretory pathway, aiding the folding and assembly of these proteins, recognizing and
targeting misfolded proteins for proteasomal degradation, regulating the activation of the
ER-localized transducers of the unfolded protein response, and serving as an ER-resident
calcium-binding protein (reviewed in (33)).
Similar to other Hsp70 family members, BiP possesses an N-terminal nucleotide
binding domain (NBD) and a C-terminal substrate binding domain (SBD), which
communicate allosterically via an interdomain linker. The ability of BiP to bind to
substrates via its SBD is regulated by the nucleotide-bound state of its NBD. ATP-bound
BiP can readily engage new client proteins as they enter the ER, however, this
conformation of BiP has a high on/off rate that does not provide a stable interaction with
substrates. ER-resident DnaJ-like proteins (ERdjs), four of which have also been
reported to directly engage client proteins (ERdj3-6), stimulate BiP’s inherently low
ATPase activity while simultaneously transferring the substrate to BiP. Hydrolysis of
ATP to ADP allows closing of the SBD ‘lid’ and thereby stable association of BiP with
its substrate. NEFs interact with BiP’s NBD and exert a torsional strain on the
nucleotide-binding cleft. This causes disengagement and release of the bound ADP. The
binding of a new ATP molecule triggers a conformational change in BiP’s SBD that
lowers the affinity for the bound substrate and causes its release (43, 45). The released
substrate can then undergo conformational maturation and traffic along the secretory
pathway to its final destination. Two ER resident proteins, SIL1 and GRP170, have been
identified that possess nucleotide exchange activity for BiP. SIL1 is ubiquitously
expressed in humans and mice and its tissue-specific expression pattern is similar to that
of BiP (63, 64). GRP170 has also been reported to function as a bona fide ER chaperone
capable of binding a substrate pool overlapping with that of BiP (49). Although the
nucleotide exchange activity of SIL1 and GRP170 is mechanistically distinct (43, 45),
partial redundancy in their function might explain the non-lethal phenotype of SIL1 loss
in humans and mouse models of MSS (50).
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SIL1 has an elongated ‘kidney-bean’-like shape, which is composed of 16 αhelices (A1-A16) and lacks any β-sheets. The central helices A3-A14 form four domains
with Armadillo-like repeats (ARM1-ARM4) (45). A crystal structure of Saccharomyces
cerevisiae Sil1p in complex with the nucleotide binding domain of BiP homolog, Kar2p,
suggests that SIL1 acts as a “wrench” that wraps around lobe IIb of BiP’s NBD
(constituting SIL1’s major BiP-interaction sites) and makes an additional contact with
lobe Ib (constituting SIL1’s minor BiP-interaction sites). This is consistent with the
formerly reported structure of SIL1’s cytosolic ortholog, HSPBP1, with domain II of
HSP70’s NBD. HSPBP1 is also composed of four ARM domains, and available
structural data implies that HSPBP1 binding to its cognate HSP70 would induce a major
distortion to its NBD, destabilizing the bound the ADP and triggering its release,
similarly as the Sil1p-Kar2p interaction (33, 172).
To-date, 46 MSS-associated SIL1 mutations have been identified. About threefourths of these mutations are due to frameshifts, splicing defects, or premature
truncations that are predicted to cause large deletions, resulting in non-functional and
unstable mutant proteins (78). Nine other disease-associated SIL1 mutations arise from
missense substitutions or in-frame deletions of only a few amino acids, but each of these
mutation results in a disease that is indistinguishable from that caused by mutations that
ablate nearly the entire protein (86). However, these SIL1 mutants have not been
thoroughly characterized before. The goal of this study is to understand the
mechanism(s) by which missense mutations and small deletions associated with MSS
lead to a loss of SIL1’s function.
Results
MSS-associated SIL1 mutations affect highly conserved regions, and in most cases
are predicted to disrupt regional alpha-helicity
These nine mutations include six missense mutations, which cause a single amino
acid substitution (p.R92W, p.L206Q, p.R298C, p.G312E, p.G312R, and p.L457P), two
in-frame deletions of either two or five amino acids, respectively (p.V231_I232del and
p.R411_D415del), and one C-terminal premature truncation of six amino acids
(p.L456X) (Table 4-1 and Figure 4-1). We shall henceforth refer to these mutations as
point mutations for the sake of simplicity. To begin to understand the functional
consequences of these nine SIL1 mutations, we first performed a bioinformatics-based
characterization. Alignment of the available species-specific protein sequences of SIL1,
ranging from humans to yeast, revealed that each of these mutations affected amino acid
residues that are highly conserved across multiple mammalian species (Figure 4-2). The
majority of these amino acid residues are either also conserved or conservatively
substituted by an amino acid with similar physicochemical properties in avian, frog,
zebrafish, and fruit fly species. Consistent with this data, SNAP2 (Screening for NonAcceptable Polymorphisms version 2) analysis predicted that all these point mutations
would detrimentally impact protein structure (Figure 4-3). Except for p.L457P, all SIL1
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Table 4-1.

MSS-associated SIL1 mutations that alter less than 6 amino acids.

Exon

Nucleotide change

Amino acid
change

Change in protein
levels / aggregation

Reference

4

c.274C>T

p.R92W

NA

(173)

6

c.617_618TC>AA

p.L206Q

NA

(174)

7

c.691_696del

p.V231_I232del

↓

(78)

9

c.892C>T

p. R298C

No change or ↑

(115)

9

c.935G>A

p.G312E

NA

(99)

9

c.934G>A

p.G312R

↓

(78)

10

c.1230_1244del

p.411_415del

↑

(78, 90)

10

c.1367T>A

p.Leu456X

NA

(88)

10

c.1370T>C

p.Leu457Pro

NA / aggregation

(88)

NA – Information not available.
NOTES: The c.617_618TC>AA mutation affecting leucine at position 206 is incorrectly
annotated as a leucine → glutamic acid substitution at position 206 (174). In fact, the
TC>AA substitution in the wild-type SIL1 mRNA sequence (NM_001037633.1) causes a
leucine → glutamine substitution at position 206 in SIL1’s protein sequence
(NP_001032722.1).
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Figure 4-1. Schematic of the human SIL1 protein indicating the known MSSassociated missense mutations and small in-frame deletions.
The nine mutations include six missense mutations (green), which cause a single amino
acid substitution, two in-frame deletions of either two or five amino acids, respectively
(gray), and one C-terminal premature truncation of six amino acids (red). The purple
segment indicates the signal sequence, the blue segment indicates the ARM-domains, and
the dotted vertical lines represent exon boundaries, beginning with exon 2 since exon 1
consists of a 5’ untranslated region.
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Figure 4-2.

Alignment of the SIL1 protein sequence across multiple species.

(A) Alignment of SIL1 protein sequences across Homo sapiens (human), Gorilla gorilla
gorilla, Chlorocebus sabaeus (monkey), Equus caballus (horse), Bos Taurus (cow),
Canis lupus familiaris (dog), Felis catus (cat), Rattus norvegicus (rat), Mus musculus
(mouse), Gallus gallus (chicken), Xenopus laevis (frog), Danio rerio (zebrafish),
Drosophila melanogaster (fruit fly), and yeast (Yarrowia lipolytica and Saccharomyces
cerevisiae) species using Clustal Omega (175). The panel below the sequence alignment
depicts the consensus amino acid sequence and score across these species. The red
asterisks indicate the positions of the labeled MSS-associated SIL1 mutations used in this
study.
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Figure 4-3.

Predicted detrimental effects of point mutations in SIL1.

The potential functional effects of the six point mutations in SIL1 scores were computed
using SNAP2 (176), which is based on a machine learning approach called “neural
network” that uses in silico derived protein information to make predictions regarding the
impact of individual substitutions on protein function. A score of >50 indicates a strong
potential for effect (dark red), scores between −50 and 50 suggest a weaker effect (light
blue to white to light red), and <−50 indicates a strong signal for neutral or no effect
(blue). The mutant SIL1 residues are indicated as vertical panels and the amino acid
substitutions across these residues are indicated on the left. The functional effect scores,
the scale for these scores, and the percentage accuracy of these predictions are displayed
at the bottom of the panel. Black squares in each column represent the wild-type amino
acid sequence at that position.
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missense mutations displayed a high functional effect score (score >50), indicating a
strong probability for detrimental effect. In the case of p.L457P, the SNAP2 prediction
score was comparatively lesser (score of 42), indicating a weaker probability for the same
effect.
Since SIL1 is primarily composed of alpha-helices, including the ARM domains,
we used the TANGO-AGADIR algorithm to determine if the selected nine SIL1
mutations cause disruptions in the alpha-helix forming propensities of the affected
regions. The arginine at position 92 in the wild-type SIL1 sequence lies upstream of a
potential alpha-helix. In keeping with this, the substitution of this arginine to a
tryptophan in the p.R92W SIL1 mutant did not affect the alpha-helical propensity of this
region (Figure 4-4A). Instead, the TANGO algorithm predicts that this missense
mutation leads to a significant increase in aggregation propensity of this region (Figure
4-5). The leucine-206 resides at the end of an alpha-helical region and the substitution to
glutamine led to significant decrease in the alpha-helix forming propensity in this region
(Figure 4-4B). In the case of p.V231_I232del, p.R298C, p.312E, p.G312R,
p.R411_D415del, p.L456X, and p.L457P, each of these mutations led to dramatic
disruptions in the alpha-helix forming propensities of the affected areas (Figure 4-4C-H).
Structural modeling suggests that the selected MSS-associated mutations affect
residues which play a key role in maintaining SIL1’s structural integrity
Human SIL1 shares 20.60% sequence identity with S. cerevisiae Sil1p and
22.89% sequence identity with human HSPBP1, whereas S. cerevisiae Sil1p is 19.75%
identical to human HSPBP1 (computed using Clustal Omega). Importantly, SIL1 regions
affected by MSS mutations are largely conserved with at least one other NEF, if not with
both Sil1p and HSPBP1. In the majority of cases, these residues are either completely
conserved or occupied by similar amino acids in HSPBP1. As structural data are
available for both Sil1p and HSPBP1 with the nucleotide binding domains of their
corresponding Hsp70s, we reasoned that these structures could be used to understand
with a reasonable degree of confidence how MSS mutations might impact their local
environment within the SIL1 protein. Although the overall sequence identity between
full length yeast Sil1p and human HSPBP1 is quite poor, these proteins share significant
structural similarities, including similar HSP70-interacting interfaces (tertiary fold-based
pair-wise structure alignments computed using the jFATCAT-flexible tool yield a Pvalue of 2.50E-09) (Figure 4-6). Structural data are available for six out of the selected
nine SIL1 mutated residues.
The MSS-associated SIL1 mutation p.L206Q, which corresponds to
phenylalanine-155 in S. cerevisiae Sil1p (Sc_Sil1p) and leucine-124 in human HSPBP1
(Hu_HSPBP1) sequences (Table 4-2). Both these amino acids reside within a
hydrophobic pocket and are involved in hydrophobic interactions between neighboring
alpha-helices (Figure 4-7 upper panel). Thus, the introduction of a polar glutamine side
chain in the p.L206Q MSS mutant is likely to disrupt the hydrophobic environment and
affect the packing of local alpha-helical units. The deleted two amino acids in the
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Figure 4-4. TANGO-AGADIR predicted alpha-helix forming propensities of the
selected SIL1 mutant.
(A-H) Graphical representation of the alpha-helical propensities of the regions affected
by p.R92W (A), p.L206Q (B), p.V231_I232del (C), p.R298C (D), p.G312E, p.G312R
(E), p.R411_D415del (F), p.L456X (G), and p.L457P (H), as predicted by the TANGOAGADIR algorithm (177). Gray bars indicate the numerical values for alpha-helical
propensities (expressed as Arbitrary Units, A.U.) for the wild-type SIL1 sequence (WT),
whereas red bars indicate the respective values for the SIL1 mutant. The wild-type and
the mutant SIL1 sequences and the position of each residue are displayed below the
graphs, and the respective mutations are highlighted by a red box.
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Figure 4-5. TANGO-predicted aggregation propensity of the region affected by
the p.R92W point mutation in SIL1.
Graphical representation of the aggregation propensities of the region affected by
p.R92W, as predicted by the TANGO algorithm (177). Gray bars indicate the numerical
values for aggregation propensity (expressed as Arbitrary Units, A.U.) for the wild-type
SIL1 sequence (WT), whereas red bars indicate the respective values for the SIL1
mutant. The wild-type and the mutant SIL1 sequences and the position of each residue
are displayed below the graphs. The p.R92W mutation is highlighted by a red box.
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Figure 4-6. The interaction of Sil1p and HSPBP1 with their respective HSP70
chaperones.
(Upper left panel) The structure of S. cerevisiae Sil1p (cyan) in complex with the
nucleotide binding domain of Kar2p (green) indicates that Sil1p engages lobe IIb of
Kar2p, and has a minor interaction with lobe Ib (PDB: 3QML) (45). The upper panel
displays a higher magnification of the Sil1p-Kar2p interaction interface. (Upper right
panel) The structure of human HSPBP1 (lilac) with lobe IIb of the human HSP70
nucleotide binding domain (dark green; PDB: 1XQS) (33, 172). The upper panel
displays a higher magnification of the HSPBP1-HSP70 interaction interface. (Lower
panel) Pairwise structural alignments of either Sc_Sil1p (3QML_C; cyan) with
Hu_HSPBP1 (1XQS_A; lilac), or Sc_Kar2p (3QML_A; green) with either Hu_HSP70
(1XQS_D; red) or Hu_BiP (5EVZ_A; yellow) computed using the jFATCAT–rigid tool.
Please note that structural data for domain I of HSP70’s NBD is not available. The
respective RMSD (Å) values for each structural alignment is noted under the aligned
structure. RMSD, root mean square deviation.
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Table 4-2.
Sil1p and HSPBP1 amino acid residues corresponding to MSSassociated human SIL1 mutants.
Hu_SIL1 amino acid

Sc_ Sil1p amino acid

Hu_HSPBP1 amino acid

p.R92W

NA

NA

p.L206Q

F155

L124

p.V231_I232del

L179_A180

L149_V150

p.R298C

Not conserved

R217

p.G312E

S265

G231

p.G312R
p.R411_D415del
(RYRQD)*
p.Leu456X

S265

G231

K374_S378 (KARQS)

R322_Q326 (RHRCQ)

NA

NA

p.Leu457Pro

NA

NA

NA – Structural data not available.
*Clustal Omega predicts that the sequence TTCRD-RYRQD in human SIL1 aligns with
QQCKA-RQSNx in yeast Sil1p. However, the structural alignment of Sil1p (PDB ID
3QML) and HSPBP1 (PDB ID 1XQS) suggests that the RYRQD motif in Hu_SIL1 more
accurately corresponds to the KARQS motif (amino acid residues 374-378) in Sc_Sil1p.
This motif superimposes on the RHRCQ motif in Hu_HSPBP1 (amino acid residues 322326), with the central arginine being conserved between all three species.
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Figure 4-7. Structural mapping of the residues corresponding to p.L206Q,
p.V231_I232del, and p.G312E/R.
The upper panel demonstrates the position of the corresponding F155 and L179-A180
residues in Sc_Sil1p (cyan, left) and L124 and L149-V150 in Hu_HSPBP1 (lilac, right),
which are affected by the p.L206Q and p.V231_I232del mutations (yellow, label in red),
respectively. The residues constituting the hydrophobic core are labeled in black. The
lower panel similarly demonstrates the location of the corresponding S265 in Sc_Sil1p
(cyan, left) and G231 in Hu_HSPBP1 (lilac, right), which are affected by the p.G312E
and p.G312R mutations (yellow, label in red), respectively. The amino acid residues
constituting the hydrophobic stretch juxtaposed to S265 and G231 are labeled in black.
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p.V231_I232del SIL1 mutant correspond to similar hydrophobic residues, leucine-179
and alanine-180 in Sc_Sil1p, and leucine-149 and valine-150 in Hu_HSPBP1,
respectively. These amino acids are also embedded within the same hydrophobic pocket
as phenylalanine-155 and leucine-124 (Figure 4-7 lower panel), and the deletion of these
amino acids might directly affect the stability of this hydrophobic core. In addition, this
deletion would be predicted to insert the subsequent polar amino acid, asparagine-181
into the hydrophobic core in Sc_Sil1p, which may not be tolerated. This asparagine is
only conserved between yeast and human SIL1 (asparagine-233).
Serine-265 in Sc_Sil1p and glycine-231 in Hu_HSPBP1 correspond to glycine312 in human SIL1, which is mutated to either an arginine or a glutamine (p.G312E/R) in
a subset of American and Dutch MSS patients. These residues are juxtaposed to a stretch
of hydrophobic residues, constituting of tyrosine-264, methionine-226, valine-268, and
valine-267 in Sc_Sil1p, and leucines at positions 229, 193, and 234 in Hu_HSPBP1
(Figure 4-7). Both serine-265 and glycine-231 are relatively small in size and offer
increased conformational flexibility, especially in tight turns, as exemplified by the
glycine-231 in Hu_HSPBP1. The substitution of these residues by either an arginine, in
the case of p.G312R, or glutamic acid, in the case of p.G312E, can have disastrous
consequences for two reasons. Both, arginine and glutamic acid, have charged sidechains
with relatively larger geometries compared to glycine. Thus, these large polar
substitutions are likely to create steric hindrances that disrupt interactions among the
neighboring alpha-helices in the hydrophobic pocket.
Although the MSS-associated p.L206Q and p.G312E/R mutations reside within
exons 6 and 9, respectively, both of which are predicted to be major BiP interactions
sites, these mutations are likely to disrupt intramolecular interactions and destabilize
SIL1 rather than affecting its BiP-interaction motif. The p.R298C and p.R411_D415del
mutations correspond to regions in Sc_Sil1p and Hu_HSPBP1 that interact with their
respective HSP70 chaperones. Arginine-298 in SIL1 corresponds to arginine-217 in
Hu_HSPBP1, while Sc_Sil1p uses a different sequence, albeit with a similar structural
interface to interact with Kar2p. Positively charged, polar arginine-217 lies at the
epicenter of a hydrogen bond network. This arginine forms hydrogen bonds with HSP70
glutamic acid-283, as well as with the mainchain and sidechain of serine-281 in HSP70,
thereby contributing to one of the major HSP70-binding interfaces of HSPBP1. In
addition, Hu_HSPBP1 glutamine-174, serine-213, and asparagine-256 sidechains form
intramolecular hydrogen bonds with the arginine-217 sidechain, thus, stabilizing the
conformation of the HSP70-interacting groove, which also includes neighboring helices
(172) (Figure 4-8 upper panel). Thus, the substitution of arginine-298 with the shorter
and uncharged cysteine-sidechain in p.R298C could be potentially destabilizing the
HSP70-binding interface of HSPBP1, in keeping with decreased alpha-helical propensity
predicted by TANGO-AGADIR, and could lead to decreased binding affinity for HSP70.
In addition, the introduction of a reactive cysteine residue adjacent to another cysteine
(i.e. cysteine-294 in Hu_SIL1 and cysteine-214 in Hu_HSPBP1) may also introduce an
aberrant disulfide bond, which can further potentiate the negative consequences of this
substitution.
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Figure 4-8.
ΔRYRQD.

Structural mapping of the residues corresponding to p.R298C and

The upper panel demonstrates the position of the corresponding R217 in Hu_HSPBP1
(lilac), which is affected by the p.R298C mutation (yellow, label in red). The structure of
HSP70 NBD and the HSP70 residues, which forms hydrogen bonds with HSPBP1 (S281
and E283), are displayed in dark green. Hydrogen bonds are illustrated as yellow dashed
lines. Neighboring HSPBP1 amino acids forming hydrogen bonds with R217 are labeled
in black. The lower panel demonstrates the positions of K374-S378 amino acids in
Sc_Sil1p (cyan) and R322-Q326 in Hu_HSPBP1 (lilac), which correspond to amino acids
affected by the ΔRYRQD mutation in human SIL1 (yellow, label in red). The structure
of the nucleotide binding domains of Kar2p and HSP70, and their residues which forms
hydrogen bonds with either Sc_Sil1p or Hu_HSPBP1 are displayed in bright and dark
green, respectively. The residues on Sc_Sil1p interacting with Kar2p are labeled in cyan,
and the residues on Hu_HSPBP1 interacting with HSP70 are labeled in purple,
respectively. Hydrogen bonds are illustrated as yellow dashed lines. Neighboring
Sc_Sil1p and Hu_HSPBP1 amino acids forming hydrogen bonds are labeled in black.
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The MSS-associated p.R411_D415del SIL1 mutation leads to an in-frame
deletion of five amino acids (RYRQD). The central arginine-413 of the deleted RYRQD
motif in human SIL1 corresponds to arginine-376 in Sc_Sil1p and arginine-324 in
Hu_HSPBP1. Although this conserved arginine does not directly interact with Kar2p or
HSP70, it seemingly plays a role in intramolecular stability of the Sil1p-Kar2p and
HSPBP1-HSP70 interaction sites (Figure 4-8 lower panel). In Sc_Sil1p, arginine-376
forms polar interactions with glutamic acid-338 and aspartate-395 of neighboring alphahelices, which additionally harbor multiple residues that directly interact with Kar2p,
such as glutamic acid-390 and aspartate-337 that form hydrogen bonds with serine-324
and arginine-326 of Kar2p, respectively. Consistent with our interpretation, mutations of
the Sc_Sil1p glutamic acid-390 and aspartate-337 residues to alanine have been reported
to significantly decrease the affinity of Sil1p for Kar2p (45). Arginine-324 in
Hu_HSPBP1 also adopts a crucial role in stabilizing the intramolecular topology of
neighboring C-terminal helices by forming inter-chain hydrogen bonds with the glutamic
acid-337 sidechain and the valine-281 mainchain of Hu_HSPBP1 (Figure 4-8 lower
panel). These reside near numerous polar interactions between the glutamic acid residues
at positions 290, 332, 333, and 336 in Hu_HSPBP1 with the HSP70 lysines at positions
248 and 250, and arginine-247. Thus, the loss of this conserved arginine can potentially
destabilize Sc_Sil1p’s and Hu_HSPBP1’s BiP-interaction site.
MSS-associated SIL1 mutants form NP40-insoluble aggregates
It has been argued that alpha helices are more robust at withstanding mutations
than beta-strands due to a greater number of inter-residue contacts in helices (178).
Alpha-helical predictions by TANGO and our structural modeling indicate that eight of
these nine SIL1 mutations are likely to disrupt regional alpha helices and modify SIL1’s
structure, whereas the remaining p.R92W mutation increases its aggregation propensity.
Thus, we examined the biochemical consequences of these mutations by exogenously
expressing them in COS-1 cells. To determine if these SIL1 mutants aggregated, we
analyzed the NP40-soluble and -insoluble fraction of cell lysates by western blotting.
Surprisingly, all mutants displayed a tendency to aggregate, as evidenced by the
accumulation of SIL1 mutants in the NP40-insoluble fraction (Figure 4-9A, B).
Although we previously reported that the p.L457P mutant, which affects the very Cterminus of SIL1, aggregates (88), these data reveal it is comparatively less aggregationprone than several other mutants.
To further explore the aggregation propensity and behavior of these SIL1 variants,
we treated COS-1 cells expressing wild-type and mutant SIL1 with a membrane
permeable, reversible cross-linker, dithiobis succinimidyl propionate (DSP), which has a
thiol cleavable disulfide bond. We processed the NP40-soluble lysates for western
blotting under non-reducing and reducing conditions. For all SIL1 mutants, we observed
higher molecular weight species under non-reducing conditions that range from
approximately 110 kDa to greater than 260 kDa, whereas wild-type migrates as a 56 kDa
band (Figure 4-9C). In all cases, when the cross-linked samples were treated with a
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Figure 4-9.

MSS-associated SIL1 mutants form NP40-insoluble aggregates.

(A) COS-1 cells were transfected with either empty pSVL vector, or pSVL containing
wild-type SIL1 or mutant SIL1 cDNA. After 24 hours, these cells were lysed with NP40
lysis buffer and the NP40-soluble and -insoluble fractions were collected and processed
for western blotting under reducing conditions and probed for SIL1. The western blots
displayed are representative of three experiments. GAPDH serves as a loading control.
(B) Graph represents densitometric quantitation of western blotting data (n=3) from (A)
for the NP40-soluble (blue) and NP40-insoluble (red) fractions. GAPDH-normalized,
NP40-soluble plus -insoluble SIL1 levels were designated as total SIL1 and expressed as
100%, whereas the NP40-soluble and -insoluble levels are displayed as a fraction of total
SIL1. Error bars indicate means ± s.e.m. (C) COS-1 cells were either transfected with
empty pSVL vector, pSVL-SIL1WT, pMT-BiPWT-NBD (BiP 44k), or pSVL-SIL1mutant.
After 24 hours, these cells were crosslinked using DSP and lysed using RIPA lysis buffer.
The RIPA-soluble lysates were processed for western blotting under non-reducing (upper
blot) and reducing (lower blots) conditions and probed with SIL1. Western blotting
results are from one experiment (n=1). Two exposures for lysates processed under
reducing conditions are displayed. The higher molecular SIL1 oligomers in the nonreducing and reducing blots are indicated on the right.
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reducing agent prior to SDS-polyacrylamide electrophoresis, the larger species were
primarily resolved into a single 55 kDa band. Thus, the slower migrating species present
in the SIL1 mutants represent NP40-soluble SIL1 oligomers and are a clear indication of
misfolding.
MSS-associated SIL1 mutants alter its half-life
We consistently observed higher steady-state expression of several SIL1 mutants.
While misfolded proteins are often retrotranslocated to the cytosol for degradation via the
ubiquitin-proteasomal system, the formation of aggregates can interfere with their
degradation. To determine if this was indeed the case, we transfected COS-1 cells with
wild-type SIL1 and the nine mutants, performed a cycloheximide (CHX) chase, and
analyzed the levels of SIL1 in the NP40-soluble fraction by western blotting. The halflife of wild-type SIL1 was determined to be approximately three hours, in accord with
our previous result (88). Interestingly, we observed that a subset of SIL1 mutants
displayed increased stability over a six-hour timeframe with minimal degradation,
whereas the remaining SIL1 mutants displayed increased turnover and degradation
kinetics, relative to wild-type levels (Figure 4-10). The subset of SIL1 mutants
displaying increased protein stability consisted of p.R92W, p.L206Q, p.R298C, p.G312E,
p.G312R, and ΔRYRQD, whereas ΔVI, p.L456X, and p.L457P mutants displayed
fasterturnover compared to wild-type SIL1. With the exception of p.L206Q, these
mutants distinctly segregate into the two classes based on their aggregation tendencies.
Discussion and Future Direction
This is currently an ongoing project within the lab and is pending completion.
Thus far, we show that the selected nine MSS-associated SIL1 point mutations affect
residues that are highly conserved in mammals. Bioinformatic analyses suggested that
these mutations are likely to have detrimental effects on SIL1 structure. The large
majority of the affected residues reside within alpha-helices, which are likely to be
disrupted by the MSS-associated pathogenic substitutions. Structural data based on yeast
Sil1p and human HSPBP1, the cytosolic ortholog of SIL1, are consistent with these
indications and further argue that the introduction of mutant residues are likely to perturb
intramolecular interactions required for achieving a native structure. In addition to
affecting intramolecular interactions, two of the mutations, p.R298C and
p.R411_D415del, affect amino acids that reside in the vicinity of a major and minor BiPinteraction interface, respectively, and thus are also likely to affect the ability of SIL1 to
interact with BiP. All nine SIL1 mutants were aggregation prone, albeit with varying
characteristics and propensities, thus, confirming that the selected MSS-associated SIL1
mutations affect the folding properties of SIL1. We additionally observed a distinction in
the half-lives of these mutants. A subset of SIL1 mutants, including p.R92W, p.G312E,
p.G312R, and p.R411_D415del mutants, displayed significantly increased stability,
whereas the p.V231_I232del, p.L456X, and p.L457P mutants were rapidly cleared by the
cell. These differences may at least partially stem from their tendency to aggregate,
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Figure 4-10. SIL1 mutations alter its stability and degradation kinetics.
(A) COS-1 cells were transfected with the pSVL vector containing either wild-type (WT)
or mutant SIL1. 24 hours later, these cells were treated with the protein synthesis
inhibitor, CHX, and chased for the indicated timeframes. These cells were then lysed
with NP40 lysis buffer and the NP40-soluble fraction was processed for western blotting
for SIL1. (B) Graphical representation of the percentage of SIL1 remaining at the
indicated timepoints. These values are derived from densitometric quantitation of the
half-lives of WT (n=3) and SIL1 mutants (n=1) from (A), normalized to 100% at the zero
timepoint. HSC70 serves as a control for equivalent loading. The error bars for WT
indicate means ± s.e.m.
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displayed a relatively lower tendency to aggregate, which is in keeping with the fact that
large protein aggregates are more difficult to retrotranslocate and degrade.
Completing studies on the half-lives of SIL1 mutants
These results indicate that the latter subset of SIL1 mutants may be effectively
recognized as targets of the ER-associated degradation (ERAD) machinery, which allow
rapid clearance, whereas the highly-aggregation prone SIL1 mutants may predominantly
depend on autophagy for the degradation of high molecular weight aggregates. This is
partially supported by our previously published data for the p.L457P mutant, which
demonstrates that the treatment of cells expressing this mutant with the proteasomal
inhibitor, MG132, resulted in stabilization of this mutant, whereas the disruption of
autophagy in these cells by ammonium chloride treatment did not have a significant
effect (88). In addition to achieving at least three experimental trials for the CHX-chase
experiments, it is important to confirm if the two classes of SIL1 mutants indeed
segregate into these classes according to their heir half-lives.
Do the selected SIL1 mutants display a dominant-negative behavior?
In keeping with our data, the SIL1 mutations used in this study affect its folding
properties and cause aggregation. It is possible that SIL1 misfolding, perhaps for a subset
of these MSS-associated mutants, may cause a dominant-negative effect by which the
mutant SIL1 protein may antagonize the function of wild-type SIL1 by co-aggregation.
This mechanism has been well exemplified in the case of epidermolysis bullosa simplex,
involving dominant-negative mutations in keratin 5 and keratin 14, and by a subset of
mutations affecting p53 in cancer (179). Engineering an N-terminal tag after the ERtargeting signal sequence for wild-type SIL1 that adds sufficient molecular weight to
distinguish the tagged wild-type and untagged mutant SIL1 proteins by SDS-PAGE
would permit co-immunoprecipitation experiments. This would allow us to determine if
SIL1 mutants co-immunoprecipitate with the wild-type SIL1, and if they form multimeric
species or higher molecular weight aggregates under non-reducing conditions. The
introduction of an N-terminal tag compared to a C-terminal tag is preferred since the
latter plays a role in maintaining SIL1’s structural integrity and may introduce
experimental artifacts (88).
Evaluating the ability of chemical chaperones to rescue SIL1 mutants
The primary criteria for selection of the SIL1 mutants used in this study out of the
46 reported MSS-associated mutations was that they affect less than six amino acids and
retain the ARM domains, which mediate SIL1’s interaction with BiP. Classically, MSS
displays Medelian, autosomal recessive inheritance and heterozygous individuals
carrying one allelic mutation in SIL1 do not apparently display the cardinal features of
MSS. Thus, it is possible that stabilizing even small amounts of SIL1 mutants may
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partially rescue the defects associated with SIL1 loss and alleviate the severity of the
MSS-associated symptoms.
Chemical chaperones are low molecular weight compounds that function
similarly as molecular chaperones, with respect to their role in maintaining proteostasis
and favoring the folded conformation of a protein, but have a nonspecific mode of action
(180). Small molecules, sodium 4-phenylbutyrate (PBA) and tauroursodeoxycholic acid
(TUDCA), are hydrophobic chemical chaperones, whose proposed mechanisms of action
involves their interaction with exposed hydrophobic protein regions, which are generally
buried in correctly folded protein conformations, but surface exposed in misfolded or
unfolded states. Both PBA and TUDCA are orally bioavailable, blood-brain-barrier
(BBB)-permeable, have a no-to-low toxicity profile, and are Food and Drug
Administration (FDA)-approved for the treatment of urea cycle disorders or primary
biliary cirrhosis, respectively for PBA and TUDCA (180). PBA has been effective in
restoring folding of mutant forms of CFTR (181, 182), α1-antitrypsin (183), serotonin
transporter (184), uromodulin (185), and nephrin (186), which are all synthesized in the
ER, and to ameliorate the aggregation of desmin intermediate filaments in an animal
model of myofibrillar myopathy and primary myotubes derived from this model (187).
TUDCA has proven effective to restore folding of mutant laminin β2 (188), and to
protect neurons against poly(GA)-induced ER stress and toxicity (189). To test the
activity of these agents in preventing aggregation or promoting the stability of mutant
SIL1 proteins that are rapidly degraded, we will transfect COS-1 cells with vectors
encoding the nine SIL1 mutants and add either PBA or TUDCA 24 to 72 hours prior to
assaying these mutant proteins. To determine the optimal concentration of PBA and
TUDCA to use for these experiments, we will perform a dose response curve based on
previously reported concentrations of these chemical chaperones, and assay SIL1 levels
in the NP40-soluble and -insoluble fractions by western blotting. We will then determine
the effects of PBA and TUDCA on the half-life of SIL1 mutant proteins, using a similar
approach as demonstrated in Figure 4-10. Lastly, for those SIL1 mutants that are
rescued by the treatment with either PBA or TUDCA, we will determine if this treatment
also restores the ability of mutant SIL1 to associate with BiP at levels comparable to the
wild-type protein as one method of determining if chemical chaperones may indeed
restore the function of SIL1 mutants.
Investigating the ability of SIL1 mutants to bind BiP
The next critical aspect of characterizing these SIL1 mutants is to test their ability
to interact with the nucleotide binding domain of BiP function, which governs the
nucleotide exchange activity of SIL1. This experiment is especially crucial to understand
the mechanisms by which the p.R298C and the p.R411_D415del mutations lead to a loss
of SIL1’s function, since both of these residues are suggested to function in maintaining
the structural integrity of the BiP-interaction interface. These predictions are consistent
with a previous report, which shows that both the p.R411_D415del and p.L457P SIL1
mutants immunoprecipitate lower amounts of full length BiP, relative to wild-type SIL1
or HSPBP1, and are aggregation-prone (78, 90). However, from a mechanistic
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standpoint, it remains unclear if BiP recognizes the mutant SIL1 proteins as partially
unfolded or misfolded substrates, or if the mutant SIL1 indeed retains its ability to
interact with BiP’s NBD. There are two strategies to solve this conundrum. The first is
co-transfecting the wild-type and mutant SIL1 along with the BiP nucleotide binding
domain, which harbors either the G226D or the G227D mutation (residues correspond to
hamster BiP sequence) in COS-1 cells, and immunoprecipitating with anti-BiP antibody
to assay the amount of co-immunoprecipitating wild-type and mutant SIL1. It has been
previously demonstrated that SIL1 preferentially binds to the ADP-bound conformation
of BiP (63, 190). The G226D and G227D BiP NBD mutations, which disrupts the ATPbinding site in each case, behave in a similar manner as the ADP-bound conformation of
BiP and readily engage SIL1 (63). These BiP NBD mutants are also unaffected by
cellular ATP, which causes disengagement of the SIL1-BiP interaction upon lysis, and
allows us to assay the interaction of BiP with the various SIL1 mutants without the
requirement for cross-linking. The second strategy relies on engineering select point
mutations in BiP that allow us to dissect the binding of SIL1 as a NEF versus as a
substrate. Two point mutations in domain IIb of Kar2p’s NBD, E311A and R317, have
been shown to selectively disrupt Sil1p binding without altering the ability to interact
with Lhs1p, the yeast GRP170 homolog (65). Conversely, the V461F and R492E
mutations in BiP’s SBD have been independently shown to significantly compromise its
ability to interact with substrates (191, 192). After optimization studies to validate the
full-length BiP mutants, we will co-transfect wild-type and mutant SIL1 encoding
cDNAs in COS-1 cells, along with either wild-type BiP, the BiP NBD mutant, or the BiP
SBD mutant, and determine the amount of SIL1 co-immunoprecipitating with each of
these BiP constructs, allowing us to determine the total amount of SIL1 that binds BiP,
and the amount of SIL1 that engages BiP as a NEF or as a client protein. The H214A
point mutation in SIL1, corresponding to histidine-163 in Sil1p, has been reported to
disrupt its binding with BiP’s NBD and can serve as a negative control for the interaction
of SIL1 with BiP as a NEF (45).
Investigating the NEF activity of corrected SIL1 mutants
For those SIL1 mutants that are able to be successfully salvaged in terms of their
aggregation propensity, stability, and their ability to interact with BiP upon treatment
with chemical chaperones, we will then determine if these SIL1 mutants have NEF
activity as the final piece in this manuscript. Since this is an in vitro assay, we will
require recombinant SIL1 protein. While we were able to successfully achieve sufficient
levels of wild-type SIL1 (63), the mutant SIL1 proteins are aggregation-prone when
expressed in mammalian cells, they are likely to form inclusion bodies in bacteria.
However, we are well equipped to circumvent this challenge and have successfully
resolubilized proteins, such as ERdj3 mutants, from inclusion bodies (193). We will
determine the ability of SIL1 mutants that are amenable for rescue by chemical
chaperones to increase BiP’s ATPase activity, which will be evaluated by both nucleotide
exchange and ATPase assays, as previously performed (63).
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Overall, our results will offer mechanistic insights into how the selected MSSassociated SIL1 mutations could disrupt regional interactions and destabilize alphahelices, rendering mutant SIL1 more aggregation prone with aberrant degradation
kinetics, thus, explaining how these mutations cause a loss of functional SIL1 and MSS.
We will further explore two approaches using hydrophobic chemical chaperones, PBA
and TUDCA, that have demonstrated promising preclinical results for various protein
misfolding indications, to rescue the defects associated with these SIL mutations.
Materials and Methods
Bioinformatics
Multiple sequence alignment
The FASTA sequences for SIL1 from numerous organisms were obtained from
UniProt (https://www.uniprot.org/). Their UniProt IDs are as follows: Homo sapiens
(Q9H173), Gorilla gorilla gorilla (G3RAN4), Chlorocebus sabaeus (A0A0D9RKX0),
Equus caballus (F6ZBH7), Bos Taurus (Q32KV6), Canis lupus familiaris (F1PLP6),
Felis catus (M3VX58), Rattus norvegicus (Q6P6S4), Mus musculus (Q9EPK6), Gallus
gallus (F1NWG7), Xenopus laevis (Q6NUA7), Danio rerio (A0A0G2KDW7),
Drosophila melanogaster (Q9VBV5), Yarrowia lipolytica (Q99158), and Saccharomyces
cerevisiae (Q08199). Multiple sequence alignment of these protein sequences, using
Clustal Omega, and the phylogenetic tree, depicting the evolutionary relationships of
these organisms with respect to the SIL1 protein sequence, was computed with the
DNASTAR® MegAlign Pro software (DNASTAR, Inc., Madison, WI).
Prediction of functional effects of missense SIL1 mutations
The functional effects of missense SIL1 mutations were predicted in silico using
the Screening for Non-Acceptable Polymorphisms software (SNAP2;
https://www.rostlab.org/services/SNAP) (176). SNAP2 is a classifier based on a machine
learning device called the “neural network,” which predicts the potential impact of single
amino acid substitutions on protein function, and has been demonstrated to outperform
SNAP, PolyPhen-2, and SIFT. The FASTA sequence for human SIL1 (UniProt ID
Q9H173) was used as input. SNAP2 reports the prediction score of all possible
substitutions for each amino acid within a protein and their percentage accuracy and
displays the prediction scores as a heatmap. Dark red indicates a high score (score>50,
strong signal for effect), white indicates weak signals (-50<score<50), and blue indicates
a high negative score (score<-50, strong signal for neutral or no effect).
Prediction of alpha-helical and aggregation propensities using TANGO
The alpha-helix and aggregation forming propensities of the various SIL1 mutants
were computed with the default parameters and conditions using TANGO
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(http://tango.crg.es/), which in turn uses AGADIR (AGADIR-1s11) with the
implementation of the multiple partition function for calculating alpha-helical
propensities. The complete sequence of either human wild-type or mutant SIL1 was used
for input. The graphs in Figure 4-4 and Figure 4-5 only portray either the alpha-helical
or aggregation propensity values for the region consisting of the mutation and ten amino
acids upstream and downstream of the mutation. Graphs were plotted using Excel 2016
(Microsoft, Inc., Redmond, WA).
Analysis of the yeast Sil1p and human HSPBP1 structures
Multiple sequence alignment of human SIL1, S. cerevisiae Sil1p, and human
HSPBP1 (UniProt ID Q9NZL4) using Clustal Omega was computed with the
DNASTAR® MegAlign Pro software. This alignment has also been previously reported
in (63). We computed pairwise structural alignments with the jFATCAT-rigid method
(http://www.rcsb.org/pdb/workbench/workbench.do), using 3QML_chain C for Sc_Sil1p
(sequence length=262 aa), 1XQS_chain A for Hu_HSPBP1 (sequence length=264 aa),
3QML_chain A for Sc_Kar2p (sequence length=377 aa), and 1XQS_chain D for
Hu_HSP70 (sequence length=165 aa).
Generation of MSS-associated SIL1 mutants using site-directed mutagenesis
pSVL-SIL1WT was used as the template to generate the nine MSS-associated SIL1
mutations (Table 4-1), and site-directed mutagenesis was performed as previously
reported (88) with a few adaptations. Briefly, Pwo DNA polymerase (identifier:
11644955001; Millipore Sigma, Burlington, MA) was used in the mutant strand synthesis
PCR reaction, instead of the reported PfuTurbo DNA polymerase in the company
protocol. Thermal cycling was performed using the DNA Engine® PTC-200 Gradient
Thermal Cycler (Bio-Rad Laboratories, Inc., Hercules, CA) with the following
parameters: 95°C for 30s, 95°C for 30s, 55°C for 60s, 72°C for 5 minutes, repeated from
step 2 for an additional 35 cycles, 72°C for 7 minutes, and held at 4°C overnight.
Following generation of the mutant strands, digestion of the amplified products was
performed using 10 U/μl of DpnI (identifier: R0176S; New England Biolabs, Ipswich,
MA) and incubated for 2 hours at 37°C, following which bacterial cells were
transformed. Sanger sequencing was performed to verify the generation of the respective
mutant cDNA for expression in COS-1 cells. The forward primer sequences were used
for site-directed mutagenesis are listed in Table 4-3, whereas the respective reverse
complement of these sequences were used as the reverse primer. The p.L457P
(c.1370T>C) SIL1 mutant has been previously reported (88). Primers were obtained
from ThermoFisher Scientific (Waltham, MA).
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Table 4-3.
Primer sequences for the generation of SIL1 mutants using sitedirected mutagenesis.
Nucleotide change

Forward primer sequence

c.274C>T

5’-ggctgtccctgcaggatcccacgtatggctgaatcttcagactgggg-3’

c.617_618TC>AA

5’-gtttggaagagaagattgctgcgcaatttgatcttgaatattatgtccatc-3’

c.691_696del

5’-gctttcctttggtggtcttcaagtgaatgggctgaacagcacagagcccc-3’

c.892C>T

5’-cctgtttgcactgtgctccctgctgtgccacttcccctatgcccagcggc-3’

c.935G>A

5’-ccagcggcagttcctgaagctcggggagctgcaggtcctgaggaccctgg-3’

c.934G>A

5’-ccagcggcagttcctgaagctcgggaggctgcaggtcctgaggaccctgg-3’

c.1230_1244del

5’-gcgtcctcctgaccacctgccgggacccccagctcggcaggacactggcc-3’

c.1367T>A

5’-gctgctgggctctgtcaacagctagctgaaggagctgagatgaggcccc-3’

NOTE: The reverse complement of the respective forward primer sequence was used as
the reverse primer. The cDNA substitution is indicated as bold and underlined in the
forward primer sequence.
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Cell culture, transfections, western blotting, and densitometric quantitations
COS-1 cells were maintained and transfected using GeneCellin (Bulldog Bio,
Inc., Portsmouth, NH) as described previously (44). 450,000 COS-1 cells were seeded
per p60 24 hours prior to transfection. Cells were transfected with 3 μg per p60 of either
wild-type or mutant SIL1 cDNA using GeneCellin, following the manufacturer’s
protocol. 24 hours after transfection, cells were harvested and lysed in 50 mM Tris (pH
7.5) buffer containing 150 mM NaCl, 0.5% Nonidet P-40 and 0.5% deoxycholic acid,
designated as the NP40 lysis buffer. The clarified lysates obtained after centrifugation at
21,130 g for 20 minutes were designated as the NP40-soluble fraction. The NP40insoluble pellets were washed once with NP40 lysis buffer and then solubilized in 50 mM
Tris (pH 8) buffer, containing 0.6% SDS, sonicated for 4 minutes (30 s ON-30 s OFF
cycles) and incubated at 95°C for 10 minutes. All buffers contained 0.25 mM
phenylmethylsulphonyl fluoride (PMSF) and 1x complete protease inhibitor tablets
without EDTA (Roche Applied Science, Indianapolis, IN, USA), as reported (194). 2%
(v/v) of the total NP40-soluble lysates and 10% (v/v) of the total insoluble lysates were
electrophoresed under reducing conditions on 8% gels. The following antibodies were
used for immunoblotting: rabbit anti-SIL1 antisera (dilution of 1:1000; reported in (63,
64) and anti-GAPDH (dilution of 1:2500; clone 6C5; identifier: MAB374; EMD
Millipore). GAPDH serves as the loading control. Western blots probed for SIL1 from
three experimental trials were quantified using ImageQuant™ TL (GE Healthcare Life
Sciences, Inc., Issaquah, WA). The values obtained from the NP40-soluble fractions
were normalized to their respective GAPDH control values and graphically expressed as
fold changes for the SIL1 mutants, relative to the wild-type SIL1 levels set to 1. The
values obtained from the NP40-insoluble fractions were normalized to their respective
NP40-soluble SIL1 levels that are corrected for equivalent loading, and graphically
expressed as fold changes for the SIL1 mutants, relative to the wild-type SIL1 levels set
to 1.
For the analysis of SIL1 accumulation as higher molecular weight species under
non-reducing and reducing conditions, COS-1 were transfected with either 3 μg of empty
pSVL, pSVL-SIL1WT, or pMT-BiP 44k alone (reported in (42)), or co-transfected with 2
μg of either wild-type or mutant SIL1 and 1 μg of pMT-BiP 44k. 24 hours after
transfection, cells were DSP-crosslinked, lysed in radioimmunoprecipitation assay
(RIPA) buffer supplemented with 0.25 mM PMSF and 1x Roche complete protease
inhibitor tablets without EDTA (Roche Applied Science, Indianapolis, IN, USA), as
reported (59), electrophoresed under non-reducing and reducing conditions on an 8% gel,
and probed for SIL1.
For the CHX-chase experiments, COS-1 were transfected with 2 μg per p60 of
either wild-type or mutant SIL1 cDNA using GeneCellin, following the manufacturer’s
protocol. 24 hours after transfection, cells were treated with 5 μg/ml CHX (identifier:
C4859; Millipore Sigma, Burlington, MA) to inhibit protein synthesis, and chased for
zero-, three-, and six-hours, respectively. Cells were then lysed with NP40 lysis buffer
and the NP40-soluble fractions were subjected to reducing electrophoresis and
immunoblotted for SIL1 and HSC70 (1:1000 dilution; identifier: sc-1059, Santa Cruz
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Biotechnology). HSC70 serves as the loading control. These western blots were
subjected to densitometric quantitation using ImageQuant™ TL. The values obtained for
wild-type and mutant SIL1 levels at the three timepoints were normalized to their
respective HSC70 values, and graphically expressed as percentage of SIL1 remaining at
the three- and six-hour timepoints, relative to the levels of SIL1 at the zero timepoint set
to 100%. to transfections, and were either untransfected or transfected with 3 μg per p60
of the p.R411_D415 del SIL1 mutant cDNA using GeneCellin, following the
manufacturer’s protocol. 24 hours after transfection, cells were harvested and lysed in
RIPA buffer supplemented with 0.25 mM PMSF and 1x Roche complete protease
inhibitor tablets without EDTA (Roche Applied Science, Indianapolis, IN, USA), as
reported previously, and electrophoresed under reducing conditions on an 8% gel,
transferred onto a PVDF membrane, and probed for SIL1.
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CHAPTER 5.

DISCUSSION

Molecular Mechanisms Underlying Marinesco-Sjögren Syndrome
SIL1 mutations and the genetic heterogeneity associated with MSS
Lagier-Tourenne et al. first mapped the MSS locus to chromosomal segment 5q31
(85). Senderek et al. and Anttonen et al. independently confirmed the genetic association
of the disease phenotype with this locus, and further refined the 5q31 locus to identify
mutations in the SIL1 gene in MSS patients of numerous ethnicities. In doing so they
also excluded mutations in the 5q31-co-resident gene, SAR1B, which was previously also
thought to be associated with MSS, and in the CCFDN (Congenital cataracts, facial
dysmorphism, and neuropathy syndrome)-causing CTDP1 gene, which serves as the
major differential diagnosis of MSS (64, 86). Although a wide gamut of SIL1 mutations
have been associated with MSS, patients present with a relatively homogeneous
phenotype and almost invariably demonstrate the characteristic clinical symptoms of
cerebellar ataxia, bilateral cataracts, intellectual disability, and myopathy (78). Thus,
conforming with the hypothesis that these mutations eventually lead to a loss of
functional SIL1, which is the root cause of MSS. Multiple subsequent studies have also
observed an absence of any SIL1 mutations in patients with typical MSS, displaying the
characteristic features of this disease, and individuals presenting atypical MSS with an
unusual involvement of white matter and peripheral neuropathy amongst other features.
This suggests that genetic heterogeneity in MSS with mutations in SIL1 plays a role in
about 60% of the total cases (64, 86, 115, 195). Since typical MSS patients with or
without SIL1 mutations display nearly identical clinical features, it is plausible that the
genetic locus underlying the disease phenotype in the remaining 40% of MSS patients
may function in the same pathway as SIL1. In support of this, loss of the BiP cochaperone, DNAJC3/ERdj6, in humans and mice leads to a similar neurodegeneration
phenotype as MSS, including early-onset ataxia, intellectual disability, short stature, and
pyramidal tract signs, in addition to diabetes mellitus due to apoptosis of pancreatic islet
cells (196, 197). ERdj6 has also been reported to function as a modifier of MSS, and loss
of this BiP co-chaperone alleviates the neurodegeneration phenotype of SIL1-deficient
mice, whereas the partial loss of GRP170, the second ER-resident nucleotide exchange
factor of BiP, seemed to exacerbate the same phenotype (91). In an extended analysis of
18 MSS-patient samples, Anttonen et al. ruled out mutations in HYOU1/GRP170,
HSPA5/BiP, and in the gene encoding alanyl tRNA synthetase (AARS), which causes an
MSS-like phenotype in mice (88). These results are in keeping with the embryonic
lethality observed in BiP-null and GRP170-deficient mice, arguing that functionally
inactivating mutations in either BiP or GRP170 are less likely to be observed in MSS
patients since these individuals display an apparently normal lifespan (35, 198). In
addition, mutations in the gene encoding the BiP-interacting protein, inositol
polyphosphate-5-phosphatase K (INPP5K), reportedly leads to a congenital muscular
dystrophy with early-onset cataracts and mild intellectual disability that overlaps with the
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spectrum of MSS-associated features, suggesting that the INPP5K locus may have a role
in atypical MSS (199).
The neurological features of MSS
The first mechanistic evidence demonstrating how the loss of SIL1 may cause the
multisystem defects observed in MSS came from SIL1-deficient mice. Recapitulating the
disease phenotype, mice with a homozygous disruption of Sil1 developed ataxia and
displayed Purkinje cell loss, which was characterized by the accumulation of
membranous autophagosomes, ubiquitinated protein aggregates, activation of the UPR,
and apoptosis (87). Interestingly, SIL1 is widely expressed in many regions of the brain
with the highest expression in the inferior olive and choroid plexus, yet the loss of SIL1
particularly affected the cerebellar Purkinje cells in lobules I-VIII and spared the lobule
X and caudal lobule IX of the vestibulocerebellum, which represents a developmentally
and functionally distinct region of the cerebellum (87). While BiP-deficiency is
embryonic lethal, the non-lethal phenotype of SIL1-deficient mice was attributed to the
redundancy of SIL1 with GRP170, which also demonstrates nucleotide exchange activity
towards BiP (44, 50, 53, 200). Consistent with this explanation, the reduction of GRP170
gene dosage worsens the cerebellar phenotype in SIL1-null mice and impacts the
previously unaffected lobules IX and X, whereas its transgenic overexpression is able to
completely rescue the Purkinje cell degeneration, proving it to be a modifier of this
disease along with ERdj6 (91). Although the transgenic overexpression of GRP170
seemed to completely ameliorate the cerebellar pathology, the endogenous ability of
different tissue systems to dramatically upregulate GRP170 might be capped since it has
been associated with cerebellar dysfunction and vacuolar degeneration in skeletal
muscles (200, 201). Mild to moderate intellectual disability is a cardinal feature of MSS
that precipitates relatively early in the course of this disease (78). Inaguma et al.
demonstrated data suggesting that SIL1 is regulated in a spatiotemporal manner during
brain development, and SIL1-depletion in ventricular zone progenitor cells of embryonic
murine brains caused an abnormal cellular morphology, aberrant neuronal migration
pattern with delayed kinetics, and slower axonal growth, resembling the phenotype
observed upon BiP-knockdown in these cells and mutant-BiP knock-in mice (78, 90,
202). The migration defects observed upon SIL1-depletion were easily rescued by
supplementation with human SIL1, whereas the MSS-associated SIL1 mutants,
p.R411_D415del and p.L457P failed to do so, highlighting the pathophysiological
significance of these SIL1 mutant proteins in MSS. The perturbation of the cortical
neuronal cytoarchitecture, combined with the potential effects of SIL1 loss on neuronal
protein quality control mediated by BiP, may cause the varying degrees of intellectual
impairment observed in MSS.
The myopathy in MSS
Multiple studies have characterized the myopathic changes observed in MSSpatient biopsies by electron microscopy and confirmed muscular dystrophy, including the
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variation in myofiber size, the presence of atrophic and hypertrophic fibers, autophagic
membranous whorls, internalization of nuclei, depletion of the predominantly glycolytic,
type IIB myofibers, and suggested that disturbed lysosomal function underlies the muscle
pathology in MSS (80-82, 203, 204). Using the two different mouse models of MSS,
which disrupt nearly identical regions of Sil1 but yield dramatically different SIL1
proteins, we and Roos et al. have demonstrated that SIL1-disruption in mice strikingly
phenocopies the ultrastructural features of the myopathy observed in MSS patients. Both
these studies further established that loss of SIL1 leads to activation of the unfolded
protein response that drives the upregulation of numerous ER chaperones, co-chaperones,
and components of the ERAD machinery display, however, led to an autophagy
impairment (100, 194). Autophagy plays a key role in regulating skeletal muscle mass,
and the absence of an unfettered response leads to loss of muscle mass and force, protein
aggregation, presence of abnormal membranous structures, and dilated sarcoplasmic
reticulum (205), which are all in keeping with the observations in SIL1-disrupted mice.
We additionally provide physiological evidence for the loss of muscle strength with aging
in Sil1Gt mice and use a proteomics approach to identify proteins that are deregulated in
the SIL1-deficient skeletal muscles. This led us to the discovery of the ER-trafficking
proteins, insulin and IGF-1 receptors, whose biosynthesis and maturation were
compromised in the absence of SIL1, and a physiological upregulation of PI3K-AKTmTOR signaling at steady state in ad libitum fed mice. In numerous conditions, such as
cancer, Cushing’s syndrome, denervation, diabetes, disuse atrophy, fasting, sepsis, and
uremia, skeletal muscles atrophy through activation of the ubiquitin–proteasomal
pathway via the FOXO transcription factors. These transcription factors upregulate the
expression of two E3 ubiquitin-ligases, Atrogin-1 and MuRF1, that serve as master
regulators of the ubiquitin–proteasomal process (206). An impending question that our
study raises is why Atrogin-1 and MuRF1 transcripts are not noticeably upregulated in
Sil1Gt skeletal muscles at the 15-month timepoint, which corresponds to a state of
ongoing myopathy? There are two potential explanations for our observations. (1) Since
we used whole skeletal muscle as our source of mRNA for Atrogin-1 and MuRF1
transcript analysis, their expression represents a gross average, which includes atrophic,
hypertrophic, and apparently normal myofibers. It is likely that the number of myofibers
undergoing marked degeneration and atrophy at a given time relative to the entire
myofiber population, which are the source of increased levels of Atrogin-1 and MuRF1
transcripts, are not very high. For the remaining hypertrophic and apparently normal
myofibers, as our western blotting data demonstrates, we observe a gross upregulation of
PI3K-AKT-mTOR signaling, which inhibits FOXO’s localization to the nucleus and
thereby its transcriptional activity, suggesting that Atrogin-1 and MuRF1 transcript levels
may be spatially distinct between myofibers. The observation of hypertrophic myofibers
conforms with the physiological activation of PI3K-AKT-mTOR axis, due to its well
established role in mediating skeletal muscle hypertrophy (158). It is noteworthy that the
myopathy observed in Sil1Gt mice mimics numerous features of sarcopenia, the agingrelated progressive loss of skeletal muscle mass and function (reviewed in (137), and
AKT-mediated downregulation of Atrogin-1 and MuRF1 is one such feature of this
process (207). (2) Our skeletal muscle data from ad libitum fed Sil1Gt mice is consistent
with the data from ad libitum fed, muscle-specific IR and IGF1R knockout mice, which
displayed a greater upregulation of Atrogin-1 and MuRF1 relative to control mice in the
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fasted state, but displayed no significant difference upon being randomly fed (208). The
authors further elaborate that the upregulation of Atrogin-1 and MuRF1 transcripts are an
acute response to skeletal muscle atrophy, which is not observed under chronic
myopathic conditions (208), offering an additional explanation of why the chronic
myopathy observed upon loss of SIL1 does not trigger a measurably sustained
upregulation of Atrogin-1 and MuRF1 transcripts.
While the constitutive activation of mTORC1 signaling alone has been shown to
trigger skeletal muscle atrophy and may explain the preferential loss of glycolytic, type
IIb fibers (209), similar to what is observed in MSS patients and in the MSS-mouse
model (194, 203), it is puzzling to understand how increased PI3K-AKT signaling may
be achieved in the face of decreased levels of its upstream transducers, IR and IGF1R. It
is possible that if other receptor tyrosine kinases, such as EGFR, remain unaffected by the
disruption of ER proteostasis in SIL1-deficient skeletal muscles, or the depletion of the
negative regulators of this pathway, such as the phosphoinositide phosphatases, may
cause a sustained activation of PI3K-AKT-mTOR signaling. The former has also been
suggested for MIGIRKO mice, which display an increase in the levels of skeletal muscle
EGFR expression (156). In keeping with these hypotheses, our proteomics data indicated
a 21% increase in EGFR levels (fold change=1.21, P=0.004, log2 ratio=0.28), and a 39%
decrease in the levels of inositol polyphosphate 4-phosphatase type II (INPP4B; fold
change=0.61, P=1.42E-06, log2 ratio=-0.70). INPP4B is highly expressed in skeletal
muscles and regulates the hydrolysis of phosphatidylinositol 3,4-bisphosphate to
phosphatidylinositol 3-phosphate, which serve as essential signaling activators of PI3KAKT signaling together with phosphatidylinositol 3,4-bisphosphate (210). Thus, the loss
of INPP4B, which has also been linked to PI3K-AKT hyperactivation (211), together
with increased EGFR levels, serve as promising mechanisms that may cause sustained
PI3K-AKT signaling in spite of a decrease in IR and IGF1R levels.
The metabolic features of MSS
Metabolic features have been rarely reported for MSS patients (85), but it remains
unclear if either typical or atypical MSS indeed presents without any metabolic
complications or if these features have not been thoroughly characterized. Both SIL1 and
BiP are highly expressed in secretory tissues, including the pancreas (63, 105). More
recently, using the Sil1wz mouse model, it has been determined that SIL1 is required to
maintain islet insulin content, islet size, glucose tolerance, and ER homeostasis in
pancreatic β cells (105). Modulation of the levels of SIL1 correlated well with insulin
content and the ability of pancreatic beta cells to secrete insulin. Importantly, loss of
SIL1rendered the Sil1wz mice more vulnerable to streptozotocin-induced type I diabetes,
and led to glucose intolerance upon high-fat diet feeding (105). However, it remains
unclear if the irregularities in insulin secretion and synthesis in Sil1wz mice are also
accompanied by aberrant glucose sensing. In support of the latter possibility, we
observed abnormal levels of numerous plasma membrane proteins and metabolic
enzymes, both of which play an essential role in the generating the signal for insulin
secretion (212). Largely, these results are in keeping with our observation of diffused

113

perinuclear vacuolization in the pancreas of aged Sil1Gt mice (213), and our evidence for
glucose intolerance and insulin resistance in these mice (Appendix Figure A-1). One
study has reported apparently normal cerebral glucose metabolic rates using radiolabeled
glucose and PET-CT (214). The brains of Sil1Gt mice displayed defects in radiolabeled
glucose uptake as well only upon stimulation with insulin, which suggests an abnormal
insulin-responsive glucose uptake mechanism (Appendix Figure A-2). If the two mouse
models of MSS do indeed recapitulate the disease in its entirety, these results emphasize
the requirement of a more thorough clinical analysis of the metabolic phenotype in MSS
patients, since pancreatic defects in insulin synthesis may be easily circumvented by
recombinant insulin supplementations.
Differences Between the Two Murine Models of MSS
It is worth noting that our data obtained in Sil1Gt mice differ in several significant
aspects from two previous reports that utilize Sil1wz mice. Both the Sil1wz (100) and
Sil1Gt (this study) mice develop a myopathy, which is characterized by the accumulation
of unfolded proteins, increases in some ER chaperones and components of cellular
degradation systems, and very similar changes in the cyto-architecture of quadriceps, as
detected by EM. Although there were changes in the onset and magnitude of UPR
activation between the two models, more significantly, the myopathy in the Sil1wz mouse
was diagnosed to be of neurogenic origin, whereas we found no significant evidence of a
neurogenic contribution to the Sil1Gt myopathy. We do not know the reason for this
difference, but it is conceivable that the effect on individual proteins varies between these
models. For instance, if a neurotransmitter or receptor was affected in Sil1wz mice but not
Sil1Gt mice it could lead to a distinct etiology. Along these lines, another study using the
Sil1wz mouse found that glucose-stimulated secretion of insulin from pancreatic cells was
impaired (105). Insulin is a known BiP client (215), and thus it is conceivable that the
loss of SIL1 interferes with BiP release and prevents its secretion; although this was not
directly measured. Nonetheless, this hypothesis is supported by SIL1 knock-down and
over-expression studies in a pancreatic cell line, where basal levels of proinsulin and
secretion of insulin corresponded to Sil1 levels (105). In contrast, we found both basal
and glucose-stimulated blood insulin levels were very similar in age-matched wild-type
and Sil1Gt mice. This argues that the Sil1Gt mice did not have a significant problem with
folding or secreting insulin and provides an example of a specific BiP client protein that
is affected distinctly by SIL1 loss. IR and IGF1R represent two other proteins that might
be affected disparately in the two mouse models. Although neither protein was directly
examined in the quadriceps of Sil1wz mice (114), they had a normal insulin tolerance test,
arguing that, unlike the Sil1Gt mice, insulin-mediated glucose uptake was not affected.
There are two unique aspects of these mice that could contribute to these inconsistencies.
First, the methods used for disrupting the Sil1 gene in these two mouse models result in
two distinct SIL1 fusion proteins. However, both SIL1 mutant proteins are unstable and
are unlikely to underlie the differences we have detected. In support of this, over 46 SIL1
mutations have been identified to date in individuals with MSS, which result in very
distinct mutant proteins, but there is no correlative evidence that disease symptoms vary
according to SIL1 mutations (99, 115). The second difference is that the Sil1wz mouse
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arose from a spontaneous transposon insertion into the Sil1 gene in a CXB5/ByJ mouse,
whereas gene-trap methodology was used to create the Sil1Gt mouse on the C57/BL6
background. Thus, it is plausible that the unique genetic backgrounds of the two mice
may play a bigger role in contributing to the variations in data.
Why Does the Loss of SIL1 in Humans and Mice Selectively Affect Some Tissues,
While Sparing Others?
The SIL1 expression-effect paradox
The selective vulnerability of certain tissues, such as the cerebellum, cerebral
cortex, skeletal muscles, pancreas, and lens, to the loss of SIL1 remains a puzzling
question for this disease (64, 78, 86, 87, 100, 105, 194). In fact, it appears that highly
secretory tissues, such as the kidney, liver, placenta, and plasma cells, where one might
expect adverse consequences when a component of the chaperone machinery is lost, are
relatively less affected by SIL1 loss (216). Instead the effects are greatest in the Purkinje
and glial cells of the cerebellum, the lens epithelial cells, and skeletal muscles (78),
which are not generally associated with the synthesis of industrial amounts of secretory
proteins that are BiP substrates. It is possible that the more classical secretory tissues
have a greater number of failsafe mechanisms built into their cellular systems and are
better able to respond to or accommodate changes in the client load of the ER.
Possibilities for selective vulnerability of certain tissues in MSS
In line with this reasoning, it is also possible that within a given cell type, cellular
subtypes may express different proteostasis programs. This can be exemplified by the
differences between motor neurons innervating fast or slow skeletal muscles (135). The
ER of fast motor neurons express relatively higher levels of components of the ERAD
machinery, such as VIMP, EDEM1, SEL1L, and OS9, and ER stress sensors, such as
PERK, IRE1, EIF2α. On the contrary, the ER of slow motor neurons express higher
levels of chaperones and co-chaperones, such as SIL1, ERP29, CRT, BiP, Grp94, and
Grp170 (135). These fast motor neurons display low-excitability, but are highly phasic
and generate short-lived powerful muscle contractions, whereas the slow motor neurons
are smaller in size, highly excitable, and extremely resistant to fatigue. In keeping with
their functional demands, the differences in their expression patterns of proteostasis
components would elicit dramatically distinct responses upon disruption of ER
proteostasis or the introduction of misfolded proteins for example. This would result in
differential vulnerabilities of these motor neuron subtypes, as demonstrated by the
selective vulnerability of fast motor neurons in fALS. Thus, it is possible that the
metabolically distinct glycolytic and oxidative skeletal muscle subtypes, the
evolutionarily distinct lobule X and ventral lobule IX of the vestibulocerebellum
compared to the other cerebellar lobules, and tissues that are affected by the loss of SIL1
versus those that remain largely unaffected, all display evolutionarily distinct proteostasis
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programs based on their function, which may also govern why certain tissues are
particularly vulnerable in MSS.
An unexpected new role for SIL1 as a BiP-reductase
Alternatively, an intriguing possibility comes from the ability of different tissue
systems to handle oxidative stress distinctly. Recent in vitro studies in yeast have shown
that Kar2p, the yeast homolog of SIL1, is a direct sensor of changes in the redox balance
within the ER via a conserved cysteine thiol within Kar2p’s NBD (cysteine-63) that is
reversibly oxidized by reactive oxygen species (67, 217). The modification of this
cysteine residue inhibits BiP’s ATPase activity, but accentuated its ability to bind to
misfolded proteins and prevent protein aggregation by decoupling its holdase activity
from the regulation by BiP’s nucleotide-bound state (67, 217). In a subsequent study, it
was shown that the nucleotide exchange factor, Sil1p, can also act as a reductase for
oxidized Kar2p, thereby restoring its chaperone activity during recovery from oxidative
stress (66). Sil1p’s reductase activity is mediated through two N-terminal cysteines
(cysteines 52 and 57). The yeast homolog of Grp170, Lhs1p, was unable to reduce
modified Kar2p and stimulate its ATPase activity (66), thus, implying that this reductase
activity is specific for Sil1p and not a common feature of Kar2p’s NEFs.
It has further been demonstrated that Sil1p’s reductase activity is in turn regulated
by its N-glycosylation status. Both Sil1p and Lhs1p are glycoproteins, and the Nglycosylation of Sil1p, but not of Lhs1p, is diminished during reductive ER stress (218).
The N-glycosylation of Sil1p is primarily mediated by the yeast
oligosaccharyltransferase, Ost3, whereas Lhs1p glycosylation is largely Ost3independent. During redox imbalance and stress, the unglycosylated Sil1p not only
retained functionality but was apparently more effective at compensating for Lhs1p loss
than its glycosylated form, outlining a possibility during redox stress where Sil1p is
crucial to facilitate nucleotide exchange for Kar2p when Lhs1p becomes limiting (218).
Adding to this line of thought, it has also been recently shown that Sil1p not only
facilitates nucleotide exchange for Kar2p, but also acts as its conformational regulator
and plays a more active role in the release of substrates from BiP than previously
anticipated (219).
Although there are two N-terminal cysteines that are highly conserved in
mammalian SIL1 sequences, algorithms for signal sequence cleavage predict that they are
not retained in the mature protein. If in fact they are part of the mature SIL1 protein, a
similar reductase activity for mammalian SIL1 could readily explain the delayed effects
on secretory pathway protein expression, as the need for this reductase activity might be
dependent on accumulated oxidative insults to the ER, leading to the oxidization and
inactivation of BiP. Further investigation is required to determine if a mammalian SIL1
possesses a reductase activity for BiP and whether this is a plausible explanation for the
selective vulnerabilities of certain tissues to the loss of SIL1 in MSS. It is further
tempting to speculate if mutations in proteins that may be involved in the redox
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homeostasis function of SIL1 could contribute to the genetic heterogeneity observed in
MSS.
Potential Strategies to Treat MSS
No treatment regimens that are specifically targeted to mitigate the pathological
mechanisms underlying MSS currently exist, and MSS is managed symptomatically with
cataract extraction and hormone replacement therapy for primary gonadal failure (220).
The logistic challenges for the treatment of MSS are synonymous with the treatment of
any ultra-rare disease, but the widespread distribution of MSS-associated SIL1 mutations,
genetic and clinical heterogeneity, and the lack of a thorough understanding of the
pathomechanisms of all the primary defects associated with MSS particularly hinder the
exploration of potential therapeutic strategies. Thus, the pharmacotherapeutic approach
for MSS to be feasible must be applicable to the majority of patient population with
varying genetic heterogeneity and clinical presentation of symptoms, as compared to a
more directed mutation-specific approach, the latter of which has shown remarkable
results in the correction of the cystic fibrosis-causing CFTR mutants (221). The two
murine models and the zebrafish model of MSS faithfully recapitulate disease
complexities and offer promise for expediting drug discovery studies (87, 100, 194, 222).
Chemical chaperones
To date, two studies have primarily undertaken different approaches to mitigate
some of the pathologies associated with MSS. Kashimada et al. detected that SIL1deficient, MSS-patient derived, lymphoblastoid cell lines displayed a greater upregulation
of BiP and spliced XBP1 when treated with a pharmacological ER stressor, and were
more prone to ER stress-induced cell death (223). Although it has been reported that
chemical stresses fail to mimic the unfolded protein response that originates from the
accumulation of unfolded or misfolded proteins (224), pretreatment of patient-derived
LBLs treated with the hydrophobic chemical chaperone, TUDCA, significantly reduced
apoptotic cell death when subsequently exposed to the chemical stressor, tunicamycin,
and displayed a significant reduction in mitochondrial depolarization and caspase
activation (223). Contrarily, pretreatment with the branch chain fatty acid, valproate, the
glucocorticoid, dexamethasone, and an alternative chemical chaperone, PBA, did not
have a major effect on apoptotic cell death, in spite of numerous reports indicating their
ability to mitigate the ER stress response (225, 226). This suggests that the mechanism
by which these small molecules prevent cell death in MSS-derived LBLs depends on
their mode of action rather than their ability to curb the ER stress response, although this
point has not been thoroughly investigated for MSS-derived LBLs. Both PBA and
TUDCA are hydrophobic chemical chaperones, whose proposed mechanisms of action
involves their interaction with exposed hydrophobic protein regions, which are generally
buried in correctly folded protein conformations, but surface exposed in misfolded or
unfolded states. Both PBA and TUDCA are orally bioavailable, BBB-permeable, have a
no-to-low toxicity profile, and despite having manifold similar features display a marked
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difference in their ability to prevent cell death in SIL1-deficient MSS-LBLs. This
difference can be attributed, at least partially, to the differences in their mechanism-ofaction supplementary to their role as a chemical chaperone. TUDCA is a bile acid and
has been shown to mediate its cytoprotective effects by reducing ROS formation,
preventing mitochondrial dysfunction, and inhibiting apoptosis via the intrinsic and
extrinsic pathway (180), which is consistent with what the authors observe for the
TUDCA-treatment of patient-derived LBLs. In keeping with these results, our
CRISPR/Cas9-engineered SIL1-null C2C12 murine myoblasts (Appendix Figures A-3
and A-4) will be a useful tool in evaluating the efficacy of both chemical chaperones in a
cell type that is affected in MSS.
Modulation of the PERK pathway
The PERK-CHOP branch of the unfolded protein response has been demonstrated
to be activate in the cerebellar Purkinje cells of Sil1wz mice prior to their degeneration
(87, 227). Grande et al. tested the therapeutic efficacy of an orally bioavailable PERK
inhibitor, GSK2606414, which would circumvent the translational attenuation response
mediated by this UPR branch (228). Chronical treatment of Sil1wz mice with
GSK2606414, beginning from a presymptomatic stage, significantly delayed the onset of
physiological and biochemical signs of cerebellar degeneration and partially modulated
the myopathy in these mice but did not prevent it altogether, which is in keeping with a
previous report demonstrating that CHOP deletion was not able to rescue Purkinje cell
loss and ataxia in Sil1wz mice (91, 227). The authors note that although the treatment
with GSK2606414 was effective at PERK inhibition, the cerebellar cells did not display
robust signs of ATF6 and XBP1 activation, which increases ER’s proteostatic capacity
and may be crucial in mitigating ER stress after rescuing protein synthesis by PERK
inhibition. Surprisingly, it was recently shown that GSK2606414 is also a potent
inhibitor of Receptor-interacting serine/threonine-protein kinase 1 (RIPK1), whose role in
mediating cell death via apoptosis and necroptosis is well established (229). Thus, it
remains unclear if the treatment with GSK2606414 partially prolongs the asymptomatic
phase of cerebellar pathology by mediating PERK inhibition or by inhibiting cell death
via RIPK1. Nonetheless, modulation of the PERK branch may be a viable strategy for
rescuing the pathology in the MSS-affected tissues from a conceptual standpoint and
need to be carefully evaluated in the available models of this disease. To this end, the
recently discovered Sephin1 and Raphin1 inhibitors of the phosphatases that negatively
regulate eIF2α phosphorylation levels, causing a transient translational halt and providing
proteostatic respite to cells, have demonstrated promise in preventing multiple
proteostasis diseases, such as Charcot-Marie-Tooth 1B syndrome, amyotrophic lateral
sclerosis, and Huntington’s disease (230, 231).
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The Role of SIL1 in the Pathogenesis of Other Diseases
SIL1 and neurodegenerative diseases
Since SIL1 plays a crucial role in maintaining ER homeostasis in neurons,
skeletal muscles, pancreas, and other cell types that are affected in MSS, it did not come
as a surprise when SIL1 was implicated as a modifier in ALS (135). SIL1
haploinsufficiency in SOD1 mutant (SOD1-G93A) mice substantially accentuated ER
stress and the associated pathology, rendering a previously resistant motor neuron
subtype now vulnerable to ER dysfunction and disease manifestation. On the other hand,
SIL1 expression was reduced in a mutant TDP-43 (TDP-43A315T) fALS murine model,
and co-localized with mutant TDP-43 in stress granule-like structures. Conversely,
AAV-mediated SIL1-overexpression rescued denervation defects, reduced cellular stress
and increased survival (135). In fact, total SIL1 levels were also found to be decreased in
the cortex and hippocampus of a murine model of Alzheimer’s disease (Tg2576) (232),
whereas the surviving hippocampal neuronal population in Alzheimer’s disease autopsies
displayed higher SIL1 levels (233). Overall, these results suggest a cytoprotective role of
SIL1 in ALS and Alzheimer’s disease.
SIL1 and gliomas, the most common central nervous system tumors
Recently, Xu et al. revealed that SIL1 was expressed at higher levels in
glioblastoma multiforme and brain lower grade gliomas, accounting for approximately
66% of patient samples, and was further upregulated in grade IV gliomas compared to
grades I-III (234). Downregulation of SIL1 using siRNA in the glioblastoma cell line
U251 caused a significant inhibition of cell proliferation, migration, AKT-mTOR
signaling, and triggered apoptosis without altering their cell cycle dynamics. This study
and our work on the loss of SIL1 in skeletal muscles emphasize the ability of SIL1 to
modulate AKT-mTOR signaling, although with opposing outcomes, which may be
explained by differences in the levels of regulators of this signaling cascade. Overall,
these results shed light on the potential beneficiary role of SIL1 in a subset of gliomas
and further offer insights into a plausible approach by which glioma progression could be
curtailed (234). In line with these results, it is tempting to speculate if MSS patients are
resistant to these central nervous system tumor subtypes. Nevertheless, the role of SIL1
in maintaining tissue homeostasis, especially for neuronal cells, is evidently clear.
Conclusions
In toto, our data demonstrates that a subset of MSS-associated SIL1 mutations,
which alter less than six amino acids, may dramatically alter the protein
microenvironment and disrupt intramolecular interactions, such that it alters the folding
properties of SIL1 and renders it aggregation-prone. This offers a potential explanation
of the mechanism(s) by which mutations in SIL1 cause a loss of its function. We confirm
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that the C57BL6 Sil1Gt mouse model, which harbors a genetic disruption of the exon 9
and exon 10 resident BiP-interaction sites, recapitulate numerous aspects of the MSSphenotype and represents a valid preclinical model system to investigate the MSSassociated pathology and explore pharmacotherapeutic strategies. We further elucidate
the molecular mechanisms by which loss of SIL1 leads to skeletal muscle myopathy and
muscular weakness with aging, identifying crucial regulators of muscle function that are
deregulated in SIL1-deficient skeletal muscles. We further provide data demonstrating
that contrary to popular belief, loss of SIL1 does not necessarily affect all BiP’s clientele,
but may rather depend on additional factors, such as aging and redox imbalance.
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APPENDIX. GLUCOSE HANDLING DEFECTS IN SIL1Gt MICE AND
GENERATION OF A CRISPR/CAS9-MEDIATED SIL1-NULL MODEL SYSTEM

Figure A-1.

Sil1Gt mice demonstrate glucose intolerance and insulin resistance.

Age-matched wild-type and Sil1Gt mice (n=8-12) were subjected to an (A) intraperitoneal
Glucose Tolerance Test (i.p.GTT), or (C) an intraperitoneal Insulin Tolerance Test
(i.p.ITT). Area Under Curve (AUC) calculations for each test is displayed next to the
respective blood glucose levels. Error bars indicate means ± s.e.m. (B) Plasma insulin
levels during the initial time-course of the i.p.GTT were measured and plotted. Statistical
comparisons were performed using t-tests; P-values are indicated as *P≤0.05, ** P ≤0.01,
*** P ≤0.001, **** P ≤0.0001.
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Figure A-2.

Loss of SIL1 leads to defects in brain glucose uptake in Sil1Gt mice.

Graphical representation of 18F-fluorodeoxyglucose uptake over 60 minutes in wild-type
(blue) and Sil1Gt (red) brains (A, B) and urinary bladders (C, D) under basal conditions
(A, C) or after an intraperitoneal injection of 0.75 mU/g body weight of human insulin
(B, D; n=4) assayed by PET-μCT. Statistical differences were computed using unpaired,
two-tailed Student’s t-tests, and are indicated in the graph. %ID/g, % injected dose per
gram body weight.
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Figure A-3. Deep sequencing reveals successful CRISPR/Cas9-mediated targeting
of the Sil1 locus in murine C2C12 myoblasts.
SgRNA sequences targeting exon 3 of the murine Sil1 gene were 5’GGAGCTAGACACCGAGATCC-3’ (sgRNA #1) and 5’GAGTTGGGTGGAACACCTCC-3’ (sgRNA #2), respectively, and were designed to
recapitulate the MSS-associated p.E60X mutation (86). DNA oligonucleotides
containing sgRNA sequences were cloned into a PX458 (SpCas9-2A-EGFP-U6-sgRNA,
Addgene 48138) all-in-one backbone using the Bbs1 restriction enzyme site. Clones
were verified by Sanger sequencing using the U6 promoter forward primer 5’GAGGGCCTATTTCCCATGAT-3’. The PX458 all-in-one vector containing either
sgRNA #1 or #2, respectively, or the vector alone (experimental control) were transfected
into the polyploid C2C12 murine skeletal muscle myoblasts (ATCC® CRL-1772™)
using Lipofectamine™ 3000, as per the company protocol. 24 hours following
transfection, GFP-expressing cells by were sorted by FACS, allowed to recover in tissue
culture and subsequently subjected to single-cell sorting by FACS. The Exon 3 region of
Sil1 from single cell-derived clonal populations was amplified using forward (5’CAGTGCTAACCCTCTCCCTAGTATTTTCTTTAACC-3’) and reverse (5’GAGCCAAGCAGCAGAGCCCAAAATAGC-3’) primers and subjected to deep
sequencing to characterize the Sil1 mutations. DNA and protein alignments of three Cas9
control and Sil1-targeted single-cell clones displayed above demonstrate efficient locus
targeting, which generated frameshift mutations that cause premature truncations of the
encoded SIL1 protein.
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Figure A-4. SIL1-null myoblasts retain the ability to differentiate into myotubes
and demonstrate molecular changes similar to that observed in Sil1Gt skeletal
muscles.
Preliminary western blot analysis of CRISPR/Cas9-engineered SIL1-null and control
myoblasts revealed that both had similar growth rates and differentiated into myotubes
that express myosin heavy chain with similar kinetics (A), confirming that SIL1 is
dispensable for myotube differentiation. Similar to Sil1Gt quadriceps (Figure 3-13C),
both IR-β and IGF1R-β were decreased and GLUT4 was increased (B), arguing that
CRISPR/Cas9-engineered SIL1-knockout myoblasts provide a useful tool for assessing
ER protein folding and quality control pathways, which are critical to muscle function.
This also was true for calsequestrin 2 levels (Figure 3-6A).
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